CA2414089A1 - Improvements in and relating to chromophores - Google Patents
Improvements in and relating to chromophores Download PDFInfo
- Publication number
- CA2414089A1 CA2414089A1 CA002414089A CA2414089A CA2414089A1 CA 2414089 A1 CA2414089 A1 CA 2414089A1 CA 002414089 A CA002414089 A CA 002414089A CA 2414089 A CA2414089 A CA 2414089A CA 2414089 A1 CA2414089 A1 CA 2414089A1
- Authority
- CA
- Canada
- Prior art keywords
- chromophore
- alkyl
- group
- chromophores
- porphyrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 71
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims abstract description 58
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 238000004458 analytical method Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 191
- -1 cyclopropanyl structure Chemical group 0.000 claims description 155
- 125000003118 aryl group Chemical group 0.000 claims description 65
- 125000001424 substituent group Chemical group 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 43
- 230000001268 conjugating effect Effects 0.000 claims description 43
- 239000002904 solvent Substances 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 239000007983 Tris buffer Substances 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 22
- 230000000295 complement effect Effects 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 102000014914 Carrier Proteins Human genes 0.000 claims description 18
- 108091008324 binding proteins Proteins 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 108090001008 Avidin Proteins 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 238000005859 coupling reaction Methods 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000005647 linker group Chemical group 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 229910000489 osmium tetroxide Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 125000002971 oxazolyl group Chemical group 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 235000019000 fluorine Nutrition 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 150000002540 isothiocyanates Chemical class 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 6
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 6
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 150000002576 ketones Chemical class 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 125000005496 phosphonium group Chemical group 0.000 claims description 6
- 125000005592 polycycloalkyl group Polymers 0.000 claims description 6
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 6
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 150000004676 glycans Polymers 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 150000004804 polysaccharides Polymers 0.000 claims description 5
- 102000000584 Calmodulin Human genes 0.000 claims description 4
- 108010041952 Calmodulin Proteins 0.000 claims description 4
- 239000004721 Polyphenylene oxide Chemical class 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000000532 dioxanyl group Chemical group 0.000 claims description 4
- 150000002118 epoxides Chemical class 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
- 229920000570 polyether Chemical class 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 claims description 4
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 claims description 4
- 125000004306 triazinyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 4
- 238000012800 visualization Methods 0.000 claims description 4
- QIBKIAFNCVIIMG-UHFFFAOYSA-N 10,20-diphenyl-21,22-dihydroporphyrin Chemical compound C1=CC(C(=C2C=CC(N2)=CC2=CC=C3N2)C=2C=CC=CC=2)=NC1=CC(=N1)C=CC1=C3C1=CC=CC=C1 QIBKIAFNCVIIMG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 150000004665 fatty acids Chemical group 0.000 claims description 3
- 150000004820 halides Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 238000005735 osmylation reaction Methods 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- BSSNZUFKXJJCBG-UPHRSURJSA-N (z)-but-2-enediamide Chemical compound NC(=O)\C=C/C(N)=O BSSNZUFKXJJCBG-UPHRSURJSA-N 0.000 claims description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 230000001627 detrimental effect Effects 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 150000002513 isocyanates Chemical class 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 125000001805 pentosyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 230000002269 spontaneous effect Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 241001515965 unidentified phage Species 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 31
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 3
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 238000000799 fluorescence microscopy Methods 0.000 abstract description 6
- 238000012921 fluorescence analysis Methods 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 231
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 216
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 90
- 239000007787 solid Substances 0.000 description 68
- 239000000243 solution Substances 0.000 description 66
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 58
- 238000006243 chemical reaction Methods 0.000 description 56
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 39
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 36
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 33
- 230000005284 excitation Effects 0.000 description 33
- 101150041968 CDC13 gene Proteins 0.000 description 32
- 239000000377 silicon dioxide Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- 229960001866 silicon dioxide Drugs 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 229910052786 argon Inorganic materials 0.000 description 19
- 238000003818 flash chromatography Methods 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 238000010828 elution Methods 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 14
- 150000004036 bacteriochlorins Chemical class 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
- 238000002428 photodynamic therapy Methods 0.000 description 11
- 230000021615 conjugation Effects 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 10
- 239000005030 aluminium foil Substances 0.000 description 9
- 150000001540 azides Chemical class 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- PBTPREHATAFBEN-UHFFFAOYSA-N dipyrromethane Chemical compound C=1C=CNC=1CC1=CC=CN1 PBTPREHATAFBEN-UHFFFAOYSA-N 0.000 description 9
- 229940093499 ethyl acetate Drugs 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 150000004035 chlorins Chemical class 0.000 description 8
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012285 osmium tetroxide Substances 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012909 foetal bovine serum Substances 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- OGIHJVCTOGFQSC-UHFFFAOYSA-N N-[4-[15-(4-methoxyphenyl)-21,23-dihydroporphyrin-5-yl]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(C1=CC=C(N1)C=C1C=CC(=N1)C(C=1C=CC(NC(C)=O)=CC=1)=C1C=CC(N1)=C1)=C2N=C1C=C2 OGIHJVCTOGFQSC-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- KXMMNJQMGILZDB-UHFFFAOYSA-N 1-(2-oxopyridine-1-carbothioyl)pyridin-2-one Chemical compound O=C1C=CC=CN1C(=S)N1C(=O)C=CC=C1 KXMMNJQMGILZDB-UHFFFAOYSA-N 0.000 description 3
- SKLUWKYNZNXSLX-UHFFFAOYSA-N 4-Acetamidobenzaldehyde Chemical compound CC(=O)NC1=CC=C(C=O)C=C1 SKLUWKYNZNXSLX-UHFFFAOYSA-N 0.000 description 3
- VPNKESXMOHOSKY-UHFFFAOYSA-N 4-[15-(4-methoxyphenyl)-21,23-dihydroporphyrin-5-yl]aniline Chemical compound C1=CC(OC)=CC=C1C(C1=CC=C(N1)C=C1C=CC(=N1)C(C=1C=CC(N)=CC=1)=C1C=CC(N1)=C1)=C2N=C1C=C2 VPNKESXMOHOSKY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000156948 Aphantopus hyperantus Species 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DJOWTWWHMWQATC-KYHIUUMWSA-N Karpoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1(O)C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C DJOWTWWHMWQATC-KYHIUUMWSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000005281 excited state Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- QAIGYXWRIHZZAA-UHFFFAOYSA-M 1-methylpyridin-1-ium;chloride Chemical compound [Cl-].C[N+]1=CC=CC=C1 QAIGYXWRIHZZAA-UHFFFAOYSA-M 0.000 description 2
- MGMOLLLDJVCXAX-UHFFFAOYSA-N 2-[15-[4-(bromomethyl)phenyl]-21,23-dihydroporphyrin-5-yl]aniline Chemical compound Nc1ccccc1-c1c2ccc(cc3ccc([nH]3)c(-c3ccc(CBr)cc3)c3ccc(cc4ccc1[nH]4)n3)n2 MGMOLLLDJVCXAX-UHFFFAOYSA-N 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 239000011542 SDS running buffer Substances 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 2
- 108010081400 fluorescein isothiocyante avidin Proteins 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- FZKCAHQKNJXICB-UHFFFAOYSA-N 2,1-benzoxazole Chemical compound C1=CC=CC2=CON=C21 FZKCAHQKNJXICB-UHFFFAOYSA-N 0.000 description 1
- RWLGLRBFZUOAGT-UHFFFAOYSA-N 2-[(4-methoxyphenyl)-(1h-pyrrol-2-yl)methyl]-1h-pyrrole Chemical compound C1=CC(OC)=CC=C1C(C=1NC=CC=1)C1=CC=CN1 RWLGLRBFZUOAGT-UHFFFAOYSA-N 0.000 description 1
- ODOQKWUKLACHRO-UHFFFAOYSA-N 2-[phenyl(1h-pyrrol-2-yl)methyl]-1h-pyrrole Chemical compound C1=CNC(C(C=2NC=CC=2)C=2C=CC=CC=2)=C1 ODOQKWUKLACHRO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FIDQDDFTUULQAU-UHFFFAOYSA-N 21,23-diphenylporphyrin Chemical compound C1(=CC=CC=C1)N1C=2C=CC1=CC=1C=CC(=CC3=CC=C(N3C3=CC=CC=C3)C=C3C=CC(C2)=N3)N1 FIDQDDFTUULQAU-UHFFFAOYSA-N 0.000 description 1
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- PSKQHECQNCDSIS-UHFFFAOYSA-N 5-(4-isothiocyanatophenyl)-15-[2-(4-methylpyridin-1-ium-1-yl)phenyl]-21,23-dihydroporphyrin Chemical compound Cc1cc[n+](cc1)-c1ccccc1-c1c2ccc(cc3ccc([nH]3)c(-c3ccc(cc3)N=C=S)c3ccc(cc4ccc1[nH]4)n3)n2 PSKQHECQNCDSIS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004160 Ammonium persulphate Substances 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- RALPYVJPBWFUDQ-UHFFFAOYSA-N C1=CC(N)=CC=C1C(C1=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=C1)=C2N=C1C=C2 Chemical compound C1=CC(N)=CC=C1C(C1=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=C1)=C2N=C1C=C2 RALPYVJPBWFUDQ-UHFFFAOYSA-N 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 101100480507 Caenorhabditis elegans tdp-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101100326607 Danio rerio cahz gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- COSICWYFCAPPJB-UHFFFAOYSA-N Fusarochromanone Chemical compound OCC(N)CC(=O)C1=CC=C2OC(C)(C)CC(=O)C2=C1N COSICWYFCAPPJB-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FEHUXMNFRKBIHX-UHFFFAOYSA-N N-(9H-fluoren-1-ylmethyl)-4-[15-(4-methoxyphenyl)-21,23-dihydroporphyrin-5-yl]aniline Chemical compound C1(=CC=CC=2C3=CC=CC=C3CC1=2)CNC1=CC=C(C=C1)C=1C2=CC=C(N2)C=C2C=CC(C(=C3C=CC(=CC=4C=CC=1N=4)N3)C1=CC=C(C=C1)OC)=N2 FEHUXMNFRKBIHX-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- LGDAGYXJBDILKZ-UHFFFAOYSA-N [2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl] 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LGDAGYXJBDILKZ-UHFFFAOYSA-N 0.000 description 1
- WOWAQKXHQPUARL-UHFFFAOYSA-N [4-[15-(2-aminophenyl)-21,23-dihydroporphyrin-5-yl]phenyl]methanol Chemical compound Nc1ccccc1-c1c2ccc(cc3ccc([nH]3)c(-c3ccc(CO)cc3)c3ccc(cc4ccc1[nH]4)n3)n2 WOWAQKXHQPUARL-UHFFFAOYSA-N 0.000 description 1
- HNLDMSCVPBNNPT-UHFFFAOYSA-N [N]1C2=CC=C1C=C(N1)C=C(CBr)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 Chemical class [N]1C2=CC=C1C=C(N1)C=C(CBr)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 HNLDMSCVPBNNPT-UHFFFAOYSA-N 0.000 description 1
- GFERWFAWHAQLLF-UHFFFAOYSA-N [N]1C2=CC=C1C=C(N1)C=C(N)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 Chemical class [N]1C2=CC=C1C=C(N1)C=C(N)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 GFERWFAWHAQLLF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- 235000019395 ammonium persulphate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002265 electronic spectrum Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- HASMBPGSUJUMKY-UHFFFAOYSA-N methyl 4-[15-(4-aminophenyl)-21,23-dihydroporphyrin-5-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C1=CC=C(N1)C=C1C=CC(=N1)C(C=1C=CC(N)=CC=1)=C1C=CC(N1)=C1)=C2N=C1C=C2 HASMBPGSUJUMKY-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- IKGXGRRJYNCDTM-UHFFFAOYSA-N sodium 2-[hydroxy(methoxy)phosphoryl]ethanolate Chemical group COP(O)(=O)CCO[Na] IKGXGRRJYNCDTM-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004722 stifle Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- YZYKBQUWMPUVEN-UHFFFAOYSA-N zafuleptine Chemical compound OC(=O)CCCCCC(C(C)C)NCC1=CC=C(F)C=C1 YZYKBQUWMPUVEN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K9/00—Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy
- C09K9/02—Organic tenebrescent materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to novel porphyrin and porphyrin-based chromophores and sets of porphyrin and porphyrin-based chromophores, which may be particularly useful in a range of photodynamic applications, including photochemotherapy and fluorescence analysis and imaging. In particular, the present invention provides new and useful porphyrin, chlorin and bacteriochlorin chromophores; methods for the production of such chromophores;
and methods for the use of such chromophores in analysis and in medicine.
and methods for the use of such chromophores in analysis and in medicine.
Description
2 PCT/GBO1/02846 IMPROVEMENTS IN AND RELATING TO CHROMOPHORES
The present invention relates to novel porphyrin and porphyrin-based chromophores and sets of porphyrin and porphyrin-based chromophores, which may be particularly useful in a range of photodynamic applications, including photochemotherapy and fluorescence analysis and imaging.
The importance of porphyrin and porphyrin-based chromophores both as research tools, for example in fluorescence-activated cell sorting (FACS), and as therapeutic agents in photodynamic therapy (PDT) fc5i- bringing about the death of targeted cells in vivo, is widely recognised in the art. Each of these applications is dependent on the ability of the chromophore to be excited by incident light to a singlet excited state, and to decay to a lower energy state with the consequent emission of energy. This energy may be emitted in the form of fluorescent light at a specific wavelength, thereby enabling a cell or biostructure attached to the decaying chromophore to be visualised, and/or sorted by FACS. Alternatively, the energy of excitation may be dissipated by initial conversion of the singlet chromophore into the triplet excited state, followed by the transfer of energy to another triplet such as dioxygen, with the consequent formation of singlet oxygen. Singlet oxygen is a powerful cytotoxic agent, and hence where this latter process occurs in or in the immediate vicinity of a cell, it will usually result in the death of that cell. Accordingly, the chromophore can be exploited both for its fluorescent properties, and for its ability to act as a photosensitiser.
Evidently, for the purposes of fluorescence imaging or analysis, or PDT, some degree of control over the localisation of the chromophore in vitro or in vivo is a prerequisite. This is particularly important in photodynamic therapy, as the typical sphere of radiation of singlet oxygen produced by decay of a chromophore is no more than 0. I L~m in diameter, so that in order to bring about the death of a target cell, the chromophore must usually be positioned immediately alongside, or preferably within, that cell.
Hitherto, however, few attempts have been made to control the targeting of porphyrin photosensitisers to particular target cells in vivo for the purposes of PDT.
Instead, reliance has typically been placed on the inherent tendency of porphyrins to accumulate in tumours in the absence of lymphatic drainage from tumour structures.
Phototi-inOO , a photosensitising agent comprising a mixture of porphyrin structures derived from hematoporphyrin-IX by treatment with acids which is commercially used in the treatment of carcinomas and sarcomas, is, for example, conventionally administered systemically to patients without any targeting vehicle or means. This is evidently undesirable, as incorrect localisation of the photosensitiser will not only decrease the efficiency of the photochemotherapy, but may also result in the death of healthy cells.
Efforts have been made to achieve the specific attachment of chromophores to biological targets in vitro, in particular for the purposes of FACS and fluorescence imaging, by covalently conjugating the chromophores to suitable protein delivery molecules. This approach has however been subject to various problems.
Firstly, the degree of background fluorescence caused by non-specific binding of porphyrin chromophores to cell surfaces has proved difficult to reduce. Secondly, it has been found that the attachment of a chromophore to a protein molecule can result in a significant decree of excited state quenching by the proximate protein, which will clearly reduce the efficacy of the chromophore as a marker or in targeted photodynamic applications.
A reduction in these effects remains a desirable objective.
According to one aspect of the present invention therefore, there is provided a porphyrin chromophore of formula (I) below:
2~ ~ ~ \
s 1/ N 21 2z H \s R3 1o Rs 19~ N 24 23 N .~ 11 /16 ~ ~ 12 17 1g 13 18 RZ (I) or a chlorin chromophore of any of formulas (II), (III), (IV), or (V) below:
~2 K "~ 1
The present invention relates to novel porphyrin and porphyrin-based chromophores and sets of porphyrin and porphyrin-based chromophores, which may be particularly useful in a range of photodynamic applications, including photochemotherapy and fluorescence analysis and imaging.
The importance of porphyrin and porphyrin-based chromophores both as research tools, for example in fluorescence-activated cell sorting (FACS), and as therapeutic agents in photodynamic therapy (PDT) fc5i- bringing about the death of targeted cells in vivo, is widely recognised in the art. Each of these applications is dependent on the ability of the chromophore to be excited by incident light to a singlet excited state, and to decay to a lower energy state with the consequent emission of energy. This energy may be emitted in the form of fluorescent light at a specific wavelength, thereby enabling a cell or biostructure attached to the decaying chromophore to be visualised, and/or sorted by FACS. Alternatively, the energy of excitation may be dissipated by initial conversion of the singlet chromophore into the triplet excited state, followed by the transfer of energy to another triplet such as dioxygen, with the consequent formation of singlet oxygen. Singlet oxygen is a powerful cytotoxic agent, and hence where this latter process occurs in or in the immediate vicinity of a cell, it will usually result in the death of that cell. Accordingly, the chromophore can be exploited both for its fluorescent properties, and for its ability to act as a photosensitiser.
Evidently, for the purposes of fluorescence imaging or analysis, or PDT, some degree of control over the localisation of the chromophore in vitro or in vivo is a prerequisite. This is particularly important in photodynamic therapy, as the typical sphere of radiation of singlet oxygen produced by decay of a chromophore is no more than 0. I L~m in diameter, so that in order to bring about the death of a target cell, the chromophore must usually be positioned immediately alongside, or preferably within, that cell.
Hitherto, however, few attempts have been made to control the targeting of porphyrin photosensitisers to particular target cells in vivo for the purposes of PDT.
Instead, reliance has typically been placed on the inherent tendency of porphyrins to accumulate in tumours in the absence of lymphatic drainage from tumour structures.
Phototi-inOO , a photosensitising agent comprising a mixture of porphyrin structures derived from hematoporphyrin-IX by treatment with acids which is commercially used in the treatment of carcinomas and sarcomas, is, for example, conventionally administered systemically to patients without any targeting vehicle or means. This is evidently undesirable, as incorrect localisation of the photosensitiser will not only decrease the efficiency of the photochemotherapy, but may also result in the death of healthy cells.
Efforts have been made to achieve the specific attachment of chromophores to biological targets in vitro, in particular for the purposes of FACS and fluorescence imaging, by covalently conjugating the chromophores to suitable protein delivery molecules. This approach has however been subject to various problems.
Firstly, the degree of background fluorescence caused by non-specific binding of porphyrin chromophores to cell surfaces has proved difficult to reduce. Secondly, it has been found that the attachment of a chromophore to a protein molecule can result in a significant decree of excited state quenching by the proximate protein, which will clearly reduce the efficacy of the chromophore as a marker or in targeted photodynamic applications.
A reduction in these effects remains a desirable objective.
According to one aspect of the present invention therefore, there is provided a porphyrin chromophore of formula (I) below:
2~ ~ ~ \
s 1/ N 21 2z H \s R3 1o Rs 19~ N 24 23 N .~ 11 /16 ~ ~ 12 17 1g 13 18 RZ (I) or a chlorin chromophore of any of formulas (II), (III), (IV), or (V) below:
~2 K "~ 1
3 7 7 2 I \ ~ 8 2 ~ \~ ~ ~2 Rs R3 3 ~ / 10 Rs 19~ N24 N~ 110 19 N4 HN 11 18 ~ '1 / / 12 16 / ~ 12 16 14 18 Rz R
z ( II) (III) 2~ 2 ~
_ 8 8 1 N21 2zN 9 1 NH N19 R3 ~ H ~ 10 R3 ~ ~ 10 R3 16~ ~ 12 X1 X2 / ~ 12 16 v 17 1~ 14 17 Y 14 13 I
(IV) 18 X2 (V) X1 R1 Rz 2 or a bacteriochlorin chromophore of any of formulas (VI) and (VII) below 7 ~ 7 2 ~ \~ ~ ~2 x1 / /
1 NH N_ 21 22 9 1 ' N 21 22 H 9 R3 ~ ~ 1o R3 R3 ~ R3 189 N HN 11 19 N24 N ~10 X4 /14 ~ 12 ~ 16~ ~ 12 x ?C3 R2 18 Rz
z ( II) (III) 2~ 2 ~
_ 8 8 1 N21 2zN 9 1 NH N19 R3 ~ H ~ 10 R3 ~ ~ 10 R3 16~ ~ 12 X1 X2 / ~ 12 16 v 17 1~ 14 17 Y 14 13 I
(IV) 18 X2 (V) X1 R1 Rz 2 or a bacteriochlorin chromophore of any of formulas (VI) and (VII) below 7 ~ 7 2 ~ \~ ~ ~2 x1 / /
1 NH N_ 21 22 9 1 ' N 21 22 H 9 R3 ~ ~ 1o R3 R3 ~ R3 189 N HN 11 19 N24 N ~10 X4 /14 ~ 12 ~ 16~ ~ 12 x ?C3 R2 18 Rz
4 (VI) (VII) wherein Rl is an aryl moiety which is linked to a conjugating group Z which is capable of conjugating the chromophore to a polypeptide molecule for delivering said chromophore to a specific biological target in vitro or in vivo; RZ is a hydrophilic aryl moiety; R3 is H or a hydrophilic aryl or hydrophilic non-aromatic moiety; and each of Xl, Xz, X~ and X:, is independently selected from H, OH, halogen, C1_3 alkyl and OC1_3 alkyl, or Xl and XZ andlor X3 and X:~ together form a bridging moiety selected from O, CH2, CH C1_3 alkyl, or C(C1_3 alkyl)Z, such that XI and X2 and/or X3 and X~ with the adjacent C-C bond form an epoxide or cyclopropanyl structure; wherein each of said Rl, RZ and R~
is optionally further substituted one or more times by -OH, -CN, -NO2, halogen, -T or -OT, where T is a Cl-CI; alkyl, cycloalkyl or aryl group or a hydroxylated, halogenated, sulphated, sulphonated or aminated derivative thereof or a carboxylic acid, ester, ether, polyether, amide, aldehyde or ketone derivative thereof.
It has been found that the inclusion of one or more hydrophilic substituents around the core of a chromophore in accordance with the invention results in enhanced solubility in basic buffer/DMSO or DMF co-solutions which are commonly used in protein bioconjugation. Increased hydrophilicity also produces a marked reduction in the tendency of the chromophore to bind non-covalently to proteins. Where the chromophore is to be conjugated to a targeting protein such as a monoclonal antibody for delivery to specific cells or tissues, for example for the purposes of PDT or FACS, a decrease in non-covalent binding between the chromophore and the protein will reduce the degree of non-specific transfer of chromophore to cell surfaces, which will substantially increase the accuracy of targeting the chromophore to the cells or tissue of interest.
Accordingly, according to yet another aspect of the present invention there is provided a method for separating a mixture which comprises one or more hydrophilic chromophores each having a hydrophilic or amphiphilic moiety, and a plurality of less hydrophilic substances and/or molecules, comprising the step of introducing said mixture to a hydrophobic eluting solvent, and passing said mixture and said eluting solvent over a hydrophilic or polar solid phase, such that said one or more chromophores are arrested on said solid phase whilst said substances and/or molecules are eluted or substantially eluted from said solid phase by said eluting solvent.
Said method may, for example, comprise chromatography on a Sephadex~ (dextran) column, or reverse-phase HPLC. Typically, said mixture of less hydrophilic substances and/or molecules may comprise a mixture of cells and/or membranes. Advantageously, said one or more hydrophilic chromophores include one or more chromophores in accordance with the present invention.
In some embodiments, each or some of Xi- X~ is H. In particularly preferred embodiments, however, each of Xl - X4 is OH. Accordingly, said chromophore may be a dihydroxychlorin of formula (II), (III), (IV) or (~ above or a tetrahydroxybacteriochlorin of formula (VI) or (VII) above. The hydrophilicity of dihydroxychlorins and tetrahydroxybacteriochlorins is found to be greater than that of the corresponding porphyrins, owing to the presence of extra hydrophilic hydroxy groups around the core of the chromophore.
Preferably, said aryl moiety Rl may comprise a phenyl ring, which phenyl ring may preferably be linked by a single bond to the macrocyclic core of said chromophore or may alternatively be linked thereto by a C1.6 branched or linear alkyl chain.
Advantageously, said conjugating group Z may be linked to said phenyl ring at the para (4') position thereof.
Said conjugating group Z may comprise a group which is capable of bonding covalently to an amine group on a polypeptide molecule; such as an isocyanate, isothiocyanate, or NHS ester group. Advantageously, therefore, each of the meso substituents around said porphyrin, chlorin or bacteriochlorin should comprise no NH-, NH~, -NHZ+- or -NH3+ groups which could become covalently bonded to said conjugating group Z. This will serve to reduce the probability of internal crass-linkage within said chromophore. Said conjugating group Z may alternatively comprise any other protein conjugating group, such as -NH2, -NH(Cl-s alkyl), maleamide, iodoacetamide, ketone or aldehyde. Methods for achieving the conjugation of such groups to protein molecules are known in the art.
In especially preferred embodiments, said conjugating group Z comprises an isothiocyanato group. Isothiocyanates react readily with lysine residues to produce a stable linkage to proteins, and hence are particularly suitable for bioconjugation of chromophores in accordance with the invention.
Said conjugating group Z may be linked directly to said aryl moiety RI by a single bond. Alternatively, said conjugating group Z may be linked to said aryl moiety Rl by a linking moiety having a relatively high degree of inflexibility and/or steric hindrance.
Said linking moiety may, for example, comprise a chain of fused or linked cycloalkyl and/or cycloaryl ring structures having a total molecular weight no greater than 1000gmo1-1. In particular, said linking moiety may comprise an anthracene, acridine, anthranil, naphthyl or naphthalene moiety, or a polyacetylene, phenylacetylene, or polyphenylacetylene moiety. When said chromophore is conjugated by said conjugating group Z to a polypeptide molecule, therefore, said linking moiety can serve to keep the photoactive core of said chromophore apart from said polypeptide, thereby helping to reduce the degree of fluorescence quenching which may be caused by said polypeptide when said chromophore is caused to fluoresce. Said linking moiety may include a hydrophilic or amphiphilic moiety of the kind described above, such as a C2-C3~
polyethylene glycol moiety. This will help to ensure that the hydrophilicity of the chromophore is not impaired by the presence of said linking moiety.
Optionally, said aryl moiety Rl may be further substituted by one or more hydrophilic substituents, such as hydroxy, which will serve to improve the hydrophilicity of said chromophore.
Said hydrophilic aryl moiety R2 may comprise a phenyl ring, which phenyl ring may be substituted one or more times, preferably at least two times, by one or more hydrophilic substituents which serve to increase the hydrophilicity of said aryl moiety R2.
Said phenyl ring may preferably be linked by a single bond to the macrocyclic core of said chromophore or may alternatively be linked thereto by a Ci-s branched or linear alkyl chain. Alternatively, said hydrophilic aryl moiety R2 may comprise a heteroaryl ring, such as a pyridyl or quaternised pyridyl (pyridiniumyl) ring, which heteroaryl ring may be substituted one or more times, preferably at least two times, by one or more hydrophilic substituents which serve to increase the hydrophilicity of said aryl moiety Rz.
Said heteroaryl ring may preferably be linked by a single bond to the macrocyclic core of said chromophore or may alternatively be linked thereto by a C1_s branched or linear alkyl chain. Said one or more hydrophilic substituents may advantageously be selected from hydroxy; alkoxy such as methoxy or ethoxy; CZ-C15 polyethylene glycol;
quatenised pyridyl (pyridiniumyl) such as N-methylpyridiniumyl; mono-, di- or poly-saccharide; Ci_ ~alkylsulfonatea phosphonium group R~P(RS)(R6)(R~), wherein R~ is a single bond or C1_G alkyl, and each of R5, R~ and R~ is independently selected from hydrogen, an aryl ring such as a phenyl ring, a heteroaryl ring such as a pyridyl ring, and a C1_6 alkyl chain, which aryl ring, heteroaryl ring or Ci_s alkyl chain is unsubstituted or is substituted one or more times by hydroxy, C1_~ alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group RgOP(O)(OR9)(ORI~) or RgP(O)(OR9)(ORI~) respectively, wherein Rg is a single bond or Cl_~ alkyl, and each of R9 and Rl~ is independently selected from hydrogen and C1_6 alkyl. Preferably, each of said R5, Rs and R~ may be the same, and may advantageously be unsubstituted phenyl. Suitably, said Rg may be methyl. Advantageously, said R9 and said Rl~ may be the same, and/or may be methyl or ethyl.
In especially preferred embodiments, said hydrophilic aryl moiety RZ is selected from m,m-(dihydroxy)phenyl HO OH
or a PEGylated derivative thereof; m,m,p-(trihydroxy)phenyl HO ~ OH
OH
or a PEGylated derivative thereof; o,p,o-(trihydroxy)phenyl HO ~ OH
OH
or a PEGylated derivative thereof; m- or p-((C1_ r)allcyltriphenylphosphonium)phenyl such as p-(methyltriphenylphosphonium)phenyl i PPh3 m- or p-(C1_6alkylphosphono-di-alkoxy)phenyl such as p-methylphosphono-di-ethoxy)phenyl O~ ~O
,P~
Et0 OEt m- or p-(C1_~alkylphosphonato-di-alkoxy)phenyl such as p-methylphosphonato-di-ethoxy)phenyl i ~P~
Et0 OEt m- or p-(N-methyl-pyridiniumyl)phenyl ( i w Me and meta- or para- sugar-substituted phenyl such as pentose-, hexose- or disaccharide-substituted phenyl OH OH
O
OH OH
In other preferred embodiments, said hydrophilic aryl moiety R2 comprises a quaternised pyridyl (pyridiniumyl) group such as a p-N-(C1_6alkyl)pyridiniumyl group or m-N-(C1_calkyl)pyridiniumyl group. Quaternised pyridyl (pyridiniumyl) groups are highly hydrophilic and display advantageous properties when incorporated into chromophores in accordance with the invention. Particularly preferred groups in this regard are m- or p-N-((C1_6)alkyl)pyridiniumyl, such as m-N-methylpyridiniumyl i N~
or p-N-methylpyridiniumyl ~+
In other especially preferred embodiments, said quaternised pyridiniumyl group may comprise a zwitterionic group, such as p-N-(C1_6alkylsulfonate)pyridiniumyl or m-N-(Cl_~alkylsulfonate)pyridiniumyl; in particular, p-N-(propylsulfonate)pyridiniumyl w N~S03 or m-N-(propylsulfonate)pyridiniumyl ~ N~\S03 Preferably, the or each quaternised pyridiniumyl group R2 may be associated with a halide counterion, such as an iodide counterion .or, in most preferred embodiments, a chloride counterion.
In some advantageous embodiments, R3 is H, such that said chromophore constitutes a S,15-diaryl-porphyrin, -chlorin or -bacteriochlorin. In other advantageous embodiments, said R3 is a hydrophilic aryl or non-aromatic moiety. For example, said R3 may comprise a hydrophilic aryl moiety as defined above in relation to R2.
Said hydrophilic aryl moiety R3 may be the same as said hydrophilic aryl moiety R2, such that the chromophore possesses the same substituents at the 10, 15 and 20 positions thereof;
or may be different from said hydrophilic aryl moiety R2. Alternatively, said R3 may comprise a hydrophilic alkyl moiety, such as a C1_6 alkyl chain which is substituted one or more times by one or more hydrophilic substituents such as hydroxy or Cz-is polyethylene glycol. In particularly preferred embodiments, said R3 comprises polyhydroxy(C1_6 alkyl), such as 1,2-dihydroxyethyl.
Chromophores in accordance with the invention wherein RZ is the same as R3 may be synthesised in accordance with methods known in the art, for example by acid catalysed condensation of benzaldehydes with pyrrole, or by means of the "MacDonald 2+3" method for synthesising porphyrins from dipyrromethanes (Arsenault et al, J.
Chen~. 'foc. 1960, 82:4384-4389 - incorporated herein by reference) .
A generalised scheme for the synthesis of 5-isothiocyanatophenyl-15-pyridinium porphyrins, chlorins and bacteriochlorins in accordance with the present invention is set out as Scheme 1 below, in which "RX" represents a quaternising group such as C1_6 alkyl or a hydrophilic substituent as defined above in relation to formulas (I) to (VII):
(i) OsQi/pyridine (ii) Hzs (i) osC7~/pyridine (ii) HzS
(i) Piperidine (i) Piperidine (i) Piperidine (ii) TDP (ii) TDP (ii) TDP
(iii) RX (iii) RX
(iii) RX
r r r R
R
Scheme 1 to A generalised scheme for the synthesis of .5-isothiocyanatophenyl-15-methylphosphoniumphenyl porphyrins, chlorins and bacteriochlorins in accordance with the present invention is set out as Scheme 2 below, wherein R represents hydrogen, C1-s alkyl, a heterocyclic group or an aromatic group (i) Os04/pyridine (ii) HAS (i) OsOqIpYridine (ii) H~.S
r- >
HO
(i) CBr~PPh3 (i) CBr4IPPh3 (i) CBrqIPPh3 (ii) PR3 ~ (ii) PR3 ~ (i7 PRg y (iii) TMSI (iii) TMSI (iii) TMSI
r"~ rno ~ (iv) TDP 1' (iv) TDP
rr~3 Scheme 2 HO
Porphyrin, chlorin and bacteriochlorin chromophores in accordance with the present invention wherein said R2 and optionally said R3 comprises pyridiniumylphenyl may be synthesised in accordance with the generalised reaction scheme set out below as Scheme 3, wherein "R" represents hydrogen or one or more hydrophilic substituents as defined above in relation to formulas (I) to (VII):
Scheme 3 Porphyrin, chlorin and bacteriochlorin chromophores in accordance with the present invention wherein said RZ and optionally said R3 comprise alkylphosphonatophenyl or alkylphosphonophenyl may be synthesised in accordance with the generalised reaction scheme set out below as Scheme 4, wherein "R"
represents OH, ONa, or O(C~_~ alkyl):
LiAIH4 Me COOMe 10~o~q~rrn3 (ii) P(OEt)3 (oi) NaOHaq or TMSBr (i) CIP(O)(OEt)Z
(ii) NaOHa9 Scheme 4 In a further aspect of the invention, there is provided a novel method for the synthesis of a 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore having selected substituents at the 5, 10, 15 and 20 meso-positions thereof;
comprising the steps of providing a 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore; attaching a leaving group Q to the 10 and 20 meso-positions of said chromophore, which leaving group Q is selected from halide and triflate;
providing a coupling reagent (R110)(R120)BR13, wherein Rn and R12 are independently selected from H or C1_6 alkyl, or Rll and R12 together constitute a C1_6 alkyl chain bridging said two O atoms, and R13 is vinyl or aryl, such as a hydrophilic aryl moiety as IJ
hereinbefore defined in relation to R3; and reacting said chromophore with said coupling reagent in the presence of a base selected from potassium phosphate, sodium phosphate, caesium carbonate and barium hydroxide, and a Pd~ catalyst; such that said R13 replaces said leaving group Q at the 10- and 20- meso positions of said chromophore.
Pdo-catalysed Suzuki coupling reactions using boronic acid or boronic ester reagents are known in the art, and are described for example in Miyaura &
Suzuki, Palladium-catalyzed cross-coupling reactions of organoboron compounds, Chern.
Rev.
( 1995) 95:2457-2483; the disclosure of which is incorporated herein by reference.
Hitherto, however, attempts to carry out Suzuki-coupling at the meso-positions of porphyrins, chlorins or bacteriochlorins, as a means of importing selected substituents onto said meso-positions, have failed. The present inventors have found however that under the reaction conditions of the invention, Suzuki-coupling proceeds rapidly and successfully at the 10- and 20- meso-positions of the starting porphyrin, chlorin or bacteriochlorin chromophore. This method thereby enables convenient synthesis of tetra-meso-substituted porphyrins, chlorins or bacteriochlorins by Suzuki-coupling.
Said leaving group Q may be chloride, bromide, iodide or triflate (trifluoromethanesulfonate). Suitably, said leaving group Q may be bromide.
Methods for the meso-bromination of di-meso-substituted porphrins, chlorins or bacteriochlorins are known in the art. For example, said 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may be halogenated at the 10- and 20- meso-positions thereof by way of reaction with halosuccinimide, such as bromosuccinimide.
Said coupling reagent may comprise a boronic ester or a boronic acid. In preferred embodiments, each of said Rl1 and R12 is H, such that said coupling reagent is a boronic acid.
Advantageously, said 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore is a chromophore in accordance with the invention, or a protected form thereof. Thus, said 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may be selected from a porphyrin chromophore of formula (VIII) below:
2 ~ ~ ~ ~ $ ,...
1/ N 21 22 H \ 9 .
\2 19 i N ~ 11 /16 / ~ 12 ( VIII) or a chlorin chromophore of any of formulas (IX), (X), (XI), and (XII) below:
K ,.4 X1 2 ~ ~ ~ $ 2 \ \~ ~ X2 1 N21 22H ,9 21 NH N-'s 19~ N24 N~ 110 1 ~ HN 11 18 ~ / ~ 12 / ~ 12 16 14 18 RS Rs SIX) (X) "4 ..4 1 N 21 22 H ~ $ , 1~ N H N - 9 s H 23 / 10 ~ 24 / 10 19 N24 N 11 19 i HN 11 14 12 X1 X2 16 / ~ 12 v 17 15 13 17 15~ 14 13 (~) 18 RS X2 (~I) X1 R5 or a bacteriochlorin chromophore of any of formulas (XIII) and (XIV) below:
IJ
Ra 1 ~ Ra 2 ~ ~~ ~ 8 X2 X1 _~ ~ ~ 8 1 ~ HN 11 19 N24 N 11 1s X4 17 16 / ~ 12 ~ ~ 12 )(3 5'RS 18 RS )(4 (XIII) (XIV) wherein R4 is a group Rl as defined above in relation to formulas (I) to (VII) or a protected form thereof or a group convertible thereto; R5 is a group Rz as defined above in relation to formulas (I) to (VII) or a protected form thereof or a group convertible thereto; and each of Xl, Xz, X3 and X4 is independently selected from H, OH, halogen, C1_~ alkyl and OC1_3 alkyl, or Xl and Xz and/or X3 and X4 together form a bridging moiety selected from 0, CHz, CH C1_3 alkyl, or C(C1_3 alkyl)z, such that Xl and Xz and/or X~ and X4 with the adjacent C-C bond form an epoxide or cyclopropanyl structure.
Accordingly, where R13 is a hydrophilic aryl substituent as defined above in relation to R3, said 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may also constitute a chromophore in accordance with the present invention.
Said Pd~ catalyst may, for example, comprise Pd(PPh3)4, PdClz(PPh3)z, or Pd(OAc)z. Advantageously, said Pd~ catalyst may comprise Pd(PPh3)4.
Said coupling reaction is performed in a solvent, which may be selected from toluene or dry THF. It is found that the coupling reaction proceeds swiftly in dry THF, and so dry THF is preferred as solvent.
Optionally, where said R13 is vinyl, said 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may be subjected following said coupling reaction to an osmylation reaction utilising Os04, such as to convert said 10-and 20- vinyl substituents to hydroxyalkyl. Said osmylation reaction may be carried out under conditions identical to those suitable for converting a porphyrin to a di-beta-hydroxy-chlorin and then to a tetra-beta-hydroxy-bacteriochlorin. It is noted that this step may be performed in accordance with the invention on 5,10(vinyl),15,20(vinyl)-meso-substituted porphyrin, chlorin or bacteriochlorin chromophores which are obtained otherwise than in accordance with the method of the invention, such as by way of Pd-catalysed Stifle coupling performed on said 5,15-di-meso-substituted chromophore in accordance with the method described in DiMagno et al, ,l. Ong. Chena.
1993:58, 5983-5993, (incorporated herein by reference) wherein vinyl tributyl tin is used as a coupling reagent.
Where said tetra-meso-substituted chromophore is a porphyrin or a chlorin' chromophore, said chromophore may be respectively converted to a chlorin or bacteriochlorin chromophore or to a bacteriochlorin chromophore in accordance with methods known to the man skilled in the art. For example, said porphyrin or chlorin chromophore may be osmylated by way of reaction with OsOd, such as to produce a di-beta-hydroxy-chlorin or a tetra-beta-hydroxy-bacteriochlorin.
Generalised schemes for reactions in accordance with the present invention are set out in Schemes 5 and 6 below. In Scheme 5, "R" and "Rl" each represents one or more hydrophilic substituents as defined above in relation to Rz and R3 respectively. In Scheme G, "R" represents one or more hydrophilic substituents as defined above in relation to RZ, and "X" represents a carbon or nitrogen atom.
(i) Pd(PPh3)a~IC3P04 R~
(ii) R~ \ / B(OH)2 R
R
Scheme 5 (i) OsO~/pyridine (3 ec OsO~/pyridine (4e~
HzS
HC (ii) HzS HC
R R R
(i) OsO~/pyridine (2eq) (i) piperidine ~ (ii) I-i~S ~ (i) piperidine (ii)TDP (iii) piperidine (ii)TDP
'I (iv)TDP
HC
HC
K R
Scheme 6 According to another aspect of the present invention, there is provided a 5,15-diphenylporphyrin, 5,15-diphenylchlorin or 5,15-diphenylbacteriochlorin chromophore, wherein each of the ortho-, meta-, and/or para- positions of each of the 5-and 15- phenyl groups is substituted by a substituent P1-PS and Q1-Q; respectively which is independently H or an inert substituent which in combination with the other substituents P1-P, and Q1-Q; does not substantially impair the fluorescent properties of the chromophore; and the chromophore further comprises a conjugating group Z which is capable of conjugating the chromophore to a polypeptide molecule for delivering said chromophore to a specific biological target in vitro or in vivo.
Such chromophores are novel, and are each capable on excitation of emitting fluorescent light at different and substantially non-overlapping wavelengths.
As indicated above, the provision of conjugating group Z enables a chromophore in accordance with the invention to be specifically targetted to a specific biological target, thus facilitating is control over the localisation of the chromophore in vitro or in vivo.
Chromophores in accordance with the invention may therefore be usefully employed in fluorescence analysis and imaging applications (including FACS), or in PDT.
Advantageously, said fluorochrome is selected from the following compounds:
pz p~ Pz \ p' pz pa a: \ Pa ( \ ~ ~ \
pt / Ps Pt / ps Pi / ps Pi / Ps X, \ \ Xz 2 ~ / / 2 3 \ 7 ~_ 8 ~ / 8 X1 ~ ~ 8 t\ NH N-s 7 1 N~1 zzN s 2 1 Nzi zzH s 1/ Nzi zzH s .t zz ~ \ z io ~ H ~ to io t N' HN ~~o is Nza HN it is Nza N 11 is/ N24 N._- 11 t8 ~ '16 /14 ~ 12 ~ ~16 /14 ~ 12 ~ 16\ 14 12 Xi /16 X14 ~ 12 17 15 13 17 15 13~ 17 15 13 t7 15 13 18 18 X2 18 di / ~ Qs Qi ~ ~ Qs Qt ~ ~ Qs Qt / ~ Qs Qz \ Ds Qz \ Qa Qz \ Qa Qz \ Qa ~7 Q7 Q3 ~.3 Pz \ P4 Pz \ Pa / P pt ~ / P
7 7 '1 2 \ \ ~ 8 X. 2 ~ \ \ a X2 i NH N- s 1 NH N
21 22 z zi 22 9 iD
tas N H N it is i4 H N ~ ~o is is X14 ~ iz X3 ~4 / .A iz 17 75 13 17 16 15 14 v Xi X3 Ot ~ ~ Ds 47 ~ ~ Qs qz Qa Llz Qa n3 q3 0., wherein each of X1, X2, X3 and X4 are as defined above in relation to the first aspect of the invention. Optionally, said chromophore may be further substituted at one or more of the 2, 3, 7, 8, 12, 13, 17 or 18 positions thereof by a Ci-3 alkyl substituent.
In the foregoing chemical structures, Z has been omitted for clarity. However, said Z substituent may be attached to any of the 1-4, 6-14, or 16-20 positions of each chromophore, or may be one of the substituents P1-Ps or Q1-Qs, or may be attached to one ofthe 5- or 15- phenyl groups through one of said substituents P1-P; or Q1-Qs.
1~
In some embodiments, each of Pl-P; is the same or substantially the same as the corresponding one of QI-Q;, such that said two primary phenyl rings are symmetrically substituted. In other embodiments, one or more of P1-P; is not the same as the corresponding one of Q1-Q;, such that said two primary phenyl rings are not symmetrically substituted. In particular, all of P1-P; and/or all of Q1-Q; may comprise H, such that one or both of said two primary phenyl rings is or are unsubstituted.
Advantageously, said substituents P1-PS and Q1-Q; collectively provide a degree of steric hindrance around the core of said chromophore which is sufficient to reduce the rate of spontaneous oxidation of said chromophore, such that said chromophore is substantially inert in air, but which does not to a substantial extent inhibit selective addition or substitution at the 2, 3, 7, 8, 12, 13, 17 or 18 positions around the core of said chromophore. Thus, each of PI, Ps, Q1 and Q; may be H. Typically, the total cumulative molecular weight of said substituents P1-P; does not exceed 1000gmol-1, and the total cumulative molecular weight of said substituents Q1-Q; does not exceed 1000gmofl.
One or more of said substituents P1-P; and Q1-Q; may comprise -OH, -CN, -NOz, halogen, -T or-OT, where T is a C1-C1; alkyl, cycloalkyl or aryl group or a hydroxylated, halogenated, sulphated or aminated derivative thereof or a carboxylic acid, ester, ether, polyether, amide, aldehyde or ketone derivative thereof. One or more of said substituents P1-P; and Ql-Q; may additionally or alternatively comprise a C3-Ciz cycloalkyl and/or aryl ring structures, or between two and six, preferably two - three, fused or linked C3-Clz cycloalkyl and/or aryl ring structures, each of which ring structures may optionally comprise one or more N, O or S atoms. In particular, one or more of said substituents P1-PS and Q1-Q; may comprise a quatenised amine or pyridyl group, such as an N-methyl pyridyl (pyridiniumyl) group.
Preferably, one of P1-P; and Q1-Q; is a conjugating substituent which comprises said conjugating group Z. In particularly preferred embodiments, said conjugating substituent is P3 or Q3, such that said conjugating group Z is provided on the para-position of one of the two primary phenyl rings.
Suitably, said conjugating group is as defined above in relation to the first aspect of the invention.
In particular, one or more of said substituents P1-PS and Q1-Q5, not being said conjugating substituent, may consist of a member independently selected from the group consisting of AlZlAla; wherein Zl is Z2, Z2A5 or Z2ASA6; Al and AS are independently selected from -(CA2A~)ri , -C(Y)(CA2A;)n-, -C(Y)Y'(CA2A;)ri , -C(Y)NA4(CA2A~)p , -NA4C(Y)(CA~A;)ri , -NAq.(CA2A;)n, -YC(Y')(CA2A~)ri and -Y(CA~A~)ri ; n = 0 - 6; Y and Y' are independently O or S; A2, A~ and Aq.
are independently H or Cl_2 alkyl which is unsubstituted or substituted by one or more tluorines; AG = - (C2H40)m or -S(O)p; m = 1 - 12; p = 0 - 2; Z2 is a single bond or Z~; Z~ is selected from Zq., ZS and Z6, wherein Z; is unsubstituted or substituted one or more times by OH, halo, CN, N02, AlAlO, A6Ag, NAlOAI l, C(Y)AN, C(Y)Y'A~, Y(CH?)qY'A~, Y(CH2)qA~, C(Y)NAlOAIl, Y(CH2)qC(Y')NAlOAI l~
Y(CH2)qC(Y')A~, NAIpC(Y)NAlOAI l, NAIOC(Y)Al l, NAIOC(Y)Y'A9, NAIOC(Y)Z~, C(NAlp)NAl0All. C~CN)NA10A11, C(NCN)SA9, NAIpC(NCN)SAc~, NAIOC(NCN)NAlOAI l, NAlOS(O)2Ag, S(O)rA9, NAl OC(Y)C(Y')NAlOAI 1, NAIOC(Y)C(Y')Al0 or Z6; q = 0, 1 or 2; r = 0 - 2; A~
is independently selected from H and A9; Ag is O or A9; A9 is Cl-4 alkyl which is unsubstituted or substituted by one or more fluorines; Al0 is OA9 or Al l; A11 is A~ or when Al0 and Al l are as NAlOAI 1 they may together with the nitrogen form a 5 to 7 membered ring comprising only carbon atoms or carbon atoms and at least one heteroatom selected from O, N and S; Z4 is C6_ 12 aryl or aryloxyC 1 _~alkyl;
ZS is selected from furanyl, tetrahydrofuranyl, indanyl, indenyl, tetrahydropyranyl, pyranyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, thienyl, C;_g cycloalkyl or Cq.-g cycloalkyl containing one or two unsaturated bonds, and C~_11 polycycloalkyl;
Z6 is selected from N-azolyl, dioxadiazinyl, dioxadiazolyl, dioxanyl, 2-N-dioxatriazinyl, dioxazinyl, N-dioxazolyl, dioxolyl, dithiadiazinyl, dithiadiazolyl, N-dithiatriazinyl, dithiazinyl, N-dithiazolyl, 1-N-imidazolyl, N-morpholinyl, pyrollyl, tetrazolyl, thiazolyl, triazolyl, oxazinyl, oxazolyl, naphthydrinyl, oxadiazinyl, oxadiazolyl, oxatetrazinyl, oxatriazinyl, oxatriazolyl, oxazinyl, oxazolyl, pentazinyl, phthalazinyl, N-piperidinyl, N,N-piperazinyl, 1-N-pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, tetrathiazinyl, tetrazinyl, 1-N-tetrazolyl, tetroxazinyl, thiadiazinyl, thiadiazoyl, thiatetrazinyl, thiatriazinyl, thiatriazolyl, thiazolyl, triazinyl, 1-N-triazolyl, trioxadazinyl, trioxanyl, trioxazinyl, trioxazolyl, trithiadiazinyl, trithiazinyl, trithiadiazolyl;
wherein Zq., ZS or Z6 may be fused to one or more other members selected independently from Zq., ZS
and Z6;
AI ~ is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyC l _;
alkyl, halo substituted aryloxyC 1_; alkyl, indanyl, indenyl, C~_ 11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C;-( cycloalkyl, or a C4_6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or a hydroxyl group.
Said conjugating substituent may consist of a member selected from the group consisting of A1Z1Z; wherein Z1 is Z2, Z2A5 or Z2ASA6; A1 and AS are independently selected from -(CA~A;)ri , -C(Y)(CA2A~)n-, -C(Y)Y'(CA2A~)ri , -C(Y)NA4(CA~Aj)ri , -NA4C(~')(CA2A3)ri , -NA4(CA2A;)n, -YC(Y')(CA2A3)ri and -Y(CA~A~)ri ; n = 0 - G; Y and Y' are independently O or S; A2, A3 and A4 are independently H or C1_2 alkyl which is unsubstituted or substituted by one or more fluorines; A~ _ - (C2H40)m or -S(O)p; m = 1 - 12; p = 0 - 2; Z2 is a single bond or Z~; Z~ is selected from Zq, ZS and Z6, wherein Z~ is unsubstituted or substituted one or more times by OH, halo, CN, NO2, AlAlO, A6Ag, NA10A11, C(Y)AN, C(Y)Y'A~, Y(CH~)~Y'A~, Y(CH2)qA~, C(Y)NA10A11, Y(CH2)~C(Y')NA10A11~
Y(CH~)~C(Y')Ag, NAIpC(Y)NA10A11, NAlpC(Y)A11, NAlpC(Y)Y'Ag, NAIOC(Y)Z6, C(NA10)NA10A11~ C~CN)NA10A11, C(NCN)SAg, NAIOC(NCN)SAg, NAIpC(NCN)NA10A11, NAIpS(O)2Ag, S(O)rAg, NAIpC(Y)C(Y')NA10A11, NAlpC(Y)C(Y')A10 or Z6; q = 0, 1 or 2; r = 0 - 2; A~ is independently selected from H and Ag; Ag is O or Ag; Ag is C1_q alkyl which is unsubstituted or substituted by one or more fluorines; A10 is OAg or Al 1; Al l is A~ or when A10 and A11 are as NAlOAI 1 they may together with the nitrogen form a 5 to 7 membered ring comprising only carbon atoms or carbon atoms and at least one heteroatom selected from O, N and S; Zq. is C6_12 aryl or aryloxyCl_3alkyl; ZS
is selected from furanyl, tetrahydrofuranyl, indanyl, indenyl, tetrahydropyranyl, pyranyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, thienyl, C;-g cycloalkyl or Cq._g cycloalkyl containing one or two unsaturated bonds, and C~_11 polycycloalkyl;
Z6 is selected from N-azolyl, dioxadiazinyl, dioxadiazolyl, dioxanyl, 2-N-dioxatriazinyl, dioxazinyl, N-dioxazolyl, dioxolyl, dithiadiazinyl, dithiadiazolyl, N-dithiatriazinyl, dithiazinyl, N-dithiazolyl, 1-N-imidazolyl, N-morpholinyl, pyrollyl, tetrazolyl, thiazolyl, triazolyl, oxazinyl, oxazolyl, naphthydrinyl, oxadiazinyl, oxadiazolyl, oxatetrazinyl, oxatriazinyl, oxatriazolyl, oxazinyl, oxazolyl, pentazinyl, phthalazinyl, N-piperidinyl, N,N-piperazinyl, 1-N-pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, tetrathiazinyl, tetrazinyl, 1-N-tetrazolyl, tetroxazinyl, thiadiazinyl, thiadiazoyl, thiatetrazinyl, thiatriazinyl, thiatriazolyl, thiazolyl, triazinyl, 1-N-triazolyl, trioxadazinyl, trioxanyl, trioxazinyl, trioxazolyl, trithiadiazinyl, trithiazinyl, trithiadiazolyl;
wherein Zq, ZS or Z6 may be fused to one or more other members selected independently from Z4, ZS
and Z6.
In particular embodiments of the present invention, said chromophore may comprise a chromophore having a structure set out as (x), (y) or (z) below:
OH
HO
fix) (Y) (z) wherein R and R' may be any of the following combinations:
R R' '~-IVIe 4-NCS
4-B r 4-NC S
4-CO~Me 4-NCS
3,4,5-tris(OMe)4-NCS
4-NC S 4-OMe 4-NC S 4-Me 4-NCS 4-C02Me 4-NCS 4-Br 4-NCS 4-COZMe In another embodiment of the present invention, said chromophore may comprise a porphyrin chromophore having the structure set out below:
s.
2 i yv 24 ~ 10 18 ~ ~ / ~ 12 16 Y 1q~
1~ 151 13 ~\
O~C~NCS
L- J ''P
wherein m = 0-G ; p = 0-15, preferably 0-5; or the corresponding chlorin or bacteriochlorin chromophore.
According to another aspect of the present invention, there is provided a set of fluorochromic markers for multicolour fluorochromic analysis, comprising at least two chromophores selected from the group consisting of a porphyrin chromophore, a chlorin chromophore and a bacteriochlorin chromophore, each of which chromophores comprises the same porphyrin skeleton, each of which chromophores comprises one or more substituents on said porphyrin skeleton, one of which substituents is a conjugating substituent L comprising a conjugating group Z, wherein Z is a conjugating group capable of conjugating each of said chromophores to a polypeptide molecule for delivering each chromophore to one of a plurality of different specific biological targets.
Preferably, each of the other of said substituents on the skeleton is independently H or an inert substituent R which together with said conjugating substituent L
and all of the other core substituents does not substantially impair the fluorescent properties of each chromophore.
It has been found that each of the chromophores in a set in accordance with the r~
present invention, on excitation, will emit fluorescent light at a different discrete wavelength. Thus, all of the chromophores within the set can be excited by a single laser, producing separate emission bands which can be substantially individually resolved.
Moreover, all of the chromophores provided in said set share substantially the same molecular structure, and will accordingly share substantially the same biochemical and physicochemical properties, including substantially the same degree of efficiency of bioconjugation to a biological target under given conditions. Accordingly, a set of chromophores in accordance with the present invention may be usefully employed in fluorescence analysis and sorting applications, including FACS, for the convenient sorting and analysis of several types of cells or other biological targets.
The components of such a set may, for example, be introduced to a mixture comprising one or more of said different specific biological targets, under conditions which will allow the delivery of each chromophore to its respective specific biological target; and said mixture may be exposed to light so as to cause said chromophores to fluoresce. A multicolour analysis may then be carried out for identifying the different emission bands produced by each chromophore, thereby permitting counting and visualisation of the location of each of the different biological targets.
Said set of chromophores may in particular comprise two or more of a porphyrin chromophore in accordance with any aspect of the present invention, the corresponding chlorin chromophore, and the corresponding bacteriochlorin chromophore. (By "corresponding" herein is meant having the same meso-substituents around the macrocyclic core of the molecule).
In a chromophore in accordance with the present invention, or in each member of a chromophore set in accordance with the present invention, said conjugating group Z
may be conjugated to a binding protein which is adapted to bind specifically to said biological target. Alternatively, said conjugating group Z may be conjugated to a bridging polypeptide which is adapted to bind to a complementary bridging polypeptide so as to couple said chromophore to said complementary bridging polypeptide.
In some embodiments, said bridging polypeptide may be bound to said complementary bridging polypeptide, and said complementary bridging polypeptide may comprise or be coupled to or fused with a binding protein which is adapted to bind specifically to said biological target. Accordingly, said chromophore may be covalently linked to said binding protein by means of said bridging polypeptide and said complementary bridging polypeptide.
According to another aspect of the present invention, there is provided a kit comprising a chromophore in accordance with the present invention or a set of chromophores in accordance with the present invention, wherein said chromophore or each chromophore is conjugated to a bridging polypeptide that is adapted to bind to a complementary bridging polypeptide so as to couple the chromophore to said complementary bridging polypeptide; and a construct or plurality of constructs each of which comprises said complementary bridging polypeptide fused or coupled to a binding protein which is adapted to bind specifically to said biological target; the arrangement being such that said chromophore or each chromophore in the kit is adapted to bind to a different construct in the kit with specificity for said specific biological target, so as to link said or each chromophore to a binding protein with specificity for said specific biological target.
Said binding protein may, for example, be an antibody such as a monoclonal or polyclonal antibody or a fragment thereof with specificity for a target specific molecule on the surface of said biological target. In particular, said antibody may be a phage antibody, that is an antibody expressed on the surface of a bacteriophage.
Alternatively said binding protein may be a protein which is adapted to bind to one or more cell surface molecules or receptors, such as a serum albumin protein. As yet a further alternative, said binding protein may comprise a low density lipoprotein, such as a fatty acid chain, which is adapted for insertion into a cell membrane. When conjugated to a chromophore, such a lipoprotein can serve to anchor the chromophore to a cell membrane.
Said bridging polypeptide may comprise calmodulin, and said complementary bridging polypeptide may comprise calmodulin binding peptide; or vice versa.
Preferably, however, said bridging polypeptide may comprise avidin or streptavidin, and said complementary bridging polypeptide may comprise biotin; or vice versa. In particular, said or each chromophore in a kit in accordance with the present invention may be conjugated to avidin, and said or each construct may comprise a biotinylated monoclonal antibody with specificity for a target specific molecule on the surface of said biological target. Accordingly, when said avidin-linked chromophore is allowed to bind said biotinylated antibody, said chromophore will become firmly linked to said antibody.
Conveniently, said or each biotinylated monoclonal antibody in the kit may be selected and/or readily substituted, so as to enable said or each chromophore to be delivered to any desired biological target. Methods for the preparation of monoclonal antibodies and for the biotinylation thereof are well known in the art.
According to another aspect of the present invention, there is provided a method for attaching a chromophore in accordance with the invention or a set of chromophores in accordance with the invention to said specific biological target or targets;
comprising the steps of providing a kit in accordance with the present invention, and introducing the components of said kit into the vicinity of said specific biological target or targets, under conditions suitable for enabling the binding of said or each binding protein to said specific biological target or targets. Advantageously, the components of said kit may be allowed to associate with one another prior to introduction to said target or targets, so as to enable the bridging polypeptide conjugated to said or each chromophore to bind to a complementary bridging polypeptide provided on one of said constructs in the kit. This will ensure that said or each chromophore in the kit is linked to a binding protein prior to introduction of said chromophore to said target or targets. Alternatively, the components of said kit may be introduced sequentially to said target or targets.
Typically, said specific biological target may be a cell or a membrane. Said specific biological target may be in vivo or in vitro (ex vivo). Said biological target may, for example, be a cancer cell, a tumour cell, a cell infected with HIV or with any other microbe or virus, a cell responsible for detrimental activity in auto-immune disease, a foreign or diseased cell, or any other such cell.
In some embodiments of the present invention, said biological target is a cell in vitro, and said target specific molecule comprises a molecule exposed on the surface of said cell, such as a polypeptide, carbohydrate, fatty acid, lipoprotein, phospholipid or other biological molecule. Preferably, said target specific molecule is specifically expressed by, or is over-expressed by, said cell. Said target specific molecule may, for example, be a T cell marker such as CD4 or CDB. Accordingly, when a chromophore in accordance with the present invention or a chromophore forming part of a set of chromophores in accordance with the present invention is attached to said cell, and said cell is illuminated so as to cause fluorescence of said chromophore, the fluorescence of the chromophore will enable said cell to be visualised and counted and/or sorted by FRCS.
According to a further aspect of the present invention, therefore, there is provided a method for fluorescence-activated sorting of target cells from a mixture of cells, comprising the step of attaching to said target cells a chromophore in accordance with the invention or a set of chromophores in accordance with the invention, illuminating said mixture of cells so as to cause fluorescence of one or more of said chromophores attached to said target cells, imparting a charge to the fluorescing cells, and passing said mixture of cells through a polarised environment so as to cause or allow said charged cells to be separated from said mixture.
According to another aspect of the present invention, there is provided a method for the visualisation and/or counting of a plurality of target cells, said target cells including cells of two or three different cell types, comprising the steps of providing a chromophore set in accordance with the present invention, which chromophore set comprises two or three chromophores each of which is adapted to be delivered to a different one of said cell types; attaching said chromophores in the set to said target cells in accordance with the method of the present invention; illuminating said target cells so as to cause the emission of fluorescence by said chromophores; detecting the fluorescent emission bands produced by each of said chromophores; and optionally measuring for each of said bands the area under an emission/wavelength curve, so as to obtain a measure of the number of fluorescent cells of each respective cell type.
In other embodiments of the present invention, said target cell is a cell in vivo, such as a cancer cell, tumour cell, or an infected, foreign or diseased cell, and said target specific molecule is a target cell specific molecule which is specifically expressed by, or is over-expressed by, or is attached to, and is exposed on, the surface of said target cell;
such as a target cell specific membrane protein. Accordingly, when a chromophore in accordance with the invention is delivered to said target specific molecule, said chromophore will be caused to be attached to said cell. If said cell is subsequently illuminated with light at a wavelength suitable for causing the excitation of said chromophore, said chromophore attached to said cell may be caused to be excited, and this may result in the production of singlet oxygen in the immediate vicinity of said cell, hence bringing about the death of the cell.
In especially preferred embodiments, said target cell specific molecule comprises an internalisation receptor on the surface of said cell, which internalisation receptor is capable of binding said binding protein and thereby mediating the internalisation of said chromophore within said cell. Accordingly, subsequent illumination of said cell with light at a wavelength suitable for causing excitation of said chromophore may result in the production of singlet oxygen within said cell, hence bringing about the death of said cell.
The present invention therefore comprehends a method for causing the death of a target cell, comprising the step of attaching a chromophore in accordance with the present invention to said cell and illuminating said cell so as to cause the production of singlet oxygen in the vicinity of said cell, thereby causing the death of the cell.
Preferably, said chromophore is attached to an internalisation receptor on the surface of said cell, which internalisation receptor is capable of mediating the internalisation of said chromophore within said cell, and said cell is thereafter illuminated such as to cause the production of ringlet oxygen within said cell, thereby causing the death of the cell.
Preferably, where said chromophore is adapted to be internalised within the cell, said chromophore comprises a cationic group such as a quatenised amine or pyridyl (pyridiniumyl) group, or a phosphonium group, so as to promote the intracellular accumulation of said chromophore around the mitochondria of the cell, owing to the net negative charge on the mitochondria) membrane. This will result in the rapid and efficient killing of the cell, on production of ringlet oxygen by decay of the chromophore.
In accordance with another aspect of the invention, there is provided a method for treating a disease or disorder which is characterised by the presence in the body of diseased or undesired cells, such as tumours, cancers, viral infections such as HIV
infection, or autoimmune disorders such as rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a patient in need thereof an effective amount of a chromophore in accordance with the invention, which chromophore is adapted to be targeted to a target cell specific molecule on the surface of said diseased or undesired cells for attachment thereto, such that the chromophore is caused to be attached to said cells, and illuminating said cells with light so as to cause the production of singlet oxygen in the vicinity of said cells, thereby killing said cells. Suitably, said target cell specific molecule comprises an internalisation receptor, and said chromophore is adapted to be internalised within said cells on delivery to said internalisation receptor, such as to enable the production of ringlet oxygen within said cells on illumination thereof.
Said chromophore may be administered topically or systemically to said patient.
For example, said chromophore may be administered by injection.
In accordance with yet another aspect of the invention, there is provided a pharmaceutical composition for administration to a patient for the treatment of a disease or disorder which is characterised by the presence in the body of diseased or undesired cells, such as tumours, cancers, viral infections such as HIV infection, or autoimmune disorders such as rheumatoid arthritis or multiple sclerosis, which composition comprises a chromophore in accordance with the present invention that is adapted to be delivered to said diseased or undesired cells, and a suitable carrier.
Yet another aspect of the invention envisages a chromophore in accordance with the invention for use in the production of a medicament, for use in the treatment of patients suffering from a disease or disorder which is characterised by the presence in the body of diseased or undesirable cells, such as tumours, cancers, viral infections including HIV infection, and autoimmune disorders including rheumatoid arthritis or multiple sclerosis; said chromophore being adapted for delivery to said diseased or undesired cells.
Detailed Description of Examples of the Invention Following are descriptions and examples, by way of illustration only, of embodiments of the invention and methods for putting the invention into effect.
Synthesis of Chromophores Instrumentation and materials Melting points are uncorrected. IH/I3C NMR spectra were recorded on Jeol JNM
FT-NMR spectrometer, and are referenced to tetramethylsilane unless otherwise stated.
LR. spectra were obtained using a series 1600 FT-LR and nominal mass spectra were obtained by Kratos Kompact MALDI II spectrometer. Accurate mass were obtained from EPSRC Mass Spectrometry Service, Swansea. The electronic spectra were obtained using Unicam UV-2 or UV-4 spectrometers and were taken in DCM unless otherwise stated.
All reagents and solvents were commercially available and of reagent grade or higher, and were, unless otherwise specified, used as received. TLC analysis were performed on Merck silica-gel 60 plates (F254, 500 p.m thickness). Merck Silica-Gel 60 (230-mesh) was used for flash chromatographic purification.
Descriptions (1) 5-(4-Acetamidophenyl)-10,15,20-tris(3,S-dimethoxyphenyl)porphyrin M Me M~ Me 4-Acetamidobenzaldehyde (3.36 g, 0.02 mol) and 3,5-dimethoxybenzaldehyde (10 mL, 0.06 mol) were stirred in propionic acid (300 mL) at 90 °C. Pyrrole (5.5 mL, 0.08 mol) was added and the mixture stirred under reflux for 30 min. Upon cooling the reaction mixture was evaporated itz vaczco to yield a dark purple solid. The crude mixture of porphyrin isomers was purified by flash chromatography (silica, eluent:
CHZC12/EtOAc, 4:1 ). Relevant fractions were combined, dried (NazS04) and evaporated itz vacuo to yield 1 as a purple solid (1.55 g, 9.1%); Rf= 0.50 (silica, CHZC12/EtOAc, 4:1); mp >350 °C
decomp.; IH NMR [270 MHz, CDCl3] ~-2.96 (2H, br s, NH), 2.23 (3H, s, NHCOCH3), 3.93 ( 18H, s, 3, 5-OCH3), 6.99 (3H, s, 10, 15, 20-Ar-4-H), 7.07 (2H, m, .I* =
8 Hz, 5-Ar-3,5-H), 7.38 (6H, s, 10, 15, 20-Ar-2,6-H), 7.44 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.86-8.93 (8H, m, (3-H), 10.42 (1H, br s, NHCOCH3); isC NMR [67.5 MHz, CDCl3] &20.4, 23.9, 103.9, 113.5, 117.3, 119, 119.4, 119.6, 120, 129, 131.1, 131.3, 131.4, 131.8, 134.5, 135.6, 136.8, 139.3, 143.1, 158.6, 160.3, 167.9, 168.7; UV-vis (CHZC12) ~,m;"; 421, 515, 551, 590, 650 nm; MS (MALDI-TOF) oz/z 852 (M+, 100%).
ivicv UWC
(2) 5-(4-Aminophenyl)-10,15,20-tris(3,5-dimethoxyphenyl)porphyrin Me Me Porphyrin 1 (500 mg, 0.587 mmol) was dissolved in 18% HCl (100 mL) and the solution heated for 2 hours under reflux. Upon cooling the reaction mixture was evaporated in vaczro to yield a crude green solid. The solid was redissolved in a 9:1 mixture of dichloromethane/triethylamine (200 mL) and stirred for 10 min at room temperature.
The solution was then washed with water (3 x 200 mL) and brine (200 mL), the organic layer separated and dried (Na2S04). Excess solvent was evaporated in vacuo and the crude purple solid purified by flash chromatography (silica, eluent:
CHZC12/EtOAc, 4:1).
Relevant fractions were combined, dried (NaZS04) and evaporated i» vacuo to yield 2 as a purple solid (426 mg, 89.7%); Rf = 0.89 (silica, CHZCI2BtOAc, 4:1); mp >350 °C
decamp.; 1H NMR [270 MHz, CDCl3] 8-2.80 (2H, br s, NH), 3.96 (18H, s, 3, 5-OCH3), 6.90 (3H, s, 10, 15, 20-Ar-4-H), 7.06 (2H, m, J* = 8 Hz, 5-Ar-3,5-H), 7.40 (6H, s, 10, 15, 20-Ar-2,6-H), 7.98 (2H, m, .l* = 8 Hz, S-Ar-2,6-H), 8.93 (8H, m, ~3-H); 13C
NMR [67.5 MHz, CDC13] 8 20.13, 100.6, 113.9, 114.3, 115.7, 119.8, 120.1, 121.4, 130.2, 131.4, 132.7, 136.1, 144.5, 144.6, 146.5, 159.3; UV-vis (CHZCl2) ~,m;,x 422, 517, 553, 593, 651 nm; MS (MALDI-TOF) »a/z 809 (M+, 100%).
rnCV Vlyle (3) ~-(4-Aminophenyl)-10,15,20-tris(3,5-dihydroxyphenyl)porphyrin To a stirred solution of 2 (1 g, 1.23 mmol) in freshly distilled chloroform (50 mL) was added boron tribromide (1.17 mL, 0.012 mol). The reaction was allowed to proceed under argon for 17 hours at room temperature. The reaction was subsequently cooled to 0 °C, water (20 mL) added and the solution stirred for a further 60 min. The reaction was evaporated to dryness in nacuo and redissolved in a 9:1 mixture of chloroform/triethylamine (S00 mL). The solution was washed with water (3 x 500 mL) and brine (500 mL), the organic layer separated, dried (Na2S0~), and evaporated in vacuo to yield a crude purple solid. The crude solid was purified by flash chromatography (silica. eluent: CHC13/MeOH, 9:1). Relevant fractions were combined, dried (Na2S04) and evaporated ire oacuo to yield 3 as a purple solid (667 mg, 74.5%); Rf=
0.19 (silica, CHCI~/MeOH, 9:1); mp >350 °C decomp.; 'H NMR [270 MHz, (CD3)ZSO] 8-2.95 (2H, br s, NH), 5.56 (2H, br s, NHZ), 6.69 (3H, s, 10, 15, 20-Ar-4-H), 7.02 (2H, m, .I* = 8 Hz,
is optionally further substituted one or more times by -OH, -CN, -NO2, halogen, -T or -OT, where T is a Cl-CI; alkyl, cycloalkyl or aryl group or a hydroxylated, halogenated, sulphated, sulphonated or aminated derivative thereof or a carboxylic acid, ester, ether, polyether, amide, aldehyde or ketone derivative thereof.
It has been found that the inclusion of one or more hydrophilic substituents around the core of a chromophore in accordance with the invention results in enhanced solubility in basic buffer/DMSO or DMF co-solutions which are commonly used in protein bioconjugation. Increased hydrophilicity also produces a marked reduction in the tendency of the chromophore to bind non-covalently to proteins. Where the chromophore is to be conjugated to a targeting protein such as a monoclonal antibody for delivery to specific cells or tissues, for example for the purposes of PDT or FACS, a decrease in non-covalent binding between the chromophore and the protein will reduce the degree of non-specific transfer of chromophore to cell surfaces, which will substantially increase the accuracy of targeting the chromophore to the cells or tissue of interest.
Accordingly, according to yet another aspect of the present invention there is provided a method for separating a mixture which comprises one or more hydrophilic chromophores each having a hydrophilic or amphiphilic moiety, and a plurality of less hydrophilic substances and/or molecules, comprising the step of introducing said mixture to a hydrophobic eluting solvent, and passing said mixture and said eluting solvent over a hydrophilic or polar solid phase, such that said one or more chromophores are arrested on said solid phase whilst said substances and/or molecules are eluted or substantially eluted from said solid phase by said eluting solvent.
Said method may, for example, comprise chromatography on a Sephadex~ (dextran) column, or reverse-phase HPLC. Typically, said mixture of less hydrophilic substances and/or molecules may comprise a mixture of cells and/or membranes. Advantageously, said one or more hydrophilic chromophores include one or more chromophores in accordance with the present invention.
In some embodiments, each or some of Xi- X~ is H. In particularly preferred embodiments, however, each of Xl - X4 is OH. Accordingly, said chromophore may be a dihydroxychlorin of formula (II), (III), (IV) or (~ above or a tetrahydroxybacteriochlorin of formula (VI) or (VII) above. The hydrophilicity of dihydroxychlorins and tetrahydroxybacteriochlorins is found to be greater than that of the corresponding porphyrins, owing to the presence of extra hydrophilic hydroxy groups around the core of the chromophore.
Preferably, said aryl moiety Rl may comprise a phenyl ring, which phenyl ring may preferably be linked by a single bond to the macrocyclic core of said chromophore or may alternatively be linked thereto by a C1.6 branched or linear alkyl chain.
Advantageously, said conjugating group Z may be linked to said phenyl ring at the para (4') position thereof.
Said conjugating group Z may comprise a group which is capable of bonding covalently to an amine group on a polypeptide molecule; such as an isocyanate, isothiocyanate, or NHS ester group. Advantageously, therefore, each of the meso substituents around said porphyrin, chlorin or bacteriochlorin should comprise no NH-, NH~, -NHZ+- or -NH3+ groups which could become covalently bonded to said conjugating group Z. This will serve to reduce the probability of internal crass-linkage within said chromophore. Said conjugating group Z may alternatively comprise any other protein conjugating group, such as -NH2, -NH(Cl-s alkyl), maleamide, iodoacetamide, ketone or aldehyde. Methods for achieving the conjugation of such groups to protein molecules are known in the art.
In especially preferred embodiments, said conjugating group Z comprises an isothiocyanato group. Isothiocyanates react readily with lysine residues to produce a stable linkage to proteins, and hence are particularly suitable for bioconjugation of chromophores in accordance with the invention.
Said conjugating group Z may be linked directly to said aryl moiety RI by a single bond. Alternatively, said conjugating group Z may be linked to said aryl moiety Rl by a linking moiety having a relatively high degree of inflexibility and/or steric hindrance.
Said linking moiety may, for example, comprise a chain of fused or linked cycloalkyl and/or cycloaryl ring structures having a total molecular weight no greater than 1000gmo1-1. In particular, said linking moiety may comprise an anthracene, acridine, anthranil, naphthyl or naphthalene moiety, or a polyacetylene, phenylacetylene, or polyphenylacetylene moiety. When said chromophore is conjugated by said conjugating group Z to a polypeptide molecule, therefore, said linking moiety can serve to keep the photoactive core of said chromophore apart from said polypeptide, thereby helping to reduce the degree of fluorescence quenching which may be caused by said polypeptide when said chromophore is caused to fluoresce. Said linking moiety may include a hydrophilic or amphiphilic moiety of the kind described above, such as a C2-C3~
polyethylene glycol moiety. This will help to ensure that the hydrophilicity of the chromophore is not impaired by the presence of said linking moiety.
Optionally, said aryl moiety Rl may be further substituted by one or more hydrophilic substituents, such as hydroxy, which will serve to improve the hydrophilicity of said chromophore.
Said hydrophilic aryl moiety R2 may comprise a phenyl ring, which phenyl ring may be substituted one or more times, preferably at least two times, by one or more hydrophilic substituents which serve to increase the hydrophilicity of said aryl moiety R2.
Said phenyl ring may preferably be linked by a single bond to the macrocyclic core of said chromophore or may alternatively be linked thereto by a Ci-s branched or linear alkyl chain. Alternatively, said hydrophilic aryl moiety R2 may comprise a heteroaryl ring, such as a pyridyl or quaternised pyridyl (pyridiniumyl) ring, which heteroaryl ring may be substituted one or more times, preferably at least two times, by one or more hydrophilic substituents which serve to increase the hydrophilicity of said aryl moiety Rz.
Said heteroaryl ring may preferably be linked by a single bond to the macrocyclic core of said chromophore or may alternatively be linked thereto by a C1_s branched or linear alkyl chain. Said one or more hydrophilic substituents may advantageously be selected from hydroxy; alkoxy such as methoxy or ethoxy; CZ-C15 polyethylene glycol;
quatenised pyridyl (pyridiniumyl) such as N-methylpyridiniumyl; mono-, di- or poly-saccharide; Ci_ ~alkylsulfonatea phosphonium group R~P(RS)(R6)(R~), wherein R~ is a single bond or C1_G alkyl, and each of R5, R~ and R~ is independently selected from hydrogen, an aryl ring such as a phenyl ring, a heteroaryl ring such as a pyridyl ring, and a C1_6 alkyl chain, which aryl ring, heteroaryl ring or Ci_s alkyl chain is unsubstituted or is substituted one or more times by hydroxy, C1_~ alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group RgOP(O)(OR9)(ORI~) or RgP(O)(OR9)(ORI~) respectively, wherein Rg is a single bond or Cl_~ alkyl, and each of R9 and Rl~ is independently selected from hydrogen and C1_6 alkyl. Preferably, each of said R5, Rs and R~ may be the same, and may advantageously be unsubstituted phenyl. Suitably, said Rg may be methyl. Advantageously, said R9 and said Rl~ may be the same, and/or may be methyl or ethyl.
In especially preferred embodiments, said hydrophilic aryl moiety RZ is selected from m,m-(dihydroxy)phenyl HO OH
or a PEGylated derivative thereof; m,m,p-(trihydroxy)phenyl HO ~ OH
OH
or a PEGylated derivative thereof; o,p,o-(trihydroxy)phenyl HO ~ OH
OH
or a PEGylated derivative thereof; m- or p-((C1_ r)allcyltriphenylphosphonium)phenyl such as p-(methyltriphenylphosphonium)phenyl i PPh3 m- or p-(C1_6alkylphosphono-di-alkoxy)phenyl such as p-methylphosphono-di-ethoxy)phenyl O~ ~O
,P~
Et0 OEt m- or p-(C1_~alkylphosphonato-di-alkoxy)phenyl such as p-methylphosphonato-di-ethoxy)phenyl i ~P~
Et0 OEt m- or p-(N-methyl-pyridiniumyl)phenyl ( i w Me and meta- or para- sugar-substituted phenyl such as pentose-, hexose- or disaccharide-substituted phenyl OH OH
O
OH OH
In other preferred embodiments, said hydrophilic aryl moiety R2 comprises a quaternised pyridyl (pyridiniumyl) group such as a p-N-(C1_6alkyl)pyridiniumyl group or m-N-(C1_calkyl)pyridiniumyl group. Quaternised pyridyl (pyridiniumyl) groups are highly hydrophilic and display advantageous properties when incorporated into chromophores in accordance with the invention. Particularly preferred groups in this regard are m- or p-N-((C1_6)alkyl)pyridiniumyl, such as m-N-methylpyridiniumyl i N~
or p-N-methylpyridiniumyl ~+
In other especially preferred embodiments, said quaternised pyridiniumyl group may comprise a zwitterionic group, such as p-N-(C1_6alkylsulfonate)pyridiniumyl or m-N-(Cl_~alkylsulfonate)pyridiniumyl; in particular, p-N-(propylsulfonate)pyridiniumyl w N~S03 or m-N-(propylsulfonate)pyridiniumyl ~ N~\S03 Preferably, the or each quaternised pyridiniumyl group R2 may be associated with a halide counterion, such as an iodide counterion .or, in most preferred embodiments, a chloride counterion.
In some advantageous embodiments, R3 is H, such that said chromophore constitutes a S,15-diaryl-porphyrin, -chlorin or -bacteriochlorin. In other advantageous embodiments, said R3 is a hydrophilic aryl or non-aromatic moiety. For example, said R3 may comprise a hydrophilic aryl moiety as defined above in relation to R2.
Said hydrophilic aryl moiety R3 may be the same as said hydrophilic aryl moiety R2, such that the chromophore possesses the same substituents at the 10, 15 and 20 positions thereof;
or may be different from said hydrophilic aryl moiety R2. Alternatively, said R3 may comprise a hydrophilic alkyl moiety, such as a C1_6 alkyl chain which is substituted one or more times by one or more hydrophilic substituents such as hydroxy or Cz-is polyethylene glycol. In particularly preferred embodiments, said R3 comprises polyhydroxy(C1_6 alkyl), such as 1,2-dihydroxyethyl.
Chromophores in accordance with the invention wherein RZ is the same as R3 may be synthesised in accordance with methods known in the art, for example by acid catalysed condensation of benzaldehydes with pyrrole, or by means of the "MacDonald 2+3" method for synthesising porphyrins from dipyrromethanes (Arsenault et al, J.
Chen~. 'foc. 1960, 82:4384-4389 - incorporated herein by reference) .
A generalised scheme for the synthesis of 5-isothiocyanatophenyl-15-pyridinium porphyrins, chlorins and bacteriochlorins in accordance with the present invention is set out as Scheme 1 below, in which "RX" represents a quaternising group such as C1_6 alkyl or a hydrophilic substituent as defined above in relation to formulas (I) to (VII):
(i) OsQi/pyridine (ii) Hzs (i) osC7~/pyridine (ii) HzS
(i) Piperidine (i) Piperidine (i) Piperidine (ii) TDP (ii) TDP (ii) TDP
(iii) RX (iii) RX
(iii) RX
r r r R
R
Scheme 1 to A generalised scheme for the synthesis of .5-isothiocyanatophenyl-15-methylphosphoniumphenyl porphyrins, chlorins and bacteriochlorins in accordance with the present invention is set out as Scheme 2 below, wherein R represents hydrogen, C1-s alkyl, a heterocyclic group or an aromatic group (i) Os04/pyridine (ii) HAS (i) OsOqIpYridine (ii) H~.S
r- >
HO
(i) CBr~PPh3 (i) CBr4IPPh3 (i) CBrqIPPh3 (ii) PR3 ~ (ii) PR3 ~ (i7 PRg y (iii) TMSI (iii) TMSI (iii) TMSI
r"~ rno ~ (iv) TDP 1' (iv) TDP
rr~3 Scheme 2 HO
Porphyrin, chlorin and bacteriochlorin chromophores in accordance with the present invention wherein said R2 and optionally said R3 comprises pyridiniumylphenyl may be synthesised in accordance with the generalised reaction scheme set out below as Scheme 3, wherein "R" represents hydrogen or one or more hydrophilic substituents as defined above in relation to formulas (I) to (VII):
Scheme 3 Porphyrin, chlorin and bacteriochlorin chromophores in accordance with the present invention wherein said RZ and optionally said R3 comprise alkylphosphonatophenyl or alkylphosphonophenyl may be synthesised in accordance with the generalised reaction scheme set out below as Scheme 4, wherein "R"
represents OH, ONa, or O(C~_~ alkyl):
LiAIH4 Me COOMe 10~o~q~rrn3 (ii) P(OEt)3 (oi) NaOHaq or TMSBr (i) CIP(O)(OEt)Z
(ii) NaOHa9 Scheme 4 In a further aspect of the invention, there is provided a novel method for the synthesis of a 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore having selected substituents at the 5, 10, 15 and 20 meso-positions thereof;
comprising the steps of providing a 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore; attaching a leaving group Q to the 10 and 20 meso-positions of said chromophore, which leaving group Q is selected from halide and triflate;
providing a coupling reagent (R110)(R120)BR13, wherein Rn and R12 are independently selected from H or C1_6 alkyl, or Rll and R12 together constitute a C1_6 alkyl chain bridging said two O atoms, and R13 is vinyl or aryl, such as a hydrophilic aryl moiety as IJ
hereinbefore defined in relation to R3; and reacting said chromophore with said coupling reagent in the presence of a base selected from potassium phosphate, sodium phosphate, caesium carbonate and barium hydroxide, and a Pd~ catalyst; such that said R13 replaces said leaving group Q at the 10- and 20- meso positions of said chromophore.
Pdo-catalysed Suzuki coupling reactions using boronic acid or boronic ester reagents are known in the art, and are described for example in Miyaura &
Suzuki, Palladium-catalyzed cross-coupling reactions of organoboron compounds, Chern.
Rev.
( 1995) 95:2457-2483; the disclosure of which is incorporated herein by reference.
Hitherto, however, attempts to carry out Suzuki-coupling at the meso-positions of porphyrins, chlorins or bacteriochlorins, as a means of importing selected substituents onto said meso-positions, have failed. The present inventors have found however that under the reaction conditions of the invention, Suzuki-coupling proceeds rapidly and successfully at the 10- and 20- meso-positions of the starting porphyrin, chlorin or bacteriochlorin chromophore. This method thereby enables convenient synthesis of tetra-meso-substituted porphyrins, chlorins or bacteriochlorins by Suzuki-coupling.
Said leaving group Q may be chloride, bromide, iodide or triflate (trifluoromethanesulfonate). Suitably, said leaving group Q may be bromide.
Methods for the meso-bromination of di-meso-substituted porphrins, chlorins or bacteriochlorins are known in the art. For example, said 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may be halogenated at the 10- and 20- meso-positions thereof by way of reaction with halosuccinimide, such as bromosuccinimide.
Said coupling reagent may comprise a boronic ester or a boronic acid. In preferred embodiments, each of said Rl1 and R12 is H, such that said coupling reagent is a boronic acid.
Advantageously, said 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore is a chromophore in accordance with the invention, or a protected form thereof. Thus, said 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may be selected from a porphyrin chromophore of formula (VIII) below:
2 ~ ~ ~ ~ $ ,...
1/ N 21 22 H \ 9 .
\2 19 i N ~ 11 /16 / ~ 12 ( VIII) or a chlorin chromophore of any of formulas (IX), (X), (XI), and (XII) below:
K ,.4 X1 2 ~ ~ ~ $ 2 \ \~ ~ X2 1 N21 22H ,9 21 NH N-'s 19~ N24 N~ 110 1 ~ HN 11 18 ~ / ~ 12 / ~ 12 16 14 18 RS Rs SIX) (X) "4 ..4 1 N 21 22 H ~ $ , 1~ N H N - 9 s H 23 / 10 ~ 24 / 10 19 N24 N 11 19 i HN 11 14 12 X1 X2 16 / ~ 12 v 17 15 13 17 15~ 14 13 (~) 18 RS X2 (~I) X1 R5 or a bacteriochlorin chromophore of any of formulas (XIII) and (XIV) below:
IJ
Ra 1 ~ Ra 2 ~ ~~ ~ 8 X2 X1 _~ ~ ~ 8 1 ~ HN 11 19 N24 N 11 1s X4 17 16 / ~ 12 ~ ~ 12 )(3 5'RS 18 RS )(4 (XIII) (XIV) wherein R4 is a group Rl as defined above in relation to formulas (I) to (VII) or a protected form thereof or a group convertible thereto; R5 is a group Rz as defined above in relation to formulas (I) to (VII) or a protected form thereof or a group convertible thereto; and each of Xl, Xz, X3 and X4 is independently selected from H, OH, halogen, C1_~ alkyl and OC1_3 alkyl, or Xl and Xz and/or X3 and X4 together form a bridging moiety selected from 0, CHz, CH C1_3 alkyl, or C(C1_3 alkyl)z, such that Xl and Xz and/or X~ and X4 with the adjacent C-C bond form an epoxide or cyclopropanyl structure.
Accordingly, where R13 is a hydrophilic aryl substituent as defined above in relation to R3, said 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may also constitute a chromophore in accordance with the present invention.
Said Pd~ catalyst may, for example, comprise Pd(PPh3)4, PdClz(PPh3)z, or Pd(OAc)z. Advantageously, said Pd~ catalyst may comprise Pd(PPh3)4.
Said coupling reaction is performed in a solvent, which may be selected from toluene or dry THF. It is found that the coupling reaction proceeds swiftly in dry THF, and so dry THF is preferred as solvent.
Optionally, where said R13 is vinyl, said 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore may be subjected following said coupling reaction to an osmylation reaction utilising Os04, such as to convert said 10-and 20- vinyl substituents to hydroxyalkyl. Said osmylation reaction may be carried out under conditions identical to those suitable for converting a porphyrin to a di-beta-hydroxy-chlorin and then to a tetra-beta-hydroxy-bacteriochlorin. It is noted that this step may be performed in accordance with the invention on 5,10(vinyl),15,20(vinyl)-meso-substituted porphyrin, chlorin or bacteriochlorin chromophores which are obtained otherwise than in accordance with the method of the invention, such as by way of Pd-catalysed Stifle coupling performed on said 5,15-di-meso-substituted chromophore in accordance with the method described in DiMagno et al, ,l. Ong. Chena.
1993:58, 5983-5993, (incorporated herein by reference) wherein vinyl tributyl tin is used as a coupling reagent.
Where said tetra-meso-substituted chromophore is a porphyrin or a chlorin' chromophore, said chromophore may be respectively converted to a chlorin or bacteriochlorin chromophore or to a bacteriochlorin chromophore in accordance with methods known to the man skilled in the art. For example, said porphyrin or chlorin chromophore may be osmylated by way of reaction with OsOd, such as to produce a di-beta-hydroxy-chlorin or a tetra-beta-hydroxy-bacteriochlorin.
Generalised schemes for reactions in accordance with the present invention are set out in Schemes 5 and 6 below. In Scheme 5, "R" and "Rl" each represents one or more hydrophilic substituents as defined above in relation to Rz and R3 respectively. In Scheme G, "R" represents one or more hydrophilic substituents as defined above in relation to RZ, and "X" represents a carbon or nitrogen atom.
(i) Pd(PPh3)a~IC3P04 R~
(ii) R~ \ / B(OH)2 R
R
Scheme 5 (i) OsO~/pyridine (3 ec OsO~/pyridine (4e~
HzS
HC (ii) HzS HC
R R R
(i) OsO~/pyridine (2eq) (i) piperidine ~ (ii) I-i~S ~ (i) piperidine (ii)TDP (iii) piperidine (ii)TDP
'I (iv)TDP
HC
HC
K R
Scheme 6 According to another aspect of the present invention, there is provided a 5,15-diphenylporphyrin, 5,15-diphenylchlorin or 5,15-diphenylbacteriochlorin chromophore, wherein each of the ortho-, meta-, and/or para- positions of each of the 5-and 15- phenyl groups is substituted by a substituent P1-PS and Q1-Q; respectively which is independently H or an inert substituent which in combination with the other substituents P1-P, and Q1-Q; does not substantially impair the fluorescent properties of the chromophore; and the chromophore further comprises a conjugating group Z which is capable of conjugating the chromophore to a polypeptide molecule for delivering said chromophore to a specific biological target in vitro or in vivo.
Such chromophores are novel, and are each capable on excitation of emitting fluorescent light at different and substantially non-overlapping wavelengths.
As indicated above, the provision of conjugating group Z enables a chromophore in accordance with the invention to be specifically targetted to a specific biological target, thus facilitating is control over the localisation of the chromophore in vitro or in vivo.
Chromophores in accordance with the invention may therefore be usefully employed in fluorescence analysis and imaging applications (including FACS), or in PDT.
Advantageously, said fluorochrome is selected from the following compounds:
pz p~ Pz \ p' pz pa a: \ Pa ( \ ~ ~ \
pt / Ps Pt / ps Pi / ps Pi / Ps X, \ \ Xz 2 ~ / / 2 3 \ 7 ~_ 8 ~ / 8 X1 ~ ~ 8 t\ NH N-s 7 1 N~1 zzN s 2 1 Nzi zzH s 1/ Nzi zzH s .t zz ~ \ z io ~ H ~ to io t N' HN ~~o is Nza HN it is Nza N 11 is/ N24 N._- 11 t8 ~ '16 /14 ~ 12 ~ ~16 /14 ~ 12 ~ 16\ 14 12 Xi /16 X14 ~ 12 17 15 13 17 15 13~ 17 15 13 t7 15 13 18 18 X2 18 di / ~ Qs Qi ~ ~ Qs Qt ~ ~ Qs Qt / ~ Qs Qz \ Ds Qz \ Qa Qz \ Qa Qz \ Qa ~7 Q7 Q3 ~.3 Pz \ P4 Pz \ Pa / P pt ~ / P
7 7 '1 2 \ \ ~ 8 X. 2 ~ \ \ a X2 i NH N- s 1 NH N
21 22 z zi 22 9 iD
tas N H N it is i4 H N ~ ~o is is X14 ~ iz X3 ~4 / .A iz 17 75 13 17 16 15 14 v Xi X3 Ot ~ ~ Ds 47 ~ ~ Qs qz Qa Llz Qa n3 q3 0., wherein each of X1, X2, X3 and X4 are as defined above in relation to the first aspect of the invention. Optionally, said chromophore may be further substituted at one or more of the 2, 3, 7, 8, 12, 13, 17 or 18 positions thereof by a Ci-3 alkyl substituent.
In the foregoing chemical structures, Z has been omitted for clarity. However, said Z substituent may be attached to any of the 1-4, 6-14, or 16-20 positions of each chromophore, or may be one of the substituents P1-Ps or Q1-Qs, or may be attached to one ofthe 5- or 15- phenyl groups through one of said substituents P1-P; or Q1-Qs.
1~
In some embodiments, each of Pl-P; is the same or substantially the same as the corresponding one of QI-Q;, such that said two primary phenyl rings are symmetrically substituted. In other embodiments, one or more of P1-P; is not the same as the corresponding one of Q1-Q;, such that said two primary phenyl rings are not symmetrically substituted. In particular, all of P1-P; and/or all of Q1-Q; may comprise H, such that one or both of said two primary phenyl rings is or are unsubstituted.
Advantageously, said substituents P1-PS and Q1-Q; collectively provide a degree of steric hindrance around the core of said chromophore which is sufficient to reduce the rate of spontaneous oxidation of said chromophore, such that said chromophore is substantially inert in air, but which does not to a substantial extent inhibit selective addition or substitution at the 2, 3, 7, 8, 12, 13, 17 or 18 positions around the core of said chromophore. Thus, each of PI, Ps, Q1 and Q; may be H. Typically, the total cumulative molecular weight of said substituents P1-P; does not exceed 1000gmol-1, and the total cumulative molecular weight of said substituents Q1-Q; does not exceed 1000gmofl.
One or more of said substituents P1-P; and Q1-Q; may comprise -OH, -CN, -NOz, halogen, -T or-OT, where T is a C1-C1; alkyl, cycloalkyl or aryl group or a hydroxylated, halogenated, sulphated or aminated derivative thereof or a carboxylic acid, ester, ether, polyether, amide, aldehyde or ketone derivative thereof. One or more of said substituents P1-P; and Ql-Q; may additionally or alternatively comprise a C3-Ciz cycloalkyl and/or aryl ring structures, or between two and six, preferably two - three, fused or linked C3-Clz cycloalkyl and/or aryl ring structures, each of which ring structures may optionally comprise one or more N, O or S atoms. In particular, one or more of said substituents P1-PS and Q1-Q; may comprise a quatenised amine or pyridyl group, such as an N-methyl pyridyl (pyridiniumyl) group.
Preferably, one of P1-P; and Q1-Q; is a conjugating substituent which comprises said conjugating group Z. In particularly preferred embodiments, said conjugating substituent is P3 or Q3, such that said conjugating group Z is provided on the para-position of one of the two primary phenyl rings.
Suitably, said conjugating group is as defined above in relation to the first aspect of the invention.
In particular, one or more of said substituents P1-PS and Q1-Q5, not being said conjugating substituent, may consist of a member independently selected from the group consisting of AlZlAla; wherein Zl is Z2, Z2A5 or Z2ASA6; Al and AS are independently selected from -(CA2A~)ri , -C(Y)(CA2A;)n-, -C(Y)Y'(CA2A;)ri , -C(Y)NA4(CA2A~)p , -NA4C(Y)(CA~A;)ri , -NAq.(CA2A;)n, -YC(Y')(CA2A~)ri and -Y(CA~A~)ri ; n = 0 - 6; Y and Y' are independently O or S; A2, A~ and Aq.
are independently H or Cl_2 alkyl which is unsubstituted or substituted by one or more tluorines; AG = - (C2H40)m or -S(O)p; m = 1 - 12; p = 0 - 2; Z2 is a single bond or Z~; Z~ is selected from Zq., ZS and Z6, wherein Z; is unsubstituted or substituted one or more times by OH, halo, CN, N02, AlAlO, A6Ag, NAlOAI l, C(Y)AN, C(Y)Y'A~, Y(CH?)qY'A~, Y(CH2)qA~, C(Y)NAlOAIl, Y(CH2)qC(Y')NAlOAI l~
Y(CH2)qC(Y')A~, NAIpC(Y)NAlOAI l, NAIOC(Y)Al l, NAIOC(Y)Y'A9, NAIOC(Y)Z~, C(NAlp)NAl0All. C~CN)NA10A11, C(NCN)SA9, NAIpC(NCN)SAc~, NAIOC(NCN)NAlOAI l, NAlOS(O)2Ag, S(O)rA9, NAl OC(Y)C(Y')NAlOAI 1, NAIOC(Y)C(Y')Al0 or Z6; q = 0, 1 or 2; r = 0 - 2; A~
is independently selected from H and A9; Ag is O or A9; A9 is Cl-4 alkyl which is unsubstituted or substituted by one or more fluorines; Al0 is OA9 or Al l; A11 is A~ or when Al0 and Al l are as NAlOAI 1 they may together with the nitrogen form a 5 to 7 membered ring comprising only carbon atoms or carbon atoms and at least one heteroatom selected from O, N and S; Z4 is C6_ 12 aryl or aryloxyC 1 _~alkyl;
ZS is selected from furanyl, tetrahydrofuranyl, indanyl, indenyl, tetrahydropyranyl, pyranyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, thienyl, C;_g cycloalkyl or Cq.-g cycloalkyl containing one or two unsaturated bonds, and C~_11 polycycloalkyl;
Z6 is selected from N-azolyl, dioxadiazinyl, dioxadiazolyl, dioxanyl, 2-N-dioxatriazinyl, dioxazinyl, N-dioxazolyl, dioxolyl, dithiadiazinyl, dithiadiazolyl, N-dithiatriazinyl, dithiazinyl, N-dithiazolyl, 1-N-imidazolyl, N-morpholinyl, pyrollyl, tetrazolyl, thiazolyl, triazolyl, oxazinyl, oxazolyl, naphthydrinyl, oxadiazinyl, oxadiazolyl, oxatetrazinyl, oxatriazinyl, oxatriazolyl, oxazinyl, oxazolyl, pentazinyl, phthalazinyl, N-piperidinyl, N,N-piperazinyl, 1-N-pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, tetrathiazinyl, tetrazinyl, 1-N-tetrazolyl, tetroxazinyl, thiadiazinyl, thiadiazoyl, thiatetrazinyl, thiatriazinyl, thiatriazolyl, thiazolyl, triazinyl, 1-N-triazolyl, trioxadazinyl, trioxanyl, trioxazinyl, trioxazolyl, trithiadiazinyl, trithiazinyl, trithiadiazolyl;
wherein Zq., ZS or Z6 may be fused to one or more other members selected independently from Zq., ZS
and Z6;
AI ~ is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyC l _;
alkyl, halo substituted aryloxyC 1_; alkyl, indanyl, indenyl, C~_ 11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C;-( cycloalkyl, or a C4_6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or a hydroxyl group.
Said conjugating substituent may consist of a member selected from the group consisting of A1Z1Z; wherein Z1 is Z2, Z2A5 or Z2ASA6; A1 and AS are independently selected from -(CA~A;)ri , -C(Y)(CA2A~)n-, -C(Y)Y'(CA2A~)ri , -C(Y)NA4(CA~Aj)ri , -NA4C(~')(CA2A3)ri , -NA4(CA2A;)n, -YC(Y')(CA2A3)ri and -Y(CA~A~)ri ; n = 0 - G; Y and Y' are independently O or S; A2, A3 and A4 are independently H or C1_2 alkyl which is unsubstituted or substituted by one or more fluorines; A~ _ - (C2H40)m or -S(O)p; m = 1 - 12; p = 0 - 2; Z2 is a single bond or Z~; Z~ is selected from Zq, ZS and Z6, wherein Z~ is unsubstituted or substituted one or more times by OH, halo, CN, NO2, AlAlO, A6Ag, NA10A11, C(Y)AN, C(Y)Y'A~, Y(CH~)~Y'A~, Y(CH2)qA~, C(Y)NA10A11, Y(CH2)~C(Y')NA10A11~
Y(CH~)~C(Y')Ag, NAIpC(Y)NA10A11, NAlpC(Y)A11, NAlpC(Y)Y'Ag, NAIOC(Y)Z6, C(NA10)NA10A11~ C~CN)NA10A11, C(NCN)SAg, NAIOC(NCN)SAg, NAIpC(NCN)NA10A11, NAIpS(O)2Ag, S(O)rAg, NAIpC(Y)C(Y')NA10A11, NAlpC(Y)C(Y')A10 or Z6; q = 0, 1 or 2; r = 0 - 2; A~ is independently selected from H and Ag; Ag is O or Ag; Ag is C1_q alkyl which is unsubstituted or substituted by one or more fluorines; A10 is OAg or Al 1; Al l is A~ or when A10 and A11 are as NAlOAI 1 they may together with the nitrogen form a 5 to 7 membered ring comprising only carbon atoms or carbon atoms and at least one heteroatom selected from O, N and S; Zq. is C6_12 aryl or aryloxyCl_3alkyl; ZS
is selected from furanyl, tetrahydrofuranyl, indanyl, indenyl, tetrahydropyranyl, pyranyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, thienyl, C;-g cycloalkyl or Cq._g cycloalkyl containing one or two unsaturated bonds, and C~_11 polycycloalkyl;
Z6 is selected from N-azolyl, dioxadiazinyl, dioxadiazolyl, dioxanyl, 2-N-dioxatriazinyl, dioxazinyl, N-dioxazolyl, dioxolyl, dithiadiazinyl, dithiadiazolyl, N-dithiatriazinyl, dithiazinyl, N-dithiazolyl, 1-N-imidazolyl, N-morpholinyl, pyrollyl, tetrazolyl, thiazolyl, triazolyl, oxazinyl, oxazolyl, naphthydrinyl, oxadiazinyl, oxadiazolyl, oxatetrazinyl, oxatriazinyl, oxatriazolyl, oxazinyl, oxazolyl, pentazinyl, phthalazinyl, N-piperidinyl, N,N-piperazinyl, 1-N-pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, tetrathiazinyl, tetrazinyl, 1-N-tetrazolyl, tetroxazinyl, thiadiazinyl, thiadiazoyl, thiatetrazinyl, thiatriazinyl, thiatriazolyl, thiazolyl, triazinyl, 1-N-triazolyl, trioxadazinyl, trioxanyl, trioxazinyl, trioxazolyl, trithiadiazinyl, trithiazinyl, trithiadiazolyl;
wherein Zq, ZS or Z6 may be fused to one or more other members selected independently from Z4, ZS
and Z6.
In particular embodiments of the present invention, said chromophore may comprise a chromophore having a structure set out as (x), (y) or (z) below:
OH
HO
fix) (Y) (z) wherein R and R' may be any of the following combinations:
R R' '~-IVIe 4-NCS
4-B r 4-NC S
4-CO~Me 4-NCS
3,4,5-tris(OMe)4-NCS
4-NC S 4-OMe 4-NC S 4-Me 4-NCS 4-C02Me 4-NCS 4-Br 4-NCS 4-COZMe In another embodiment of the present invention, said chromophore may comprise a porphyrin chromophore having the structure set out below:
s.
2 i yv 24 ~ 10 18 ~ ~ / ~ 12 16 Y 1q~
1~ 151 13 ~\
O~C~NCS
L- J ''P
wherein m = 0-G ; p = 0-15, preferably 0-5; or the corresponding chlorin or bacteriochlorin chromophore.
According to another aspect of the present invention, there is provided a set of fluorochromic markers for multicolour fluorochromic analysis, comprising at least two chromophores selected from the group consisting of a porphyrin chromophore, a chlorin chromophore and a bacteriochlorin chromophore, each of which chromophores comprises the same porphyrin skeleton, each of which chromophores comprises one or more substituents on said porphyrin skeleton, one of which substituents is a conjugating substituent L comprising a conjugating group Z, wherein Z is a conjugating group capable of conjugating each of said chromophores to a polypeptide molecule for delivering each chromophore to one of a plurality of different specific biological targets.
Preferably, each of the other of said substituents on the skeleton is independently H or an inert substituent R which together with said conjugating substituent L
and all of the other core substituents does not substantially impair the fluorescent properties of each chromophore.
It has been found that each of the chromophores in a set in accordance with the r~
present invention, on excitation, will emit fluorescent light at a different discrete wavelength. Thus, all of the chromophores within the set can be excited by a single laser, producing separate emission bands which can be substantially individually resolved.
Moreover, all of the chromophores provided in said set share substantially the same molecular structure, and will accordingly share substantially the same biochemical and physicochemical properties, including substantially the same degree of efficiency of bioconjugation to a biological target under given conditions. Accordingly, a set of chromophores in accordance with the present invention may be usefully employed in fluorescence analysis and sorting applications, including FACS, for the convenient sorting and analysis of several types of cells or other biological targets.
The components of such a set may, for example, be introduced to a mixture comprising one or more of said different specific biological targets, under conditions which will allow the delivery of each chromophore to its respective specific biological target; and said mixture may be exposed to light so as to cause said chromophores to fluoresce. A multicolour analysis may then be carried out for identifying the different emission bands produced by each chromophore, thereby permitting counting and visualisation of the location of each of the different biological targets.
Said set of chromophores may in particular comprise two or more of a porphyrin chromophore in accordance with any aspect of the present invention, the corresponding chlorin chromophore, and the corresponding bacteriochlorin chromophore. (By "corresponding" herein is meant having the same meso-substituents around the macrocyclic core of the molecule).
In a chromophore in accordance with the present invention, or in each member of a chromophore set in accordance with the present invention, said conjugating group Z
may be conjugated to a binding protein which is adapted to bind specifically to said biological target. Alternatively, said conjugating group Z may be conjugated to a bridging polypeptide which is adapted to bind to a complementary bridging polypeptide so as to couple said chromophore to said complementary bridging polypeptide.
In some embodiments, said bridging polypeptide may be bound to said complementary bridging polypeptide, and said complementary bridging polypeptide may comprise or be coupled to or fused with a binding protein which is adapted to bind specifically to said biological target. Accordingly, said chromophore may be covalently linked to said binding protein by means of said bridging polypeptide and said complementary bridging polypeptide.
According to another aspect of the present invention, there is provided a kit comprising a chromophore in accordance with the present invention or a set of chromophores in accordance with the present invention, wherein said chromophore or each chromophore is conjugated to a bridging polypeptide that is adapted to bind to a complementary bridging polypeptide so as to couple the chromophore to said complementary bridging polypeptide; and a construct or plurality of constructs each of which comprises said complementary bridging polypeptide fused or coupled to a binding protein which is adapted to bind specifically to said biological target; the arrangement being such that said chromophore or each chromophore in the kit is adapted to bind to a different construct in the kit with specificity for said specific biological target, so as to link said or each chromophore to a binding protein with specificity for said specific biological target.
Said binding protein may, for example, be an antibody such as a monoclonal or polyclonal antibody or a fragment thereof with specificity for a target specific molecule on the surface of said biological target. In particular, said antibody may be a phage antibody, that is an antibody expressed on the surface of a bacteriophage.
Alternatively said binding protein may be a protein which is adapted to bind to one or more cell surface molecules or receptors, such as a serum albumin protein. As yet a further alternative, said binding protein may comprise a low density lipoprotein, such as a fatty acid chain, which is adapted for insertion into a cell membrane. When conjugated to a chromophore, such a lipoprotein can serve to anchor the chromophore to a cell membrane.
Said bridging polypeptide may comprise calmodulin, and said complementary bridging polypeptide may comprise calmodulin binding peptide; or vice versa.
Preferably, however, said bridging polypeptide may comprise avidin or streptavidin, and said complementary bridging polypeptide may comprise biotin; or vice versa. In particular, said or each chromophore in a kit in accordance with the present invention may be conjugated to avidin, and said or each construct may comprise a biotinylated monoclonal antibody with specificity for a target specific molecule on the surface of said biological target. Accordingly, when said avidin-linked chromophore is allowed to bind said biotinylated antibody, said chromophore will become firmly linked to said antibody.
Conveniently, said or each biotinylated monoclonal antibody in the kit may be selected and/or readily substituted, so as to enable said or each chromophore to be delivered to any desired biological target. Methods for the preparation of monoclonal antibodies and for the biotinylation thereof are well known in the art.
According to another aspect of the present invention, there is provided a method for attaching a chromophore in accordance with the invention or a set of chromophores in accordance with the invention to said specific biological target or targets;
comprising the steps of providing a kit in accordance with the present invention, and introducing the components of said kit into the vicinity of said specific biological target or targets, under conditions suitable for enabling the binding of said or each binding protein to said specific biological target or targets. Advantageously, the components of said kit may be allowed to associate with one another prior to introduction to said target or targets, so as to enable the bridging polypeptide conjugated to said or each chromophore to bind to a complementary bridging polypeptide provided on one of said constructs in the kit. This will ensure that said or each chromophore in the kit is linked to a binding protein prior to introduction of said chromophore to said target or targets. Alternatively, the components of said kit may be introduced sequentially to said target or targets.
Typically, said specific biological target may be a cell or a membrane. Said specific biological target may be in vivo or in vitro (ex vivo). Said biological target may, for example, be a cancer cell, a tumour cell, a cell infected with HIV or with any other microbe or virus, a cell responsible for detrimental activity in auto-immune disease, a foreign or diseased cell, or any other such cell.
In some embodiments of the present invention, said biological target is a cell in vitro, and said target specific molecule comprises a molecule exposed on the surface of said cell, such as a polypeptide, carbohydrate, fatty acid, lipoprotein, phospholipid or other biological molecule. Preferably, said target specific molecule is specifically expressed by, or is over-expressed by, said cell. Said target specific molecule may, for example, be a T cell marker such as CD4 or CDB. Accordingly, when a chromophore in accordance with the present invention or a chromophore forming part of a set of chromophores in accordance with the present invention is attached to said cell, and said cell is illuminated so as to cause fluorescence of said chromophore, the fluorescence of the chromophore will enable said cell to be visualised and counted and/or sorted by FRCS.
According to a further aspect of the present invention, therefore, there is provided a method for fluorescence-activated sorting of target cells from a mixture of cells, comprising the step of attaching to said target cells a chromophore in accordance with the invention or a set of chromophores in accordance with the invention, illuminating said mixture of cells so as to cause fluorescence of one or more of said chromophores attached to said target cells, imparting a charge to the fluorescing cells, and passing said mixture of cells through a polarised environment so as to cause or allow said charged cells to be separated from said mixture.
According to another aspect of the present invention, there is provided a method for the visualisation and/or counting of a plurality of target cells, said target cells including cells of two or three different cell types, comprising the steps of providing a chromophore set in accordance with the present invention, which chromophore set comprises two or three chromophores each of which is adapted to be delivered to a different one of said cell types; attaching said chromophores in the set to said target cells in accordance with the method of the present invention; illuminating said target cells so as to cause the emission of fluorescence by said chromophores; detecting the fluorescent emission bands produced by each of said chromophores; and optionally measuring for each of said bands the area under an emission/wavelength curve, so as to obtain a measure of the number of fluorescent cells of each respective cell type.
In other embodiments of the present invention, said target cell is a cell in vivo, such as a cancer cell, tumour cell, or an infected, foreign or diseased cell, and said target specific molecule is a target cell specific molecule which is specifically expressed by, or is over-expressed by, or is attached to, and is exposed on, the surface of said target cell;
such as a target cell specific membrane protein. Accordingly, when a chromophore in accordance with the invention is delivered to said target specific molecule, said chromophore will be caused to be attached to said cell. If said cell is subsequently illuminated with light at a wavelength suitable for causing the excitation of said chromophore, said chromophore attached to said cell may be caused to be excited, and this may result in the production of singlet oxygen in the immediate vicinity of said cell, hence bringing about the death of the cell.
In especially preferred embodiments, said target cell specific molecule comprises an internalisation receptor on the surface of said cell, which internalisation receptor is capable of binding said binding protein and thereby mediating the internalisation of said chromophore within said cell. Accordingly, subsequent illumination of said cell with light at a wavelength suitable for causing excitation of said chromophore may result in the production of singlet oxygen within said cell, hence bringing about the death of said cell.
The present invention therefore comprehends a method for causing the death of a target cell, comprising the step of attaching a chromophore in accordance with the present invention to said cell and illuminating said cell so as to cause the production of singlet oxygen in the vicinity of said cell, thereby causing the death of the cell.
Preferably, said chromophore is attached to an internalisation receptor on the surface of said cell, which internalisation receptor is capable of mediating the internalisation of said chromophore within said cell, and said cell is thereafter illuminated such as to cause the production of ringlet oxygen within said cell, thereby causing the death of the cell.
Preferably, where said chromophore is adapted to be internalised within the cell, said chromophore comprises a cationic group such as a quatenised amine or pyridyl (pyridiniumyl) group, or a phosphonium group, so as to promote the intracellular accumulation of said chromophore around the mitochondria of the cell, owing to the net negative charge on the mitochondria) membrane. This will result in the rapid and efficient killing of the cell, on production of ringlet oxygen by decay of the chromophore.
In accordance with another aspect of the invention, there is provided a method for treating a disease or disorder which is characterised by the presence in the body of diseased or undesired cells, such as tumours, cancers, viral infections such as HIV
infection, or autoimmune disorders such as rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a patient in need thereof an effective amount of a chromophore in accordance with the invention, which chromophore is adapted to be targeted to a target cell specific molecule on the surface of said diseased or undesired cells for attachment thereto, such that the chromophore is caused to be attached to said cells, and illuminating said cells with light so as to cause the production of singlet oxygen in the vicinity of said cells, thereby killing said cells. Suitably, said target cell specific molecule comprises an internalisation receptor, and said chromophore is adapted to be internalised within said cells on delivery to said internalisation receptor, such as to enable the production of ringlet oxygen within said cells on illumination thereof.
Said chromophore may be administered topically or systemically to said patient.
For example, said chromophore may be administered by injection.
In accordance with yet another aspect of the invention, there is provided a pharmaceutical composition for administration to a patient for the treatment of a disease or disorder which is characterised by the presence in the body of diseased or undesired cells, such as tumours, cancers, viral infections such as HIV infection, or autoimmune disorders such as rheumatoid arthritis or multiple sclerosis, which composition comprises a chromophore in accordance with the present invention that is adapted to be delivered to said diseased or undesired cells, and a suitable carrier.
Yet another aspect of the invention envisages a chromophore in accordance with the invention for use in the production of a medicament, for use in the treatment of patients suffering from a disease or disorder which is characterised by the presence in the body of diseased or undesirable cells, such as tumours, cancers, viral infections including HIV infection, and autoimmune disorders including rheumatoid arthritis or multiple sclerosis; said chromophore being adapted for delivery to said diseased or undesired cells.
Detailed Description of Examples of the Invention Following are descriptions and examples, by way of illustration only, of embodiments of the invention and methods for putting the invention into effect.
Synthesis of Chromophores Instrumentation and materials Melting points are uncorrected. IH/I3C NMR spectra were recorded on Jeol JNM
FT-NMR spectrometer, and are referenced to tetramethylsilane unless otherwise stated.
LR. spectra were obtained using a series 1600 FT-LR and nominal mass spectra were obtained by Kratos Kompact MALDI II spectrometer. Accurate mass were obtained from EPSRC Mass Spectrometry Service, Swansea. The electronic spectra were obtained using Unicam UV-2 or UV-4 spectrometers and were taken in DCM unless otherwise stated.
All reagents and solvents were commercially available and of reagent grade or higher, and were, unless otherwise specified, used as received. TLC analysis were performed on Merck silica-gel 60 plates (F254, 500 p.m thickness). Merck Silica-Gel 60 (230-mesh) was used for flash chromatographic purification.
Descriptions (1) 5-(4-Acetamidophenyl)-10,15,20-tris(3,S-dimethoxyphenyl)porphyrin M Me M~ Me 4-Acetamidobenzaldehyde (3.36 g, 0.02 mol) and 3,5-dimethoxybenzaldehyde (10 mL, 0.06 mol) were stirred in propionic acid (300 mL) at 90 °C. Pyrrole (5.5 mL, 0.08 mol) was added and the mixture stirred under reflux for 30 min. Upon cooling the reaction mixture was evaporated itz vaczco to yield a dark purple solid. The crude mixture of porphyrin isomers was purified by flash chromatography (silica, eluent:
CHZC12/EtOAc, 4:1 ). Relevant fractions were combined, dried (NazS04) and evaporated itz vacuo to yield 1 as a purple solid (1.55 g, 9.1%); Rf= 0.50 (silica, CHZC12/EtOAc, 4:1); mp >350 °C
decomp.; IH NMR [270 MHz, CDCl3] ~-2.96 (2H, br s, NH), 2.23 (3H, s, NHCOCH3), 3.93 ( 18H, s, 3, 5-OCH3), 6.99 (3H, s, 10, 15, 20-Ar-4-H), 7.07 (2H, m, .I* =
8 Hz, 5-Ar-3,5-H), 7.38 (6H, s, 10, 15, 20-Ar-2,6-H), 7.44 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.86-8.93 (8H, m, (3-H), 10.42 (1H, br s, NHCOCH3); isC NMR [67.5 MHz, CDCl3] &20.4, 23.9, 103.9, 113.5, 117.3, 119, 119.4, 119.6, 120, 129, 131.1, 131.3, 131.4, 131.8, 134.5, 135.6, 136.8, 139.3, 143.1, 158.6, 160.3, 167.9, 168.7; UV-vis (CHZC12) ~,m;"; 421, 515, 551, 590, 650 nm; MS (MALDI-TOF) oz/z 852 (M+, 100%).
ivicv UWC
(2) 5-(4-Aminophenyl)-10,15,20-tris(3,5-dimethoxyphenyl)porphyrin Me Me Porphyrin 1 (500 mg, 0.587 mmol) was dissolved in 18% HCl (100 mL) and the solution heated for 2 hours under reflux. Upon cooling the reaction mixture was evaporated in vaczro to yield a crude green solid. The solid was redissolved in a 9:1 mixture of dichloromethane/triethylamine (200 mL) and stirred for 10 min at room temperature.
The solution was then washed with water (3 x 200 mL) and brine (200 mL), the organic layer separated and dried (Na2S04). Excess solvent was evaporated in vacuo and the crude purple solid purified by flash chromatography (silica, eluent:
CHZC12/EtOAc, 4:1).
Relevant fractions were combined, dried (NaZS04) and evaporated i» vacuo to yield 2 as a purple solid (426 mg, 89.7%); Rf = 0.89 (silica, CHZCI2BtOAc, 4:1); mp >350 °C
decamp.; 1H NMR [270 MHz, CDCl3] 8-2.80 (2H, br s, NH), 3.96 (18H, s, 3, 5-OCH3), 6.90 (3H, s, 10, 15, 20-Ar-4-H), 7.06 (2H, m, J* = 8 Hz, 5-Ar-3,5-H), 7.40 (6H, s, 10, 15, 20-Ar-2,6-H), 7.98 (2H, m, .l* = 8 Hz, S-Ar-2,6-H), 8.93 (8H, m, ~3-H); 13C
NMR [67.5 MHz, CDC13] 8 20.13, 100.6, 113.9, 114.3, 115.7, 119.8, 120.1, 121.4, 130.2, 131.4, 132.7, 136.1, 144.5, 144.6, 146.5, 159.3; UV-vis (CHZCl2) ~,m;,x 422, 517, 553, 593, 651 nm; MS (MALDI-TOF) »a/z 809 (M+, 100%).
rnCV Vlyle (3) ~-(4-Aminophenyl)-10,15,20-tris(3,5-dihydroxyphenyl)porphyrin To a stirred solution of 2 (1 g, 1.23 mmol) in freshly distilled chloroform (50 mL) was added boron tribromide (1.17 mL, 0.012 mol). The reaction was allowed to proceed under argon for 17 hours at room temperature. The reaction was subsequently cooled to 0 °C, water (20 mL) added and the solution stirred for a further 60 min. The reaction was evaporated to dryness in nacuo and redissolved in a 9:1 mixture of chloroform/triethylamine (S00 mL). The solution was washed with water (3 x 500 mL) and brine (500 mL), the organic layer separated, dried (Na2S0~), and evaporated in vacuo to yield a crude purple solid. The crude solid was purified by flash chromatography (silica. eluent: CHC13/MeOH, 9:1). Relevant fractions were combined, dried (Na2S04) and evaporated ire oacuo to yield 3 as a purple solid (667 mg, 74.5%); Rf=
0.19 (silica, CHCI~/MeOH, 9:1); mp >350 °C decomp.; 'H NMR [270 MHz, (CD3)ZSO] 8-2.95 (2H, br s, NH), 5.56 (2H, br s, NHZ), 6.69 (3H, s, 10, 15, 20-Ar-4-H), 7.02 (2H, m, .I* = 8 Hz,
5-Ar-3,5-H), 7.06 (6H, s, 10, 15, 20-Ar-2,6-H), 7.87 (2H, m, ,J* = 8 Hz, 5-Ar-2,6-H), 8.94 (8H, s, (3-H), 9.75 (6H, br s, 3, 5-OH); 13C NMR [67.5 MHz, (CD3)2S0] S
102.3, 112.5, 113.9, 114.1, 119.2, 119.7, 121.5, 127.5, 128.3, 130.7-131.3, 135.5, 142.8, 142.9, 148.6, 156.4, 156.5; UV-vis (CHZC12) a.max 422, 517, 553, 592, 649 nm; MS
(MALDI-TOF) »~% 726 (M+ 100%).
3=~
v vn (4) ~-(4-Acetamidophenyl)-10,15,20-tris(4-pyridyl)porphyrin N
4-Acetamidobenzaldehyde (3.26 g, 0.02 mol) and 4-pyridinecarboxaldehyde (5.66 mL, 0.06 mol) were stirred in propionic acid (300 mL) at 90 °C. Pyrrole (5.4 mL, 0.08 mol) was added and the mixture stirred under reflux for 30 min. Upon cooling the reaction mixture was evaporated izz vacuo to yield a dark purple solid. The crude mixture of porphyrin isomers was purified by flash chromatography (silica, eluent:
CHCl3/IVIeOH, 19:1). Relevant fractions were combined, dried (Na2S0~) and evaporated izz vacuo to yield 4 as a purple solid (526 mg, 3.9°f°); Rf= 0.22 (silica, CHCl3/MeOH, 19:1); mp >350 °C decomp.; 1H NMR [270 MHz, CDC13] 8 -2.79 (2H, br s, NH), 2.49 (3H, s, NHCOCH;), 8.07 (2H, m, ,I* = 8 Hz, 5-Ar-3,5-H), 8.21-8.28 (8H, m (overlapping), 5-Ar-2,6-H & 10, 15, 20-Py-2,6-H), 8.84-9.06 (8H, m, ~3-H), 9.10-9.15 (6H, m, 10, 15, 20-Py-3,5-H), 10.35 (1H, br s, NHCOCH3); isC NMR [67.5 MHz, CDCl3] 826.8, 106.9, 110.1, 110.2, 117.9, 121.1, 121.5, 122.1, 122.2, 123.3, 123.8, 123.9, 134.7, 140.1, 142.5, 145.1, 148.2, 149, 149.3, 149.4, 149.6, 150.1, 175.2; UV-vis (CHZCIz) 7~m:~x 418, 514, 548, 587, 644 nm; MS (MALDI-TOF) rn/z 675 (M+, 100%).
JJ
(~) ~-(4-Aminophenyl)-10,15,20-tris(4-pyridyl)porphyrin N
Porphyrin 4 (500 mg, 0.74 mmol) was dissolved in 18% HCl (100 mL) and the solution heated for 2 hours under reflux. Upon cooling the reaction mixture was evaporated in 1'CIC;IlI) to yield a crude green solid. The solid was redissolved in a 9:1 mixture of dichloromethane/triethylamine (200 mL) and stirred for 10 min at room temperature.
The solution was then washed with water (3 x 200 mL) and brine (200 mL), the organic layer separated and dried (NazS04). Excess solvent was evaporated in vacuo and the purple crude solid purified by flash chromatography (silica, eluent:
CHCl3/MeOH, 20:1).
Relevant fractions were combined, dried (Na2S0~) and evaporated in vacuo to yield 5 as a purple solid (422 mg, 90.1%); Rf = 0.31 (silica, CHC13/MeOH, 20:1); mp >350 °C
decomp.; ~H NMR [270 MHz, CDC13] 8-2.86 (2H, br s, NH), 4.09 (2H, br s, NHZ), 7.08 (2H, m, ,l* = 8 Hz, 5-Ar-3,5-H), 7.98 (2H, m, ,I* = 8 Hz, 5-Ar-2,6-H), 8.16 (6H, m, J* _ Hz, 10, 15, 20-Py-2,6-H), 8.80-9.01 (8H, m, [3-H), 9.04 (6H, m, J* = 5 Hz, 10, 15, 20-Py-3,5-H); 1~C NMR [67.5 MHz, CDCl3] 8 113.6, 116.7, 117.4, 117.9, 122.7, 129.5, 131.7, 135.9, 146.5, 148.4, 148.5, 149.8, 150.2; UV-vis (CHZCl2) ~,,t,~X 418, 515, 552, 592, 653 nm; MS (FAB) rrzi'~ 633 (M+, 100%).
102.3, 112.5, 113.9, 114.1, 119.2, 119.7, 121.5, 127.5, 128.3, 130.7-131.3, 135.5, 142.8, 142.9, 148.6, 156.4, 156.5; UV-vis (CHZC12) a.max 422, 517, 553, 592, 649 nm; MS
(MALDI-TOF) »~% 726 (M+ 100%).
3=~
v vn (4) ~-(4-Acetamidophenyl)-10,15,20-tris(4-pyridyl)porphyrin N
4-Acetamidobenzaldehyde (3.26 g, 0.02 mol) and 4-pyridinecarboxaldehyde (5.66 mL, 0.06 mol) were stirred in propionic acid (300 mL) at 90 °C. Pyrrole (5.4 mL, 0.08 mol) was added and the mixture stirred under reflux for 30 min. Upon cooling the reaction mixture was evaporated izz vacuo to yield a dark purple solid. The crude mixture of porphyrin isomers was purified by flash chromatography (silica, eluent:
CHCl3/IVIeOH, 19:1). Relevant fractions were combined, dried (Na2S0~) and evaporated izz vacuo to yield 4 as a purple solid (526 mg, 3.9°f°); Rf= 0.22 (silica, CHCl3/MeOH, 19:1); mp >350 °C decomp.; 1H NMR [270 MHz, CDC13] 8 -2.79 (2H, br s, NH), 2.49 (3H, s, NHCOCH;), 8.07 (2H, m, ,I* = 8 Hz, 5-Ar-3,5-H), 8.21-8.28 (8H, m (overlapping), 5-Ar-2,6-H & 10, 15, 20-Py-2,6-H), 8.84-9.06 (8H, m, ~3-H), 9.10-9.15 (6H, m, 10, 15, 20-Py-3,5-H), 10.35 (1H, br s, NHCOCH3); isC NMR [67.5 MHz, CDCl3] 826.8, 106.9, 110.1, 110.2, 117.9, 121.1, 121.5, 122.1, 122.2, 123.3, 123.8, 123.9, 134.7, 140.1, 142.5, 145.1, 148.2, 149, 149.3, 149.4, 149.6, 150.1, 175.2; UV-vis (CHZCIz) 7~m:~x 418, 514, 548, 587, 644 nm; MS (MALDI-TOF) rn/z 675 (M+, 100%).
JJ
(~) ~-(4-Aminophenyl)-10,15,20-tris(4-pyridyl)porphyrin N
Porphyrin 4 (500 mg, 0.74 mmol) was dissolved in 18% HCl (100 mL) and the solution heated for 2 hours under reflux. Upon cooling the reaction mixture was evaporated in 1'CIC;IlI) to yield a crude green solid. The solid was redissolved in a 9:1 mixture of dichloromethane/triethylamine (200 mL) and stirred for 10 min at room temperature.
The solution was then washed with water (3 x 200 mL) and brine (200 mL), the organic layer separated and dried (NazS04). Excess solvent was evaporated in vacuo and the purple crude solid purified by flash chromatography (silica, eluent:
CHCl3/MeOH, 20:1).
Relevant fractions were combined, dried (Na2S0~) and evaporated in vacuo to yield 5 as a purple solid (422 mg, 90.1%); Rf = 0.31 (silica, CHC13/MeOH, 20:1); mp >350 °C
decomp.; ~H NMR [270 MHz, CDC13] 8-2.86 (2H, br s, NH), 4.09 (2H, br s, NHZ), 7.08 (2H, m, ,l* = 8 Hz, 5-Ar-3,5-H), 7.98 (2H, m, ,I* = 8 Hz, 5-Ar-2,6-H), 8.16 (6H, m, J* _ Hz, 10, 15, 20-Py-2,6-H), 8.80-9.01 (8H, m, [3-H), 9.04 (6H, m, J* = 5 Hz, 10, 15, 20-Py-3,5-H); 1~C NMR [67.5 MHz, CDCl3] 8 113.6, 116.7, 117.4, 117.9, 122.7, 129.5, 131.7, 135.9, 146.5, 148.4, 148.5, 149.8, 150.2; UV-vis (CHZCl2) ~,,t,~X 418, 515, 552, 592, 653 nm; MS (FAB) rrzi'~ 633 (M+, 100%).
(6) 5-(4-Acetamidophenyl)-10,15,20-tris(3-pyridyl)porphyrin 4-Acetamidobenzaldehyde (5 g, 0.031 mol) and 3-pyridinecarboxaldehyde (8.67 mL, 0.092 mol) were stirred in propionic acid (300 mL) at 90 °C. Pyrrole (8.5 mL, 0.123 mol) was added and the mixture stirred under reflux for 30 min. Upon cooling the reaction mixture was evaporated in vcrcuo to yield a dark purple solid. The crude mixture of porphyrin isomers was purified by flash chromatography (silica, eluent:
CHCl3/MeOH, 19:1). Relevant fractions were combined, dried (Na2S04) and evaporated ifZ
vacuo to yield G as a purple solid (0.96 g, 4.6%); Rf= 0.26 (silica, CHC13/MeOH, 19:1);
mp >350 °C decomp.; 1H NMR [270 MHz, GDCl3] 8-2.97 (2H, br s, NH), 2.17 (3H, s, NHCOCH;), 7.40 (2H, m, .I* = 8 Hz, 5-Ar-3,5-H), 7.49 (3H, m, 10, 15, 20-Py-5-H), 7.98 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.21-8.33 (3H, m, 10, 15, 20-Py-6-H), 8.57-8.82 (11H, m (overlapping), 10, 15, 20-Py-4-H & (3-H), 8.99 (1H, br s, NHCOCH3), 9.26 (3H, m, 10, 15, 20-Py-2-H); UV-vis (CH2C12) 7~m~X 419, 516, 552, 592, 648 nm; MS (MALDI-TOF) ~rz; z 675 (M+, 100%).
37 w
CHCl3/MeOH, 19:1). Relevant fractions were combined, dried (Na2S04) and evaporated ifZ
vacuo to yield G as a purple solid (0.96 g, 4.6%); Rf= 0.26 (silica, CHC13/MeOH, 19:1);
mp >350 °C decomp.; 1H NMR [270 MHz, GDCl3] 8-2.97 (2H, br s, NH), 2.17 (3H, s, NHCOCH;), 7.40 (2H, m, .I* = 8 Hz, 5-Ar-3,5-H), 7.49 (3H, m, 10, 15, 20-Py-5-H), 7.98 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.21-8.33 (3H, m, 10, 15, 20-Py-6-H), 8.57-8.82 (11H, m (overlapping), 10, 15, 20-Py-4-H & (3-H), 8.99 (1H, br s, NHCOCH3), 9.26 (3H, m, 10, 15, 20-Py-2-H); UV-vis (CH2C12) 7~m~X 419, 516, 552, 592, 648 nm; MS (MALDI-TOF) ~rz; z 675 (M+, 100%).
37 w
(7) ~-(4-Aminophenyl)-10,15,20-tris(3-pyridyl)porphyrin Porphyrin 6 (300 mg, 0.45 mmol) was dissolved in 18% HCl (100 mL) and the solution heated for 2 hours under reflux. Upon cooling the reaction mixture was evaporated in nacwo to yield a crude green solid. The solid was redissolved in a 9:1 mixture of dichloromethane/triethylamine (200 mL) and stirred for 10 min at room temperature.
The solution was then washed with water (3 x 200 mL) and brine (200 mL), the organic layer separated and dried (Na2S0~). Excess solvent was evaporated in vacuo and the purple crude solid purified by flash chromatography (silica, eluent:
CHC13/MeOH, 20:1).
Relevant fractions were combined, dried (Na2S0~) and evaporated ire vacz~o to yield 7 as a purple solid (206 mg, 68.5%); Rf= 0.38 (silica, CHC13/MeOH, 20:1); mp >350 °C
decomp.; 1H NMR [270 MHz, CDCl3] 8-2.74 (2H, br s, NH), 3.93 (2H, br s, NH2), 6.91 (2H, m, .l* = 8 Hz, 5-Ar-3,5-H), 7.67 (3H, m, 10, 15, 20-Py-S-H), 7.93 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.48 (3H, m, 10, 15, 20-Py-6-H), 8.79-9.02 (11H, m (overlapping), 10, 15, 20-Py-4-H & (3-H), 9.47 (3H, s, 10, 15, 20-Py-2-H); 13C NMR [67.5 MHz, CDC13] 8 113.3, 115.6, 116.1, 116.7, 121.9, 122.3, 131, 131.4, 131.8, 132.1, 132.3, 135.7, 137.5, 137.7, 137.8, 140.8, 146.3, 149, 149.2, 153.5; UV-vis (CHZC12) ~,m;"420, 517, 553, 597, 649 nm; MS (MALDI-TOF) nz/z 632 (M+, 100%).
The solution was then washed with water (3 x 200 mL) and brine (200 mL), the organic layer separated and dried (Na2S0~). Excess solvent was evaporated in vacuo and the purple crude solid purified by flash chromatography (silica, eluent:
CHC13/MeOH, 20:1).
Relevant fractions were combined, dried (Na2S0~) and evaporated ire vacz~o to yield 7 as a purple solid (206 mg, 68.5%); Rf= 0.38 (silica, CHC13/MeOH, 20:1); mp >350 °C
decomp.; 1H NMR [270 MHz, CDCl3] 8-2.74 (2H, br s, NH), 3.93 (2H, br s, NH2), 6.91 (2H, m, .l* = 8 Hz, 5-Ar-3,5-H), 7.67 (3H, m, 10, 15, 20-Py-S-H), 7.93 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.48 (3H, m, 10, 15, 20-Py-6-H), 8.79-9.02 (11H, m (overlapping), 10, 15, 20-Py-4-H & (3-H), 9.47 (3H, s, 10, 15, 20-Py-2-H); 13C NMR [67.5 MHz, CDC13] 8 113.3, 115.6, 116.1, 116.7, 121.9, 122.3, 131, 131.4, 131.8, 132.1, 132.3, 135.7, 137.5, 137.7, 137.8, 140.8, 146.3, 149, 149.2, 153.5; UV-vis (CHZC12) ~,m;"420, 517, 553, 597, 649 nm; MS (MALDI-TOF) nz/z 632 (M+, 100%).
(8) 5-(4-Acetamidophenyl)-15-(4-methoxyphenyl)porphyrin, The DDP was synthesised according to the method of Dolphin et al.(1998 5-Phenyldipyrromethane and 5, 15-Diphenylporphyrin Org. Synth. 76, 287-293 incorporated herein by reference) The resulting mixture of three porphyrins was chromatographed, eluting initially with DCM to allow removal of 5,15-(4-methoxy)-DPP, and then continuing with ethyl acetate/DCM ( 1:4) to elute the required product as purple crystals (150 mg, 12%); R~= 0.40 (DCM/MeOH, 19:1); mp 305-307°C
(decomposed); UV-vis (DCM) 7~n,~" (relative intensity) 410 (1.0), 502 (0.04), 538 (0.02), 578 (0.015), 630 (0.01) nm; 1H NMR (270 MHz, CDC13) b 10.35 (s, 2H, 10+20-H),
(decomposed); UV-vis (DCM) 7~n,~" (relative intensity) 410 (1.0), 502 (0.04), 538 (0.02), 578 (0.015), 630 (0.01) nm; 1H NMR (270 MHz, CDC13) b 10.35 (s, 2H, 10+20-H),
9.43 (d, 4H, J = 4.8 Hz, ,(3 ~, 9.14 (d, 4H, J = 4.8 Hz, ~3 H), 8.65 (m, ZH, J =
7.2 Hz, .5-nz-An), 8.22-8.12 (m, 4H, (overlapping), J = 8.1 Hz, .i+IS-o Ar), 7.56 (m, 2H, J = 8.1 Hz, l~-ni-Ar), 4.14 (s, 3H, CHj), -3.00 (br s, 2H, NH); MALDI-MS m/z 550.3 (M+, 100%).
(9) 5-(4-Aminophenyl)-15-(4-methoxyphenyl)porphyrin, 5-(4-Acetamido phenyl)-15-(4-methoxyphenyl)porphyrin 8 (1 eq., 100 mg, 0.182 mmol) was dissolved in 5 M aqueous HCI (100 mL) and the solution heated for 3 h under reflux.
The hot reaction mixture was concentrated irz vaczco to yield a crude green solid. The solid was re-dissolved in a mixture of DCM/triethylamine (9:1) (200 mL) and stirred for min at room temperature. The solution was then washed with water (3 x 200 mL), saturated brine (200 mL) and the organic layer separated and dried (NazSOa), then concentrated in vaezio. The crude purple solid was chromatographed, eluting with DCM, and gave the desired porphyrin as a purple crystalline solid (51 mg, 54%), Rf=
0.30 (DCM), mp 300°C (decomposed); UV-vis (DCM) ~,t"a~ (relative intensity) 410 (1.0), 503 (0.045), 538(0.02), 578 (0.015), 630 (0.005) nm; Fluorescence (DCM) ~,max 634 nm (~, excitation = 410 nm); 1H NMR (270 MHz, CDC13) 8 10.30 (s, 2H, 10+,~0-~~
9.39 (d, 4H, J = 4.9 Hz, ~ H), 9.17 (d, 2H, J = 4.9 Hz, ,Q H), 9.10 (d, 2H, J = 4.9 Hz, ~3-H), 8.19 (m, 2H, J = 8.8 Hz, IS-o Ar), 8.07 (m, 2H, J = 8.1 Hz, 5-o An), 7.35 (m, 2H, J
= 8.8 Hz, L5-nz Ay~), 7.14 (m, 2H, J = 8.1 Hz, 5-m Ar), 4.13 (s, 3H, CHj), 4.08 (br s, 2H, NH), -3.06 (br s, 2H NH); MALDI-MS m/z 508.3 ([M+1]+, 100%). ES-HRMS calcd. for C33HzsNsO
([M+1]T) 508.2137, found 508.2144.
7.2 Hz, .5-nz-An), 8.22-8.12 (m, 4H, (overlapping), J = 8.1 Hz, .i+IS-o Ar), 7.56 (m, 2H, J = 8.1 Hz, l~-ni-Ar), 4.14 (s, 3H, CHj), -3.00 (br s, 2H, NH); MALDI-MS m/z 550.3 (M+, 100%).
(9) 5-(4-Aminophenyl)-15-(4-methoxyphenyl)porphyrin, 5-(4-Acetamido phenyl)-15-(4-methoxyphenyl)porphyrin 8 (1 eq., 100 mg, 0.182 mmol) was dissolved in 5 M aqueous HCI (100 mL) and the solution heated for 3 h under reflux.
The hot reaction mixture was concentrated irz vaczco to yield a crude green solid. The solid was re-dissolved in a mixture of DCM/triethylamine (9:1) (200 mL) and stirred for min at room temperature. The solution was then washed with water (3 x 200 mL), saturated brine (200 mL) and the organic layer separated and dried (NazSOa), then concentrated in vaezio. The crude purple solid was chromatographed, eluting with DCM, and gave the desired porphyrin as a purple crystalline solid (51 mg, 54%), Rf=
0.30 (DCM), mp 300°C (decomposed); UV-vis (DCM) ~,t"a~ (relative intensity) 410 (1.0), 503 (0.045), 538(0.02), 578 (0.015), 630 (0.005) nm; Fluorescence (DCM) ~,max 634 nm (~, excitation = 410 nm); 1H NMR (270 MHz, CDC13) 8 10.30 (s, 2H, 10+,~0-~~
9.39 (d, 4H, J = 4.9 Hz, ~ H), 9.17 (d, 2H, J = 4.9 Hz, ,Q H), 9.10 (d, 2H, J = 4.9 Hz, ~3-H), 8.19 (m, 2H, J = 8.8 Hz, IS-o Ar), 8.07 (m, 2H, J = 8.1 Hz, 5-o An), 7.35 (m, 2H, J
= 8.8 Hz, L5-nz Ay~), 7.14 (m, 2H, J = 8.1 Hz, 5-m Ar), 4.13 (s, 3H, CHj), 4.08 (br s, 2H, NH), -3.06 (br s, 2H NH); MALDI-MS m/z 508.3 ([M+1]+, 100%). ES-HRMS calcd. for C33HzsNsO
([M+1]T) 508.2137, found 508.2144.
(10) 17,18-Dihydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl)chlorin and
(11) 7,8-dihydroxy 5-(4-aminophenyl)-15-(4-methoxyphenyl)chlorin regioisomers, Porphyrin 9 (28 mg, 55.2 p.mol) was converted into the required mixture of chlorin regioisomers following the procedure of Sutton et c~l.(2000 Functionalised diphenylchlorins and bacteriochlorins - their synthesis and bioconjugation for targeted photodynamic therapy and tumour cell imaging J. Po~ph~rir~ ccnd Phthalocyaraines 4, 655-658) The crude reaction mixture was then chromatographed, eluting with 1%
MeOH
in DCM. First, some un-reacted starting material was eluted, then the higher Rf chlorin isomer 10 as a brown-purple crystalline solid; RJ-= 0.28 (DCM/MeOH, 19:1). The lower Rt~ isomer 11 was obtained by further elution with 2.5% MeOH in DCM and gave also a brown-purple crystalline solid (Rf= 0.17 (DCM/MeOH, 19:1).
High Rt~ chlorin regioisomer (17,18-dihydroxy-15-(4-methoxy phenyl)-5-(4-aminophenyl)chlorin assigned previously(26)) (7.0 mg, 24%), mp 165-167°C
(decomposed); UV-vis (DCM) ~,",ax (relative intensity) 401 (0.99), 414 (1.0), 503 (0.08), 535 (0.07), 582 (0.035), 636 (0.22) nm; Fluorescence (DCM) 7~~"ax 639 nm (~, excitation = 412 nm); 1H NMR (270 MHz, 10% CD30D in CDC13) 8 9.95 (s, 1H, 10-I~, 9.42 (s, 1H, 20-I~, 9.17 (d, 1H, J = 4.8 Hz, ~3-I~, 9.03 (d, 1H, J = 4.0 Hz, ,(3-~, 8.97 (s, 2H, /.3 I~
8.78 (d, 1H, J = 4.8 Hz, ,(3-I~, 8.51 (d, 1H, J = 4.8 Hz, ,~3 I~, 8.05 (m, 2H, J = 8.9 Hz, o-Ar), 7.94 (m, 2H, J = 8.1 Hz, o'-An), 7.25 (m, 2H, J = 8.9 Hz, na Ar), 7.12 (m, 2H, J = 8.1 Hz, m '-Ar), 6.42 (d, 1H, J = 6.5 Hz, 17-I~, 6.03 (d, 1H, J = 6.5 Hz, 18-I~, 4.08 (s, 3H., H; ), (NH'.s exchanged & CFI '.s~ not observed); MALDI-MS m/z 542.2 ([M+H]''-, 100%);
ES-HRMS calcd. for C33H28NSO3 ([M+H]+) 542.2192, found 542.2187.
Low Rt~ chlorin regioisomer (7,8-dihydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl)chlorin) (8.5 mg, 30%), mp 168-171°C (decomposed); UV-vis (DCM) 7~",~" (relative intensity) 401(0.99), 413 (1.0), 507 (0.08), 536 (0.06), 586 (0.025), 637 (0.20) nm; Fluorescence (DCM) ~,m~X 639 nm (~, excitation = 412 nm); 1H NMR
(270 1VJIIz, 10% CD30D in CDC13) d 9.96 (s, 1H, 20-I~, 9.40 (s, 1H, 10-I-~, 9.18 (d, 1H, J =
4.8 Hz, ,Q-I~, 9.05 (d, 1H, J = 4.8 Hz, ~3-I~, 8.98 (d, 1H, J = 4.0 Hz, ~3 I~
8.92 (d, 1H, J
= 4. 0 Hz, ~3-I~, 8. 74 (d, 1 H, J = 4 . 0 Hz, ~3 I~, 8 . 5 8 (d, 1 H, J = 4.
0 Hz, ,Ci I~, 8.13 (m, 1 H, J = 8.9 Hz, e~ An), 8.08 (m, 1H, J = 8.9 Hz, o-Ar~), 7.95 (m, 1H, J = 8.1 Hz, o'-Ar), ?.79 o -( m, 1 H, J = 8 .1 Hz, o ' Ar), 7. 3 6 (m, 1 H, J = 8. 9 Hz, m-Ar), 7. 3 0 (m, 1 H, J = 8. 9 Hz, m-Ar), 7.11 (m, 1H, J = 8.1 Hz, m' Ar), 7.05 (m, 1H, J = 8.1 Hz, m' Ar), 6.42 (d, 1H, J = 6.5 Hz, 7-H), 6.09 (d, 1H, J = 6.5 Hz, f-H), 4.11 (s, 3H, CH3), (NH's exchanged &
OH's not observed); MALDI-MS m/z 542.2 ([M+H]+, 100%) ES-HRMS calcd. for C33HZ8NSO3 ([NI+H]T) 542.2192, found 542.2185.
MeOH
in DCM. First, some un-reacted starting material was eluted, then the higher Rf chlorin isomer 10 as a brown-purple crystalline solid; RJ-= 0.28 (DCM/MeOH, 19:1). The lower Rt~ isomer 11 was obtained by further elution with 2.5% MeOH in DCM and gave also a brown-purple crystalline solid (Rf= 0.17 (DCM/MeOH, 19:1).
High Rt~ chlorin regioisomer (17,18-dihydroxy-15-(4-methoxy phenyl)-5-(4-aminophenyl)chlorin assigned previously(26)) (7.0 mg, 24%), mp 165-167°C
(decomposed); UV-vis (DCM) ~,",ax (relative intensity) 401 (0.99), 414 (1.0), 503 (0.08), 535 (0.07), 582 (0.035), 636 (0.22) nm; Fluorescence (DCM) 7~~"ax 639 nm (~, excitation = 412 nm); 1H NMR (270 MHz, 10% CD30D in CDC13) 8 9.95 (s, 1H, 10-I~, 9.42 (s, 1H, 20-I~, 9.17 (d, 1H, J = 4.8 Hz, ~3-I~, 9.03 (d, 1H, J = 4.0 Hz, ,(3-~, 8.97 (s, 2H, /.3 I~
8.78 (d, 1H, J = 4.8 Hz, ,(3-I~, 8.51 (d, 1H, J = 4.8 Hz, ,~3 I~, 8.05 (m, 2H, J = 8.9 Hz, o-Ar), 7.94 (m, 2H, J = 8.1 Hz, o'-An), 7.25 (m, 2H, J = 8.9 Hz, na Ar), 7.12 (m, 2H, J = 8.1 Hz, m '-Ar), 6.42 (d, 1H, J = 6.5 Hz, 17-I~, 6.03 (d, 1H, J = 6.5 Hz, 18-I~, 4.08 (s, 3H., H; ), (NH'.s exchanged & CFI '.s~ not observed); MALDI-MS m/z 542.2 ([M+H]''-, 100%);
ES-HRMS calcd. for C33H28NSO3 ([M+H]+) 542.2192, found 542.2187.
Low Rt~ chlorin regioisomer (7,8-dihydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl)chlorin) (8.5 mg, 30%), mp 168-171°C (decomposed); UV-vis (DCM) 7~",~" (relative intensity) 401(0.99), 413 (1.0), 507 (0.08), 536 (0.06), 586 (0.025), 637 (0.20) nm; Fluorescence (DCM) ~,m~X 639 nm (~, excitation = 412 nm); 1H NMR
(270 1VJIIz, 10% CD30D in CDC13) d 9.96 (s, 1H, 20-I~, 9.40 (s, 1H, 10-I-~, 9.18 (d, 1H, J =
4.8 Hz, ,Q-I~, 9.05 (d, 1H, J = 4.8 Hz, ~3-I~, 8.98 (d, 1H, J = 4.0 Hz, ~3 I~
8.92 (d, 1H, J
= 4. 0 Hz, ~3-I~, 8. 74 (d, 1 H, J = 4 . 0 Hz, ~3 I~, 8 . 5 8 (d, 1 H, J = 4.
0 Hz, ,Ci I~, 8.13 (m, 1 H, J = 8.9 Hz, e~ An), 8.08 (m, 1H, J = 8.9 Hz, o-Ar~), 7.95 (m, 1H, J = 8.1 Hz, o'-Ar), ?.79 o -( m, 1 H, J = 8 .1 Hz, o ' Ar), 7. 3 6 (m, 1 H, J = 8. 9 Hz, m-Ar), 7. 3 0 (m, 1 H, J = 8. 9 Hz, m-Ar), 7.11 (m, 1H, J = 8.1 Hz, m' Ar), 7.05 (m, 1H, J = 8.1 Hz, m' Ar), 6.42 (d, 1H, J = 6.5 Hz, 7-H), 6.09 (d, 1H, J = 6.5 Hz, f-H), 4.11 (s, 3H, CH3), (NH's exchanged &
OH's not observed); MALDI-MS m/z 542.2 ([M+H]+, 100%) ES-HRMS calcd. for C33HZ8NSO3 ([NI+H]T) 542.2192, found 542.2185.
(12) 5-(4-Fluorenylmethylaminophenyl)-15-(4-methoxyphenyl)porphyrin, To a stirred solution of porphyrin 9 (28 mg, 55 p.mol) in anhydrous 1,4-dioxane (2.5 mL) was added solid sodium hydrogen carbonate (6 eq., 28 mg, 0.33 mmol). To this mixture was then added a solution of 9-fluorenylmethyl chloroformate (2 eq., 0.11 mmol, 28.5 mg) in 1,4-dioxane (0.5 mL) under N2. The reaction flask was covered with aluminium foil to exclude light and stirred at room temperature for a period of 3 h. At this time the reaction was complete (as monitored by TLC). The 1,4-dioxane was removed in-vacuo and the residue partitioned between water (25 mL) and DCM (2 x 25 mL). The combined organic extracts were washed with saturated brine (25 mL) then dried (Na2SOa), filtered and concentrated in vacuo. The required porphyrin was obtained by chromatography, eluting with DCM. The desired porphyrin was obtained as purple crystals (38 mg, 95%), R'= 0.39 (DCM), mp 292-295°C (decomposed); UV-vis (DCM) ~,max (relative intensity) 410 ( 1.0), 505 (0.042), 541 (0.02), 578 (0.015), 633 (0.01) nm; Fluorescence (DCM) ~,max 635 nm (~, excitation = 410 nm); 1H NMR (270 MHz, CDC13) b 10.35 (s, 2H, 10+20 ~, 9.69 (br. s, 1H, NH), 9.44 (d, 4H, J = 4.8 Hz, ,~33-F~, 9.12 (d, 4H, J = 4.8 Hz, ~3-H), 8.20-8.17 (m (overlapping), 4H, J ='8.1 Hz, .5+IS-o-Ar), 7.85 (m, 4H, .S+IS-nz Ar), 7.76-7.66 (m, 2H,,fZuorerro Ar), 7.51-7.30 (m, 6H, fZuo~°eno Ar), 4.69 (d, 2H, J
= 7.2 Hz, CHI), 4.30 (t, 1H, J = 7.2 Hz, CH), 4.13 (s, 3H, CH3), -3.15 (br. s, 2H, NH); MALD-MS m/z 731.5 ([M+H]+, 100°J°), 508.3 ([M-FMOC+2]~, 50%); ES-HRMS calcd. for C4gH36N5O3 ([M+H]~) 730.2818, found 730.2809.
(13, 14) cis/traps-7,8,17,18-Tetrahydroxy-5-(4-fluorenylmethylaminophenyl)-15-(4-methoxyphenyl) bacteriochtorins Porphyrin 12 (35 mg, 48.0 pmol) was converted into the required mixture of bacteriochlorin stereoisomers by minor modification of the procedure of Sutton et al. (2000 Functionalised diphenylchlorins and bacteriochlorins - their synthesis and bioconjugation for targeted photodynamic therapy and tumour cell imaging J.
Porphyrin arzcl Phthcrlocyarzines 4, 655-658 - incorporated herein by reference) (reaction carried out using 1,4-dioxane (5 mL) to allow dissolution of 12). The crude reaction mixture was chromatographed, eluting initially with 1% MeOH in DCM to remove chlorin by-products. Further elution with 2% MeOH/DCM allowed isolation of both stereoisomeric bacteriochlorin tetrols. The higher R~~trans bacteriochlorin isomer 13 was isolated as a pink-green crystalline solid, (6 mg, 15%), Rf= 0.25 (DCM/MeOH, 19:1), mp 142-145oC
(decomposed); UV-vis (DCM) ~.",:1~ (relative intensity) 374 (1.0) 512 (0.23), 702 (0.52) nm; Fluorescence (DCM) 7~",~, 708 nm (7,, excitation = 512 nm); 1H NMR (270 MHz, 10% CD30D in CDCl3) d 9.20 (s, 2H, 10+?0-H), 8.78 (d, 2H, J = 4.0 Hz, ~3 H), 8.36 (d, 2H, J = 4.0 Hz, ,(3-H), 7.95 (m, ZH, o-Ar), 7.85 (m, 2H, J = 7.3 Hz, fZzcor~erzo-Ar), 7.79 (m, 2H o '-Ar~), 7.65 (m, 2H, rn ' Ar), 7.47-7.3 8 (m, 6H, fZuor°erzo-Ar), 7.24 (m, 2H, rn-Ar"), 6.27-6.24 (m, 2H, 7+17-H), 5.85 (m, 2H, 8+18-H), 4.65 (d, 2H, J = 7.2 Hz, CHz), 4.39 (t, 1H, J = 7.2 Hz, CH), 4.06 (s, 3H, CHj), -1.94 (br s (partly exchanged), 2H, NH), (OH's not observed); MALDI-MS m/z 800.4 ([M+H]+, 100%); ES-HRMS calcd. for C~,RH:,«N;O~ ([M+H]+) 798.2927, found 798.2921.
The lower Rt~ cis-bacteriochlorin isomer 14 was isolated as a pink-green crystalline solid, (8.5 mg, 21%), Rf= 0.2 (DCM/MeOH, 19:1), mp 148-150oC (decomposed); UV-vis (DCM) ~,",:" (relative intensity) 374 (1.0) 512 (0.24), 703 (0.54) nm;
Fluorescence (DCM) ~,",:1~ 708 nm (7~ excitation = 512 nm); 1H NMR (270 MHz, 10% CD30D in CDC13) 8 9.12 (s, 2H, 10+20-H), 8.76 (d, 2H, J = 4.8 Hz, /3-H), 8.34 (d (overlapping), 2H, J = 4.8 Hz, ,(3-H), 8.02 (m, 2H, o-Ar), 7.85 (m (obscured), 2H, J = 8.0 Hz, o' AY), 7.83 (m, 2H, J = 7.3 Hz, fZuoYerzo Ar~), 7.76 (m, 2H, J = 8.0 Hz, rn'-Ar), 7.50-7.38 (m, 6H, f7zcoueroo-Ar~), 7.24 (m, 2H, rn Ar~), 6.27-6.23 (m, 2H, 7+ 17-H), 5.85-5.82 (m, 2H, 8+18-H), 4.65 (d, 2H, J = 7.2 Hz, CHI), 4.39 (t, 1H, J = 7.2 Hz, CH), 4.05 (s, 3H, CH3), -1.88 (br. s (partly exchanged), 2H, NH), (OH's not observed); MALDI-MS mlz 800.4 ([M+H]T, 100%); ES-HRMS calcd. for Ca$H4~N50~ ([M+H]+) 798.2927, found 798.2921.
(15) 5-(3,4,5-Trismethoxyphenyl)dipyrromethane 3,4,5-Trismethoxybenzaldehyde (5.0 g, 25.5 mmol) was dissolved in freshly distilled pyrrole (75 ml) and the solution degassed by bubbling with dry NZ for 10 min.
TFA
(0.075 eq. , 0.15 ml, 1.91 mmol) was added and the mixture stirred under NZ
until no starting aldehyde could be detected by TLC (ca. 10 min). The reaction mixture was concentrated lr2 VaCZlO at water aspirator pressure (evaporator water bath temp 75°C ) then under high vacuum for 16 h to remove excess pyrrole. The crude product was recrystallised from hot ethylacetate/ nHexane and afforded the required dipyrromethane as a white solid, ( 5.41 g, 68%): v",a~ (nujol mull)/ cm i 3378 (br. NH), 1594 (C=C), 1233, 1040; UV-VIS (MeOH) ~.",a~/ (rel. intensity) 222 (1.0), 280 (0.75) nm;
c~H(270 MHz; CDC13) 8.07 (2H, br. s, NH), 7.53 (2H, m, I-H), 6.68 (2H, s, 2'-H), 6.37 (2H, m, ?-H), 5.93 (2H, m, 3-H), 5.38 (1H, s, rr7etharae), 3.80 (3H, s, -~'-OCH;), 3.73 (6H, s, 3 '+~ '-UCH;); bC(68 MHz; CDC13) 152.7 (CH, 2'-C), 137.3 (q, 3'+5'-C), 136.1 (q, 4'-C), 131.8 (q, 4-C), 116.7 (CH, 1-C), 107.9 (CH, 2-C), 106.6 (CH, 3-C), 104.9 (q, 1'-C), 60.3 (CH;), 55.5 (CH;), 43.7 (CH., methane); MS (MALDI) m/e 311.2 (100%, (M-1)+).
(16) 5-(4-Acetomidophenyl)dipyrromethane The dipyrromethane was synthesised using the general procedure detailed above using the same molar quantity of starting aldehyde. The crude reaction mixture was chromatographed on flash silica-gel (350 ml), (dry loaded on to 50 ml flash silica-gel from ethylacetate) and eluted with 40% ethylacetate/ DCM and afforded the pure product as an off white solid, (4.3 g, 50%): vm~,,; (nujol mull)/ cm 1 3409 (NH, amide), 3248 (br.
NH), 1650 (C=O), 1593 (C=C), 1320, 1009; UV-VIS (MeOH) ~,m~;;/ (rel.
intensity) 224 ( 1.0) nm; dH(270 MHz; CDC13) 8.00 (ZH, br. s, NH), 7.40 (2H, d, J = 8.5 Hz, o-Ar ), 7.30 (1H, br. s, NH-acetotnido), 7.13 (2H, d, J= 8.5 Hz, m-Ar), 6.68 (2H, m, I-H), 6.16 (2H, m, ?-I~, 5.90 (2H, m, 3-H), 5.42 (1H, s, rnetharze), 2.14 (3H, s, NH~~); 8C(68 MHz;
CDC13) 168.4 (q, LOCH;), 138.2 (q, 4'-C), 136.5 (q, 2'-C), 132.4 (q, 4-C), 128.9 (CH, 2'-C), 120.3 (CH, 3'-C), 117.2 (CH, 1-C), 108.4 (CH, 2-C), 107.1 (CH, 3-C), 43.4 (CH., methane), 24.5 (CH3); MS (MALDI) m/e 279.4 ( 100%, (M)~).
(17) ~-(4-Methoxyphenyl)dipyrromethane The dipyrromethane was synthesised using the general procedure detailed above using the same molar quantity of starting aldehyde. The crude reaction mixture was chromatographed on flash silica-gel (350 ml), (dry loaded on to 50 ml flash silica-gel from ethylacetate) and eluted with 30% nHexane/ DCM and afforded the pure product as an off white solid, (4.3 g, 50%): vma;; (nujol mull)/ cm 1, 3382 (br. NH), 1598 (C=C), 1300, 1050; UV-VIS (MeOH) 7~",a,~/ (rel. intensity) 224 (1.0) nm; 8H(270 MHz;
CDC13) 7.87 (2H, br. s, NIA, 7.10 (2H, d, J = 8.8 Hz, m-Ar ), 6.83 (2H, d, J = 8.8 Hz, o-An), 6.66 (2H, m, I-I~, 6.14 (2H, m, ?-I~, 5.89 (2H, m, 3-I~, 5.40 (1H, s, rrZethane);
MS (MALDI) m/e 252.4 (100°J°, (M)+).
Example 1 s-(4-Isothiocyanatophenyl)-10,15,20-tris(3,5-dihydroxyphenyl)porphyrin H
H~
To a stirred solution of 3 (100 mg, 0.137 mmol) in freshly distilled THF (25 mL) was added 1,1'-thiocarbonyldi-2(ll~-pyridone (64 mg, 0.276 mmol). The reaction was allowed to proceed under argon for 4 hours at room temperature. Excess solvent was evaporated lf7 VClCZlO to yield a crude purple solid. The solid was dissolved in a minimal amount of chloroform/methanol (9:1) and purified by flash chromatography (silica, eluent: CHC13/MeOH, 9:1). Relevant fractions were combined, dried (Na2S0a) and evaporated irZ ocrcuo to yield the above compound as a purple solid (67.5 mg, 63.8%); Rf = 0.29 (silica, CHCl3/MeOH, 9:1); mp >350 °C decomp.; 1H NMR [270 MHz, CDC13/CD30D, 3:1] 86.77 (3H, s, 10, 15, 20-Ar-4-H), 7.12 (6H, s, 10, 15, 20-Ar-2,6-H), 7.64 (2H, m, .I* = 8 Hz, 5-Ar-3,5-H), 8.19 (2H, m, J* = 8 Hz, S-Ar-2,6-H), 8.76-9.0 (8H, m, (3-H); 13C NMR [67.5 MHz, CDC13/CD30D, 3:1] 8101.9, 107.1, 114.7, 117.6, 119.9, 120, 120.1, 123.9, 130.9, 134, 135.2, 136.1, 141.2, 142, 143.6, 155.8; UV-vis (MeOH) w vn ~.",~"422, 516, 552, 592, 648 nm; HRMS (ES) m/z calc'd for C45Hz9N5OsS [M+H]+
768.1914, found 768.1908.
Example 2 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-pyridyl)porphyrin To a stirred solution of 5 (100 mg, 0.158 mmol) in freshly distilled dichloromethane (20 mL) was added l,1'-thiocarbonyldi-2(11-pyridone (320 mg, 1.38 mmol). The reaction was allowed to proceed under argon for 4 hours at room temperature. Excess solvent was evaporated in vacuo to yield a crude purple solid. The solid was dissolved in a minimal amount of chloroform and purified by flash chromatography (silica, eluent: CHCl3/MeOH, 49:1). Relevant fractions were combined, dried (NazSO:~) and evaporated in vacuo to yield the above compound as a purple solid ( 104 mg, 97.5%); Rf= 0.57 (silica, CHCI3IMeOH, 49:1); mp >350 °C
decomp.; 1H NMR
[270 MHz, CDC13] 8-2.91 (2H, br s, NH), 7.65 (2H, m, J* = 8 Hz, 5-Ar-3,5-H), 8.15-8.21 (8H, m (overlapping), 10, 15, 20-Py-2,6-H & 5-Ar-2,6-H), 8.67 (8H, br s, (3-H), 9.06 (6H, m, J* = 5 Hz, 10, 15, 20-Py-3,5-H); 13C NMR [67.5 MHz, CDCl3] 8117.4, 117.6, 119.7, 124.7, 129.3, 131.6, 135.4, 136.9, 140.6, 148.4, 149.8; UV-v15 (CHZCIz) a,max 417, 514, 548, 587, 643 nm; HRMS (ES) m/z calc'd for C4zHz6NsS (M+H) 675.2079, found 675.2078.
Example 3 5-(4-Isothiocylnatophenyl)-10,15,20-tris(3-pyridyl)porphyrin (160) To a stirred solution of 7 (200 mg, 0.316 mmol) in freshly distilled dichloromethane (40 mL) was added l,1'-thiocarbonyldi-2(lf~-pyridone (640 mg, 2.76 mmol). The reaction was allowed to proceed under argon for 17 hours at room temperature. Excess solvent was evaporated in vacz.ro to yield a crude purple solid. The solid was dissolved in a minimal amount of chloroform and purified by flash chromatography (silica, eluent: CHCl3/MeOH, 49:1). Relevant fractions were combined, dried (Na2S0:,) and evaporated irz vacuo to yield the above compound as a purple solid ( 171 mg, 80.3%); Rf= 0.55 (silica, CHCl3/MeOH, 49:1); mp >350 °C
decomp.; 1H NMR
[270 MHz, CDC13] 8-2.83 (2H, br s, NH), 7.65 (2H, m, J* = 8 Hz, 5-Ar-3,5-H), 7.78 (3H, m, 10, 15, 20-Py-5-H), 8.20 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.54 (3H, m, 10, 15, 20-Py-6-H), 8.83-8.88 (8H, m, (3-H), 9.07 (3H, m, 10, 15, 20-Py-4-H), 9.07 (3H, s, 10, 15, 20-Py-2-H); 13C NMR [67.5 MHz, CDCl3] 8116.6, 122.1, 124.2, 131.5, 135.5, 137.7, 140.8, 140.9, 149.2, 153.5; UV-vis (CHZCIz) a,mah 421, 513, 547, 587, 657 rim;
MS
(MALDI-TOF) nZ~s 674 (MT, 100%).
=~6 Example 4 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-N methylpyridiniumyl) porphyrin triiodide I Me- -Me I
N
I
Me I
To a solution of Example 2 (50 mg, 0.074 mmol) in anhydrous DMF (10 mL, distilled from CaHz, 0.1 torr) was added iodomethane (1 mL, 0.016 mol). The reaction was stirred under argon for 3 hours at room temperature, monitored by TLC
(normal phase silica) in a water/saturated aqueous potassium nitrate/acetonitrile (1:1:8) solvent system. Upon reaction completion excess DMF was evaporated in vacuo (0.1 torr) at 30-40 °C to yield the above compound as a lustrous purple solid (77 mg, 95%); Rf = 0.32 (silica, H20/sat.aq. KN03/MeCN, 1:1:8); mp >350 °C decomp.; 1H NMR [270 MHz, (CD3)zS0] 8-3.03 (2H, br s, NH), 4.74 (9H, br s, N CH3-pyridine), 7.96 (2H, m, J* = 8 Hz, 5-Ar-3 , 5-H), 8. 3 2 (2H, m, J* = 8 Hz, 5-Ar-2, 6-H), 9. 03 (6H, m, J* =
6 Hz, 10, 15, 20-Py-2,6-H), 9.16 (8H, m, (3-H), 9.50 (6H, m, J* = 6 Hz, 10, 15, 20-Py-3,5-H); 13C
NMR [67.5 MHz, (CD3)zSO] X47.9, 114.7, 115.3, 121.1, 124.8, 130.6, 132, 134.7, 135.4, 139.7, 144. l, 156.3, 156.4; UV-vis (Hz0) ~,m;~X 423, 520, 585 nm; MS (FAB) nalz 719 (MT, 100%), 704 (M-CH3, 26%), 689 (M-2CH3, 20%), 674 (M-3CH3, 5%); HRMS (ES) nz/z calc'd for C:~;H35N8S (M+H) 719.2705, found 719.2686.
E~cample 5 5-(4-Isothiocyanatophenyl)-10,15,20-tris(3-N methylpyridiniumyl) porphyrin triiodide I
~e ME
I
me I
To a solution of Example 3 (50 mg, 0.074 mmol) in anhydrous DMF (5 mL, distilled from CaH, 0.1 torr) was added iodomethane (1 mL, 0.016 mol). The reaction was stirred under argon for 4 hours at room temperature, monitored by TLC
(normal phase silica) in a water/saturated aqueous potassium nitrate/acetonitrile (1:1:8) solvent system. Upon reaction completion excess DMF was evaporated irt mcuo (0.1 torr) at 30-40 "C to yield the above compound as a lustrous purple solid (72 m~, 89%); Rf = 0.46 (silica, H~O/sat.aq. KN03/MeCN, 1:1:8); mp >350 °C decomp.; iHNMR [270 MHz, (CDs)ZSO] ~-3.07 (2H, br s, NH), 4.69 (9H, br s, N CH3-pyridine), 7.97 (2H, m, ,l* = 8 Hz, 5-Ar-3,5-H), 8.31 (2H, m, J* = 8 Hz, S-Ar-2,6-H), 8.64 (3H, m, 10, 15, 20-Py-5-H), 9.03-9.25 (8H, m, (3-H), 9.35 (3H, m, 10, 15, 20-Py-6-H), 9.57 (3H, m, 10, 15, 20-Py-4-H), 10.03 (3H, s, 10, 15, 20-Py-2-H); 13C NMR [67.5 MHz, (CD3)ZSO] 848.3, 112.3, 112.9, 120.7, 124.8, 126.3, 126.4, 126.6, 130.6, 132.1, 132.3, 132.4, 132.6, 132.8, 133.1, 133.4, 134.7, 135.4, 139.8, 139.9, 140, 145.5, 145.6, 147.4, 147.5, 147.8, 147.9, 148.5, 155.9; UV-vis (H20) ~,",<«419, 516, 552, 581, 637 nm; MS (MALDI-TOF) m%z 689 ([M-2CH~]T, 100%).
Example 6 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-N methylpyridiniumyl) porphyrin trichloride Ci Me- ~ Me Cl Me To a solution of Example 4 (30 mg, 0.027 mmol) in anhydrous methanol (30 mL) was added Amberlite° IRA 400 (lg) and the mixture stirred for 1 hour at room temperature. Amberlite° IRA 400 resin was filtered under vacuum and the porphyrin filtrate recovered, dried (Na2S0~) and evaporated i~z vacuo to yield the above compound as a water soluble purple solid (22 mg, 96.4%). Porphyrins of Examples 4 and 6 were distinguished only by their respective solubility in water.
Example 7 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-N methylpyridiniumyl) porphyrin trichloride 49 =
CI
~e Me Cl IVIC
CI
To a solution of 5 (30 mg, 0.027 mmol) in anhydrous methanol (30 mL) was added Amberlite° IR.A 400 (lg) and the mixture stirred for 1 hour at room temperature.
Amberlite° IRA 400 resin was filtered under vacuum and the porphyrin filtrate recovered, dried (NaZS04) and evaporated ifZ vacuo to yield the above compound as a water soluble purple solid (21 mg, 92.0%). Porphyrins of Examples 5 and 7 were distinguished only by their respective solubility in water.
Example 8 17,18-Dihydroxy-5-(4-isothiocyanltophenyl)-15-(4-methoxyphenyl)chlorin, The higher Rt~regioisomeric chlorin 10 (17.5 mg, 23.2 p.mol) was converted into the corresponding isothiocyanate according to the following method. To a stirred solution of ( 1 ec~., 50 mg, 0.099 mmol) in freshly distilled DCM (20 mL) was added 1,1'-thiocarbonyldi-2(11~-pyridone (2 eq., 46 mg, 0.198 mmol). The reaction was allowed to stir under argon for 2 h at room temperature, after which the reaction mixture was filtered, and concentrated then chromatographed, eluting with 1% MeOH in DCM
to afford the title compound. The title compound was isolated as a brown-purple crystalline solid, (17 mg, 90%), Rf= 0.36 (DCM/MeOH, 19:1), mp 155-158°C
(decomposed); UV-vis (DCM) ~.",,1~ (relative intensity) 410 (1.0) 505 (0.09), 534 (0.06), 586 (0.04), 637 (0.18) nm; Fluorescence (DCM) 7~",~~ 639 nm (~, excitation = 412 nm); 1H NNiR
(270 MHz, 10% CD30D in CDC13) 8 10.0 (s, 1H, 10-I~, 9.45 (s, 1H, 20-I~, 9.20 (d, 1H, J =
4.8 Hz, ,C~H), 9.06 (d, 1H, J = 4.0 Hz, ~ H), 9.02 (d, 1H, J = 4.8 Hz, ~3 H) 8.84 (d, 1H, J =
4.8 Hz, ,C~H), 8.64 (d, 1H, J = 4.0 Hz, ~3 H), 8.55 (d, 1H, J = 4.8 Hz, ~3 H), 8.21 (m, 1H, J
= 8.1 Hz, ~-o-Ar), 8.15 (m, 1H, J = 8.1 Hz, ~-o An), 8.05 (m, 1H, J = 8.9 Hz, 1.5-o-Ar~) 7.93 (m, 1H, J = 8.9 Hz, !~-o-Af~), 7.65 (m, 2H, ~-n~-An), 7.24 (m, 2H, l.iayz-Ar), 6.43 (d, 1H, J = 6.5 Hz, 17-H), 6.04 (d, 1H, J = 6.5 Hz, 18-H), 4.08 (s, 3H, CH;), (NH's exchanged & OH's not observed); MALDI-MS m/z 583.7 ([M=H]+, 100%); ES-HRMS
calcd. for C3aH2~N;03S ([M+H]t) 584.1757, found 584.1756.
Example 9 cis-7,8,17,18-Tetrahydroxy-5-(4-isothiocyanatophenyl)-15-(4-methoxyphenyl)bacteriochlorin The ci.s-bacteriochlorin 14 (8.5 mg, 10.7 p.mol) in 25% MeOH in DCM (1.25 mL) was treated with piperidine (.SO eq., 53 p.l , 0.53 mmol) and left to stir for a period of 3 h at room temperature under N2 with light excluded. The reaction mixture was concentrated ira vcrc~ro (0.1 torr) to remove all traces of piperidine. The crude amine was then converted into the reduired isothiocyanate following the procedure described above The cis-bacteriochlorin_isothiocyanate was isolated as a pink-green crystalline solid (5.0 mg, 76%), Rf~= 0.40 (DCMIMeOH, 19:1), mp 132-135°C (decomposed); UV-vis (DCM) ~,max (relative intensity) 375 (1.0) 516 (0.22), 702 (0.48) nm; Fluorescence ~,max 709 nm (~, excitation = 516 nm); 1H NMR (270 MHz, 10% CD30D in CDC13) 8 9.20 (s, 1H, meso-H), 9.18 (s, 1H, n2eso-H), 8.77 (d, 2H, J = 4.8 Hz, ,l3-H), 8.40 (d, 1H, J =
4.8 Hz, ,<3 H), 8.34 (d, 1H, J = 4.8 Hz, ,Q-H), 8.14 (m, 2H, o Af~), 8.05 (m, 2H, o' An), 7.42-7.08 (m, 4H, ~+l~-m-Ar), 6.20 (m, 2H, 7+17-H), 5.98 (m, 1H, 8-H), 5.93 (m, 1H, 18 I~, 4.04 (s, 3H, CH;), -1.80 (br s, 2H, partly exchanged-NH), (OH's not observed); MALDI-MS m/z 618.9 ([M+H]+, 100%); ES-HRMS calcd. for C3~IZgN;OSS ([M+H]+) 618.1815, found 618.1810.
Examples 10, 11, 12, 13 17,18-Dihydroxy-5-(4-acetamidophenyl)-15-(4-methoxyphenyl)chlorinl7,8-dihydroxy-5-(4-acetamidophenyl)-15-(4-methoxyphenyl)chlorin regioisomers, and cis/trap.s-7,8,17,18-tetrahydroxy-5-(4-acetamidophenyl)-15-(4-methoxyphenyl)bacteriochlorin stereoisomers, Porphyrin 8 (100 mg, 0.18 mmol) was converted, in a single reaction, to a mixture of chlorin diols/bacteriochlorin tetrols following the procedure of Sutton et al.
After 38 h the reaction was stopped. The crude reaction mixture was then chromatographed, eluting with 2% MeOH in DCM to give first, some un-reacted starting material then the higher Ri~ chlorin isomer of Example 10 as a brown-purple crystalline solid (5 mg, 5%). The lower Rt~ isomer of Example 11 was obtained by further elution with 3.5% MeOH
in DCM and gave also a brown-purple crystalline solid (7.0 mg, 7%). Further elution with 5% MeOH in DCM afforded the required tj~ar~sicis-bacteriochlorin tetrols of Examples 12 and 13 respectively as pink/green solids (5.0 mg, 5%) and (7.0 mg, 7%) respectively.
High Rt~ chlorin regioisomer of Example 10 (17,18-dihydroxy-15-(4-methoxyphenyl)-5-(4-acetamidophenyl) chlorin assigned on the basis of past data)(~6) R~= 0.40 (DCM/MeOH, 37:3), mp 186-188°C (decomposed); UV-vis (DCM) ~,max (relative intensity) 410(1.0), 505.5 (0.12), 535 (0.08), 585.5 (0.05), 637 (0.18) nm;
Fluorescence (DCM) 7~",;,~ 639 nm (~, excitation = 410 nm); 1H NMR (270 MHz, CDCl3) 8 9.97 (s, 1H, 10-I~, 9.42 (s, 1H, 20-H), 9.19 (d, 1H, J = 4.0 Hz, ~3-H), 9.03 (d, 1H, J =
4.0 Hz, ,(3-H), 8.98 (d, 1H, J = 4.8 Hz, /3-H) 8.89 (d, 1H, J = 4.0 Hz, ,~3-H), 8.70 (d, 1H, J
= 4.8 Hz, /3 H), 8.52 (d, 1H, J = 4.8 Hz, ,(3-H), 8.14-8.10 (m, 3H, S-olna At~), 7.96-7.82 (m, 3H, ~+IS-o%jn-Ar), 7.50 (s, 1H, NH), 7.34 (m, 2H, IS-na Af°), 6.48 (m, 1H, 17-H), 6.20 (m, 1H, I~-H), 4.08 (s, 3H, CH;), 2.38 (s, 3H, CH;), -1.89, -2.20 (s, 2H, NH); MALDI-MS
miz 582.6 ([M+H]~, 100%); ES-HRMS calcd. for C3sHzsNsOa ([M+H]+) 582.2141, found 582.2137.
Low Rt~ chlorin regioisomer of Example 11 (7,8-dihydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl)chlorin) Rf= 0.35 (DCM/MeOH, 37:3), mp 182-185°C
(decomposed);
UV-vis (DCM) ~,",a,; (relative intensity) 410(1.0), 505.5 (0.1), 535 (0.07), 585 (0.04), 636 (0.19) nm; Fluorescence (DCM) ~,",ax 639 nm (~, excitation = 410 nm); 1H NMR
(270 MHz, 10% DMSO-d~ in CDC13) 8 9.96 (s, 1H, 10 ~, 9.92 (s, 1H, NH), 9.42 (s, 1H, H), 9.22 (m, 1H, ~H), 9.02 (d, 1H, J = 4.8 Hz, ,(3-H), 9.00 (m, 1H, ,l3-I~
8.92 (m, 1H, ,l3 H), 8.70 (d, 1H, J = 4.8 Hz, ,(3-FI), 8.53 (m, 1H, ,(3 I~, 8.18-7.91 (m, 6H, 5+1.5-olm Ar), 7.33-7.28 (m, 2H, L5-n~ Ar), 6.36 (m, 1H, 7-H), 5.96 (m, 1H, 8 II), 4.10 (s, 3H, CHj), 2.30 (s, 3H, CH;), -1.74, -2.17 (s, 2H, NH); MALDI-MS m/z 582.6 ([M+H]+, 100%). ES-HRMS calcd. for C35H28N;Oa ([M+H]+) 582.2141, found 582.2135.
High Rt~trccrts bacteriochlorin of Example 12; Rf= 0.29 (DCM/MeOH, 37:3:1), mp 155°C (decomposed); UV-vis (DCM) ~.max (relative intensity) 373.5 (1.0) 514 (0.25), 702 (0.49) nm; Fluorescence (DCM) ~,max 708 nm (~, excitation = 514 nm); 1H NMR
(270 MHz, DMSO-d~) 8 10.27 (s, 1H, NH), 9.16 (s, 2H, 10+20-H), 8.96 (d, 2H, J = 4.0 Hz, ~
H), 8.24 (d, 2H, J = 4.0 Hz, /.~H), 7.99-7.89 (m, 6H, 5+1 S-olm Ar), 7.25 (m, 2H, I S-m-An), 6.30 (m, 2H, 7+17-H), 6.15 (m, 2H, 8+18 l~, 5.63 (m, 2H, Ol~, 5.32 (m, 2H, OH), 3.99 (s, 3H, CH3), 2.20 (s, 3H, CH3), -1.87 (br s, 2H, NH); MALDI-MS m/z 616.3 ([M+H]1, 100%). ES-HRMS calcd. for C35H3oNsOs ([M+H]+) 616.2196, found 616.2192.
Low Rt~ cis-bacteriochlorin 13; Rf= 0.24 (DCM/MeOH, 19:1), mp 148-151°C
(decomposed); UV-vis (DCM) ~,maX (relative intensity) 373.5 (1.0) 514.5 (0.24), 703 (0. SO) nm; Fluorescence (DCM) ~,max 708 nm (~, excitation = 514 nm); 1H NMR
(270 MHz, 20% CD30D in CDC13) 8 9.20 (s, 2H, 10+20-H), 8.78 (m, 2H, ,Q H), 8.35 (m, 2H, /.3 H), 8.05 (m, 2H, 5-~ AY), 7.89-7.86 (m, 3H, 5+IS-olm Ar), 7.75 (m, 1H, IS-o Ar), 7.20-7.17 (m, 2H, 15-m Ar), 6.25 (m, 2H, 7+17-F~, 5.86 (m, 2H, 8+18-H), 4.06 (s, 3H, C:H;), 2.31 (s, 3H, CHj), (NH's exchanged); MALDI-MS m/z 616.4 ([M+H]+, 100%).
ES-HRMS calcd. for C35H30N506 ((M+H]~) 616.2196, found 616.2192.
Example 16 5-(4-Isothiocyanatophenyl)-10,15,20-tri(4-methylphosphoniumphenyl)- porphyrin and 5-(4-isothiocyanatophenyl)-15-(4-methylphosphoniumphenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(4-aminophenyl)-10,25,20-tri-(4-carbomethoxyphenyl) porphyrin and 5-(4-aminophenyl)-15-(4-carbomethoxyphenyl) porphyrin were synthesised by mixed condensation using Lindsey conditions (Lindsey, J.S., Schreiman, LC., Hsu, H.C., I~earney, P.C., Marguerettaz, A.M. (1987) .I. Org. Che»a. 52, 827) or by 2+2 condensation methodology via the appropriately substituted 5-phenyldipyrromethanes as described by Boyle et al (Boyle, R.W., Bruckner, C., Posakony, J., James, B.R., Dolphin, D. ( 1999) Ongarzic Sy~ztheses. 76, 287 - incorporated herein by reference) respectively.
The (4-carbomethoxyphenyl) groups on these porphyrins were then converted to (4-(1-bromomethyl)phenyl) groups using the following standard procedure: the porphyrin (0.2 53 =
mmol) was dissolved in dry THF (25 ml) at 0°C and stirred under argon for 10 minutes.
Lithium aluminium hydride (0.7 mmol) was added and the stirring continued for hours. The reaction was monitored by TLC and, when the reaction was complete ethyl acetate (2 ml) was added and the mixture washed with aqueous HCl (0.2 M, 20 ml), saturated sodium bicarbonate solution (30 ml) and finally, brine (20 ml). The organic layer was dried (MgSO~) and evaporated to dryness to yield the corresponding (4-(1-hydroxymethyl)phenyl) substituted porphyrins, bearing three or one reduced carbomethoxy groups respectively. (4-(1-Hydroxymethyl)phenyl) substituted porphyrins (0.2 mmol) were dissolved in dry chloroform (40 ml) and stirred under argon while triphenylphosphine (1.0 mmol) and carbon tetrabromide (1.6 mmol) were added.
The reaction was stirred, in the dark, for 24 hours and then monitored by TLC.
Once all the hydroxymethyl groups had been converted to bromomethyl groups the reaction mixture was diluted with dichloromethane (40 ml), washed with saturated sodium bicarbonate (2 x 20 ml) then brine (2 x 20 ml) and the organic layer dried (MgSO~,). Removal of solvent by evaporation in vacuo afforded the corresponding bromomethyl porphyrins as purple crystalline solids.
Boc N-protected 5-(aminophenyl)-10,25,20-tri-(4-bromomethylphenyl) porphyrin and 5-(aminophenyl)-15-(4-bromomethylphenyl) porphyrin (0.75 mmol) were dissolved in dry dichloromethane (50 ml) under an atmosphere of argon at 25°C. Triaryl or trialkylphosphine (7.5 mmol) dissolved in dry dichloromethane (10 ml) was injected by syringe and the progress of the reaction was followed by TLC. Upon completion the solvent was evaporated from the reaction in vacuo and the crude product was purified by flash column chromatography (silica; gradient elution: dichloromethane to methanol) to give the required Boc-N-protected-5-(aminophenyl)-methylphosphonium-meso-aryl porphyrins as lustrous purple crystalline solids. The Boc protecting group was removed by dissolution of the porphyrin in chloroform or acetonitrile, depending upon solubility, and addition of trimethylsilyl iodide (5.0 equivalents), after 30 minutes the reaction was quenched with methanol (10 ml). Removal of solvent by evaporation, followed by purification by flash column chromatography (silica; gradient: dichloromethane to methanol) gave the 5-(aminophenyl)-methylphosphonium-meso-aryl porphyrins which were converted to the required mono-4-(isothiocyanatophenyl) compounds by treatment ~4 --with 1,1'-thiocarbonyldi-2(1H)-pyridone using standard procedures (Clarke, O.J. and Boyle, R.W. (1999.LC.S. Chem. Cornmicn. 2231).
Example 17 5-(4-Isothiocyanatophenyl)-10,15,20-tri((4-methylphosphono-di-ethoxy)phenyl)-porphyrin and 5-(4-isothiocyanatophenyl)-15-((4-methylphosphono-di-ethoxy)phenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(4-aminophenyl)-10,15,20-tri-(4-bromomethylphenyl) porphyrin and 5-(aminophenyl)-15-(4-bromomethylphenyl) porphyrin (0.75 mmol) were dissolved in a mixture of triethyl phosphite (15 mmol) and dry acetonitrile (50 ml). A reflux condenser was fitted and the reaction was refluxed under argon. The reaction was followed by TLC
and upon completion was washed with saturated sodium bicarbonate (2 x 20 ml), water (2 x 20 ml) and brine (2 x 20 ml). The organic layer was then dried (MgSO:~) and the solvent evaporated in vacuo. The crude product was then purified by flash column chromatography (silica; gradient elution:
dichloromethane to ethyl acetate) to give the title compounds as purple crystalline solids. The methylphosphono-di-ethoxy groups were then deprotected to either methylphosphono-mono-ethoxy sodium groups by sonication in aqueous sodium hydroxide for 1 hour followed by reversed phase medium pressure chromatography (C18; gradient elution 0.1%
aqueous TFA to methanol) (Boyle, R.W. and van Lier, J.E. (1993) Synlett 351), or to the fully deprotected methylphosphonic acids by treatment with bromotrimethylsilane (2 equivalents per methylphosphono-di-ethoxy group) for 2 hours followed by reversed phase chromatographic purification chromatography (CIB; gradient elution 0.1%
aqueous TFA to methanol) (McI~enna, C.E., Higa, M.T., Cheung, N.H., McI~enna, M-C.
(1977) 2, 155). Boc deprotection (see above) followed by conversion of the unmasked 4-(aminophenyl) group to its isothiocyanato analogue was performed using standard procedures (Clarke, O.J. and Boyle, R.W. (1999 J. C. S. Chena. Com~rrura.
2231)_ Example 18 5-(4-Isothiocyanatophenyl)-10,15,20-tri((4-methylphosphonato-di-ethoxy)phenyl)-porphyrin and 5-(4-isothiocyanatophenyl)-15-((4-methylphosphonato-di-ethoxy)phenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(aminophenyl)-10,15,20-tri-(4-hydroxymethylphenyl) porphyrin and 5-(aminophenyl)-15-(4-hydroxymethylphenyl) porphyrin (0.75 mmol) were dissolved in a mixture of dry dichloromethane and pyridine (4:1) under an atmosphere of argon.
Diethyl chlorophosphate (2 equivalents per hydroxymethyl group) was injected and the mixture was stirred for 16 hours. Evaporation of solvent from the reaction mixture followed by chromatographic purification gave the corresponding tri or mono ((4-methylphosphonato-di-ethoxy)phenyl) porphyrins. Treatment with aqueous sodium hydroxide ( 1M) gave the sodium salts of tri or mono ((4-methylphosphonatoethoxy)phenyl) porphyrins (Boyle, R.W. and van Lier, J.E.
(1995) Synthesis 1079). Boc deprotection and generation of the isothiocyanato group were performed as described above.
Example 19 5-(4-Isothiocyanatophenyl)-10,15,20-tri((4-methylpyridiniumyl)phenyl)- porphyrin and 5-(4-isothiocyanatophenyl)-15-((4-methylpyridiniumyl)phenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(aminophenyl)-10,25,20-tri-(4-bromomethylphenyl) porphyrin and 5-(aminoophenyl)-15-(4-bromomethylphenyl) porphyrin (0.75 mmol) were dissolved in dichloromethane (50 ml) and pyridine (15 mmol), or substituted pyridine (15 mmol), as required, were added. A reflux condenser was fitted and the reaction was refluxed under argon. The reaction was followed by TLC and, upon completion, was evaporated to dryness in vacuo. The residue was purified by reversed phase medium pressure chromatography (C1R; gradient elution 0.1% aqueous TFA to methanol) to yield the N-Boc protected 4-aminophenyl compounds. Deprotection of the aminophenyl groups) and conversion to the isothiocyanato analogues) were conducted using the standard protocols (see above).
~6 =
Example 20 5-(4-Isothiocyanatophenyl)-15-axyl-10,20-(1,2-dihydroxyethyl)-porphyrin - General Synthetic Procedure The Fmoc protected 5-(4-aminophenyl)-15-aryl porphyrin (0.8 mmol) was dissolved in dry chloroform (300 ml) under an atmosphere of argon. Freshly recrystallised N-bromosuccinimide (1.8 mmol) in dry chloroform (20 ml) was injected by syringe and the mixture was stirred for 30 min. The solvent was then evaporated in vacuo and the crude product purified by flash column chromatography (silica; gradient elution:
hexane to ethyl acetate) to give the required 5, 15-dibromo-10, 20-diarylporphyrin as a purple crystalline solid. The product was then metallated by refluxing in a chloroform/methanol (9:1 ) solution of zinc acetate dihydrate (80 mmol). The metallation was followed by visible spectroscopy and, upon completion, was passed through a short column of neutral alumina to remove uncoordinated zinc. The zinc 5,15-dibromo-10, 20-diarylporphyrin (0,6 mmol) was dissolved in dry THF to which had been added tetrakis(triphenylphosphine)-palladium(0) (0.6 mmol) and vinyltributyltin (1.4 mmol).
The mixture was refluxed under nitrogen for 48 hours after which the solvent was evaporated in vacuo and the residue chromatographed by flash column (silica;
gradient elution: dichloromethane to ethyl acetate) to give zinc 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin as a purple crystalline solid. Zinc 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin was demetallated by dissolution in a solution of trifluoroacetic acid in dichloromethane (1% vlv) to give 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin after extracting with water and evaporation of solvent from the organic layer in vacuo. Finally the 10 and 20 ethenyl groups were hydroxylated by osmium tetroxide as described (Sutton J, Fernandez N, Boyle RW (2000) J.
Porphyrins and Phthalocyanines 4, 655), however due to the rapidity of the reaction between the ethenyl groups and osmium tetroxide it was possible to selectively hydroxylate these groups by control of reaction time and stoichiometry. In a typical set of conditions the 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin, when treated with osmium tetroxide (5 equivalents) in 10°f° pyridine/chloroform for 24 -48 hours, gave the desired 5-(Fmoc aminophenyl)-15-aryl-10,20-bis(1,2-dihydroxyethyl) porphyrin, while if longer reaction times (72 hours) and higher molar ratios of osmium tetroxide (7.5 or equivalents) are used under the same conditions 5-(Fmoc aminophenyl)-15-aryl-10,20-bis( 1,2-dihydroxyethyl) 7,8-dihydroxychlorin and 5-(Fmoc aminophenyl)-15-aryl-10,20-bis( 1,2-dihydroxyethyl) 7,8,17,18-tetrahydroxybacteriochlorin respectively are obtained.
All the above products are converted cleanly to the corresponding isothiocyanates upon piperidine mediated deprotection of the amino group (see above) and treatment with l, l'-thiocarbonyldi-2(1H)-pyridone using standard procedures (Clarke, O.J. and Boyle, R.W.
( 1999 ,I. C. S. Chena. Common. 2231 ).
Example 21 5-(4-Isothiocyanatophenyl)-15-phenyl-10,20-(diaryl)-porphyrins -Synthesis from 5,15-diphenyl porphyrins by Pd° mediated Suzuki coupling Boc N-protected 5-(aminophenyl)-15-phenyl porphyrin was brominated at the 10 and 20 meso positions as described above. The meso-10,20-dibrominated product (0.75 mmol) was dissolved in dry THF (50 ml) or toluene (50 ml), depending upon the boronic acid used in the coupling reaction, tetrakis-(triphenylphosphine) palladium (0) (0.75 mmol) and anhydrous potassium phosphate (0.75 mmol) were added, a reflux condenser was then fitted to the flask and the whole apparatus was placed under an atmosphere of argon.
The required aryl or heterocyclic boronic acid was then added as a solution in the appropriate solvent (10 ml) by injection. The reaction was brought to reflux and followed to completion by TLC. On completion the crude reaction mixture was diluted with dichloromethane (100 ml) and extracted with saturated sodium bicarbonate (2 x 50 ml), water (2 x 50 ml) and brine (2 x 50 ml). The organic phase was dried (Mg SOa) and concentrated by evaporation in vacuo. Finally, the residue was purified by flash column chromatography (silica; gradient elution: dichloromethane to methanol) to give the Boc N-protected 5-(aminophenyl)-15-phenyl-10,20-(diaryl)-porphyrin as a purple crystalline solid. The Boc protecting group was removed by dissolution of the porphyrin in chloroform or acetonitrile, depending upon solubility, and addition of trimethylsilyl iodide (1.2 equivalents), after 30 minutes the reaction was quenched with methanol (10 ml). Removal of solvent by evaporation followed by purification by flash column chromatography (silica; gradient: dichloromethane to methanol) gave the 5-(aminophenyl)-15-phenyl-10,20-(diaryl)-porphyrin which was converted to the title compound by treatment with 1,1'-thiocarbonyldi-2(1H)-pyridone using standard procedures (Clarke, O.J. and Boyle, R.W. (1999 J. C. S. Chem. Conamun. 2231).
58 _ Example 22 5-(4-lsothiocyanatophenyl)-10,15,20-tri(4-glycosylphenyl)-porphyrin and 5-(4-isothiocyanatophenyl)-15-(4-glycosylphenyl)- porphyrin - General Synthetic Procedure 4-(2',3',4',6'-tetra-O-acetyl-(3-D-glucopyranosyloxy)benzaldehyde was condensed with 4-nitrobenzaldehyde and pyrrole using Lindsey conditions (Sol, V., Blais, J.C., Carre, V., Granet, R., Guilloton, M., Spiro, M., I~rausz, P. (1999) J. Org. Chenz. 64, 4431) and the crude reaction mixture purified by flash column chromatography to give 5-(4-nitrophenyl)-10,15,20-tris[4-(2',3',4',6'-tetra-O-acetyl-(3-glucopyranosyloxy)phenyl]
porphyrin. Alternatively, 4-(2',3',4',6'-tetra-O-acetyl-(3-D-glucopyranosyloxy)benzaldehyde was used to synthesise 5-(4-(2',3',4',6'-tetra-O-acetyl-(3-D-glucopyranosyloxy)phenyl) dipyrromethane using the method of Boyle (Boyle, R.W., Bruckner, C., Posakony, J., James, B.R., Dolphin, D. (1999) Organic Syntheses.
76, 287) which was then condensed to give 5-(4-nitrophenyl)-15,-[4-(2',3',4',6'-tetra-O-acetyl-[i-glucopyranosyloxy)phenyl] porphyrin. Reduction of the nitro group of these porphyrins was performed by dissolution in THF and addition of 10% palladium on carbon. Stirring of the mixture under HZ for 5 hours followed by filtration through Celite and purification by flash column chromatography gave the corresponding amino porphyrins, which were N-protected by reaction with Fmoc chloride (2 equivalents) in anhydrous 1,4-dioxane in the presence of sodium bicarbonate (6 equivalents) under argon. The reaction was monitored by TLC and, upon completion, diluted with dichloromethane and washed with water then brine before drying the organic layer (MgSO~). Purification by flash column chromatography gave the Fmoc N-protected 5-(4-aminophenyl)-10,15,20-tris[4-(2',3',4',6'-tetra-O-acetyl-(3-glucopyranosyloxy)phenyl]
porphyrin or 5-(4-aminophenyl)-15,-[4-(2',3',4',6'-tetra-O-acetyl-(3-glucopyranosyloxy)phenyl] porphyrin. N and O protecting groups were removed by dissolution of the porphyrin in dichloromethane/morpholine (1:1) and stirring for 1 hour.
Removal of solvent by evaporation in vacuo was followed by redissolution of the residue in a mixture of dichloromethane and methanol (4:1). Sodium methanolate in dry methanol(1.5 equivalents per OAc group) was added and the mixture stirred for 1 hour.
The fully deprotected porphyrin was recovered by precipitation with hexane.
Finally, the 59 =
5-(4-aminophenyl) porphyrin was dissolved in dry methanol and l, l'-thiocarbonyldi-2(1H)-pyridone (2 equivalents) was added. The reaction was stirred under argon for 2 hours and monitored by TLC, upon completion, solvent was evaporated in vacuo~and the crude product was purified by preparative medium pressure reversed phase chromatography (Clg;gradient elution: 0.1% aqueous TFA to methanol).
Example 23 : Symmetrical Porphyrin/ Chlorin Diol/ Bacteriochlorin Tetrol Series ~,1~-(3,4,~-Tris»zetlzoxyphenyl)porphyrin (,general procedure) To a 3 L round bottom flask was added 5-(3,4,5-trismethoxyphenyl)dipyrromethane (1.86 g, 6 mmol), then DCM (1L) under NZ. To this stirred solution was added trimethylorthoformate (48 ml, mmol). A pressure equalizing dropping funnel containing a solution of trichloroacetic acid (23.0 g, mmol) in DCM (500 ml) was then fitted to the flask and the solution added dropwise to the reaction mixture over a period of 10 min.
The reaction vessel was covered in aluminium foil to exclude light and allowed to stir under NZ for a period of 3.5 h. Pyridine was then added to the reaction mixture, rapidly with stirring, and the reaction allowed to stir for a further 16 h. at room temperature under NZ with the light excluded. The aluminium foil was removed and air was bubbled through the solution for a period of 20 min. After this the reaction was left to stir unstoppered for a further period of 3 h. at room temperature with the aluminium foil removed.
The reaction mixture was then concentrated in vacuo to remove DCM and remaining pyridine by evaporator, then high vacuum. The crude reaction mixture was then chromatographed on flash silica-gel (250 ml), (dry loaded on to 50 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting with chloroform . The title compound was obtained as purple crystalline solid (347 mg, 18%); ~,max/
(relative intensity) 410 (1.0), 502 (0.04), 538 (0.02), 578 (0.015), 630 (0.01) nm; UV-VIS
(CH~CIz) (fluorescence) 7~""t, = 634 nm (7~ excitation = 408 nm); (270 MHz, CDCl3) 10.32 (2H, s, I Q-H, ?D-H), 9.40 (4H, d, J = 4.8 Hz, ~3 H), 9.18 (4H, d, J =
4.8 Hz, ,(3 H), 7.52 (4H, s, o An), 4.20 (6H, s, CHj), 4.00 (12H, s, CHj), -3.10 (2H, br. s, NH); MS
(MALDI) m/z = 643.4 (100%, M+).
7, 8-Dihplroxy ~,1 ~-(3, 4, ~-trismethoxyphenyl) clzlorin (A General procedure) To a stirred solution of 5,15-(3,4,5-trismethoxyphenyl)porphyrin (50 mg, 77.8 p.mol) in HPLC grade chloroform (5.0 ml) was added a solution, in anhydrous pyridine (0.5 ml), of osmium tetroxide (~..5 eq., 0.195 mmol, 49 mg). The reaction vessel was flushed with NZ
and sealed with a lightly greased glass stopper, then covered in aluminium foil to exclude the light and left to stir for 72 h at room temperature. After this period the reaction vessels glass stopper was replaced With a plastic stopper and a continuous stream of hydrogen sulfide gas was bubbled through the reaction mixture for 5 min., (a gas outlet needle was attached and allowed excess hydrogen sulfide gas to escape into a series of Dreshel bottles filled with mineral oil and a bleach solution respectively).
After this time the reaction mixture was filtered through Celite~ and then concentrated in vacuo. Any excess pyridine was removed under high vacuum. The crude reaction mixture was then chromatographed on flash silica-gel (100 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting with 1%
methanol in DCM. Some starting material was recovered (15%) and the title compound was obtained as browny-purple crystalline solid , (26 mg, 50%); m.p. 170 °C
(decomposed);
UV-VIS (CHZC12) 7~ma~ (relative intensity) 410 (1.0) 504 (0.09), 534 (0.06), 582 (0.04), 636 (0.18) nm; UV-VIS (CHZC12) (fluorescence) ~,max 639 nm (~, excitation 410 nm);
SH(270 MHz, CDC13) 9.98 (1H, s, 10-H), 9.42 (1H, s, ?0-H), 9.20 (1H, m,,QH), 9.04 ( 1 H, d, J = 4. 0 Hz, /.3 I~, 8 . 99 (2H, s, ~3 H), 8. 79 ( 1 H, d, J = 4. 0 Hz, ,(3 H), 8. 66 ( 1 H, m, ,~i H), 7.45 (1H, d, J = 1.6 Hz, l~-o Ar), 7.42 (1H, d, J = 1.6 Hz, l.i-o-Ar), 7.40 (1H, d, J =
1.6 Hz, ~-o Ar), 7.19 ( 1 H, d, J = 1.6 Hz, 15-o Ar), 6.49 ( 1 H, d, J = 7. 3 Hz, 7-H), 6.23 (1H, d, J = 7.3 Hz, 8-H), 4.17 (3H, s, GH;), 4.15 (3H, s, CH3), 4.04 (3H, s, CH3), 4.00 (3H, s, CHI), 3.98 (3H, s, CH3), 3.91(3H, GH3), -1.80 (1H, br. s, NH), -2.19 (1H, br. s, NH), (OH'.s not observed); MS (MALDI) m/z = 677.3 (100%, M+); HRMS calcd. for C3RH~~N:~Og: 676.2533. Found: 676.2587.
7,8,17,18-Tetrahydroxy~,l~-(3,4,x-trismethoxyphenyl) bacteriochlorin ( n r 1 r ce ure) To a stirred solution of 5,15-(3,4,5-trismethoxyphenyl)porphyrin (50 mg, 77.8 pmol) in HPLC grade chloroform (5.0 ml) was added a solution, in anhydrous pyridine (0.5 ml), of osmium tetroxide (~.0 ed., 0.39 mmol, 49 mg). The reaction vessel was flushed with NZ
and sealed with a lightly greased glass stopper, then covered in aluminium foil to exclude the light and left to stir for 72 h at room temperature. After this period the reaction vessels glass stopper was replaced with a plastic stopper and a continuous stream of hydrogen sulfide gas was bubbled through the reaction mixture for 5 min., (a gas outlet needle was attached and allowed excess hydrogen sulfide gas to escape into a series of Dreshel bottles filled with mineral oil and a bleach solution respectively).
After this time the reaction mixture was filtered through Celite~ and then concentrated in vcrcuo. Any excess pyridine was removed under high vacuum. The crude reaction mixture was then chromatographed on flash silica-gel (100 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting initially with 1%
methanol in DCM to elute chlorin by-product then 2.5 % methanol in DCM to elute the major bacteriochlorin isomer (assumed as tr~ans form Bruckner et cal (1995) Tetrahedron Lett. 3G, 9425). The title compound was obtained as a greeny-pink crystalline solid, (20 mg, 3G%); m.p. 135°C (decomposed); UV-VIS (CH2Clz) ~.max (relative intensity) 374 (1.0) 512 (0.23), 702 (0.52) nm; UV-VIS (CHZCIz) (fluorescence) 7~,na,; 708 nm (~, excitation 512 nm); 8H(270 MHz, CDCl3) 9.23 (2H, s, 10-H, 20-H), 8.79 (2H, d, J = 3.2 Hz, ~3-H), 8.44 (2H, d, J = 3.2 Hz, ,~ 1~, 7.37 (2H, s, 5+15-o-Ar), 7.13 (2H, s, S + 15-0-Ar~), G.31 (2H, d, J = 6. 5 Hz, 7-H, 17-H), 6.01 (2H, d, J = 6.5 Hz, ~-H, I ~-H), 4.12 (6H, s, CH;), 3.92 (GH, s, CH;), 3.89 (6H, s, CH3), -1.97 (2H, br. s, NH), (OH's not observed);
MS (1VIALDI) m/z = 712.4 (100%, (M+1)~'); HRMS calcd. for C3gH36N~O1~:
710.2590.
Found: 710.2607.
Example 24 : Unsymmetrical Porphyrin/ Chlorin Diol/ Bacteriochlorin Tetrol Fluorochrome Sets for Bioconjugation ~-(4-AcetomidoplZenyl)-1 ~-(4-naetlaoxyplzenyl)porplZyrin The required unsymmetrical diphenylporphyrin was synthesised using the general procedure outlined earlier, but with only slight modification. In this example a mixture of dipyrromethanes were used. Due to the different reactivities of the respective dpyrromethanes, the amounts needed for optimisation of mixed porphyrin were different.
For the same scale reaction 5-(4-methoxyphenyl)dipyrromethane (505 mg, 2 mmol) and 5-(4-acetomidophenyl)dipyrromethane (838 mg, 3 mmol) were used. The porphyrin mixture was chromatographed on silica-gel (400 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting initially with DCM ( 1 glass pipette full of triethylamine was added to 500 ml of eluent to aid elution) to remove 5,15-(methoxyphenyl)porphyrin byproduct. After separation of this component the elution was continued with chloroform to allow 5-(4-Acetomidophenyl)-15-(4-methoxyphenyl)porphyrin collection. The desired porphyrin was obtained as purple crystals; (150 mg, 12%); 7~r"~,/ (relative intensity) 410 (1.0), 502 (0.04), 538 (0.02), 578 (0.015), 630 (0.01) nm; 8H(270 MHz, CDC13) 10.35 (2H, s, 10-H, 20-H), 9.43 (4H, d, J =
4. 8 Hz, ,(3-H), 9.14 (4H, d, J = 4. 8 Hz, f3 H), 8.65 (2H, d, J = 7.2 Hz, 5-»a-Ar), 8.22-8.12 (4H, d (overlapping), J= 8.1 Hz, .5-o Ar+IS-o Ar), 7.56 (2H, d, J= 8.1 Hz, IS-rrz Ar), 4.14 (3H, s, C:H;), -3.00 (2H, br. s, NH); MS (MALDI) m/z = 550.3 (100%, M~).
~-(4-Anzinophenyl)-1 ~-(4-i~iethoxyphenyl)porphyrin 5-(4-Acetomidophenyl)-15-(4-methoxyphenyl)porphyrin (100 mg, 0.182 mmol) was treated with 18% hydrochloric acid (200 ml) and fitted with an air condenser.
The green solution was left to warm to 85oC for a period of 3 h. Prior to cooling, the reaction mixture was concentrated irz vacuo (water aspirator; evaporator water bath at 75°C) to remove excess hydrochloric acid then treated carefully with a solution of triethylamine (50 ml) in DCM. The organic extract was washed with water (100 ml) then saturated brine ( 100 ml) prior to drying (arzhyd. Na2S0~), filtering via Buckner funnel and finally concentration ifz vacuo. The required porphyrin was obtained by chromatography on silica-gel (100 ml), (liquid loaded in 10 ml DCM) eluting with DCM (1 glass pipette full of triethylamine was added to 500 ml of eluent to aid elution). The desired porphyrin was obtained as purple crystals; (150 mg, 12%); ~,",a,I (relative intensity) 410 (1.0), 503 (0.045), 538(0.02), 578 (0.015), 630 (0.005) nm; UV-VIS (CHZC12) (fluorescence) ~,m~X=
634 nm (~, excitation = 410 nm); dH(270 MHz, CDC13) 10.30 (2H, s, 10-H, 20-H), 9.39 (4H, d, J = 4.9 Hz, ,l3-H), 9.17 (2H, d, J = 4.9 Hz, ,(3 H), 9.10 (2H, d, J =
4.9 Hz, ,l3 H), 8.19 (2H, d, J = 8.8 Hz, LS-o Ar), 8.07 (2H, d, J = 8.1 Hz, 5-o Ar), 7.35 (2H, d, J = 8.8 Hz, I~-na Ar), 7.14 (2H, d, J = 8.1 Hz, S-m Ar), 4.13 (3H, s, CH3), 4.08 (2H, br. s, NH), -3.06 (2H, br. s, NH); MS (MALDI) m/z = 508.3 (100%, (M+1)~).
~-(~-Fluorenonzetlzylanzinoplzenyl)-I'-(9-nze'tlzoxyphenyl)porphyrin To a stirred solution of 5-(4-aminophenyl)-15-(4-methoxyphenyl)porphyrin (28 mg, 55 ymol) in anhydrous 1,4-dioxane (2.5 ml) was added solid sodium hydrogen carbonate (6 ed., 28 mg, 0.33 mmol). To this mixture was then added a solution of 9-fluorenomethylchloroformate (2 eq., 0.11 mmol, 28.5 mg) in 1,4-dioxane (0.5 ml) under N~. The reaction flask was covered with aluminium foil to exclude light and stirred at room temperature for a period of 3 h. At this time the reaction had gone to completion (as monitored by TLC). The 1,4-dioxane was removed irz-vacuo and the residue partitioned between water (25 ml) and DCM (2 x 25 ml). The combined organic extracts were washed with saturated brine (25 ml) then dried (anlzyd. Na2S04), filtered and concentrated irmacuo. The required porphyrin was obtained by chromatography on silica-gel ( 100 ml), (dry loaded on to 10 ml flash silica-gel from DCM and a little methanol for solubility) eluting with DCM. The desired porphyrin was obtained as purple crystals; ( 38 mg, 95%); 7~",a,I (relative intensity) 410 (1.0), 505 (0.042), 541 (0.02), 578 (0.015), 633 (0.01) nm; UV-VIS (CH2C12) (fluorescence) 7~",ax = 635 nm (~, excitation =
410 nm); bH(270 MHz, CDC13) 10.35 (2H, s, I D-H, 20-H), 9.69 (1H, br. s, NH), 9.44 (4H, d, J = 4. 8 Hz, ,(3-H), 9.12 (4H, d, J = 4.8 Hz, /3 H), 8.20-8.17 (4H, 2 x d (overlapping), J = 8.1 Hz, 5+I~-o Ar), 7.85 (4H, m, 5+15-»z Ar), 7.76-7.66 (2H, m, fTll()7'E'll0-Ar), 7.51-7.30 (6H, m, fZurerzo Ar), 4.69 (2H, d, J = 7.2 Hz, CH2), 4.30 (1H, t, J
= 7.2 Hz, CH), 4.13 (3H, s, CH3), -3.15 (2H, br. s, NH); MS (MALDI) mlz =
731.5 (100%, (M+1)+), 508.3 (52%, (M-FMOC+1)'~).
17,18-Dilzydroxy-S-(~ anzinoplzenyl)-l~-(4-nzethoxyplzenyl) chlorin and 7,8-dihydroxy ~-(~l-caminopfzenyl)-1 ~-(4-nzetlzoxyplzenyl) chlorin regioisomers 5-(4-aminophenyl)-15-(4-methoxyphenyl)porphyrin (28 mg, 55.2 p,mol) was converted to a mixture of chlorin diol regioisomers using the general chlorin formation procedure given earlier. The crude reaction mixture was then chromatographed on flash silica-gel (200 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting with 1% methanol in DCM to elute first some unreacted starting material then the higher Rf chlorin isomer as a browny-purple crystalline solid. The lower Rt~ isomer was obtained by further elution with 2.5%
methanol in DCM and gave also a browny-purple crystalline solid.
~Hiah t chlorin regioisomer (2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-aminophenyl) chlorin, from nOe measurements and JPP paper): (8.5 mg, 30%); m.p.
165°C
(decomposed); UV-VIS (CHZC12) Amax (relative intensity) 401 (0.99), 414 (1.0), (0.08), 535 (0.07), 582 (0.035), 636 (0.22) nm; UV-VIS (CHZC12) (fluorescence) 7~max 639 nm (~, excitation 412 nm); 8H(270 MHz, 10% MeOH-d4 in CDC13) 9.95 (1H, s, H), 9.42 ( 1 H, s, 20-H), 9.17 ( 1 H, d, J =4. 8 Hz, ~3 H), 9.03 ( 1 H, d, J=4.0 Hz, ~3-H), 8. 97 (2H, s, ,(3-H) 8.78 (1H, d, J = 4.8 Hz, ,(3-H), 8.51 (1H, d, J = 4.8 Hz, ,f3-H), 8.05 (2H, d, J =
8.9 Hz, v Ar), 7.94 (2H, d, J = 8.1 Hz, o' Ar), 7.25 (2H, d, J = 8.9 Hz, m Ar), 7.12 (2H, d, J = 8 .1 Hz, na '-Ar), 6.42 ( 1 H, d, J = 6. 5 Hz, 17-H), 6. 03 ( 1 H, d, J =
6. 5 Hz, I ~-H), 4.08 (3H, s, CH;), (NH's exchanged), (OH's not observed).; MS (MALDI) m/z = 642.2 ( 100%, (M+1 )~).
Low Rt~ chlorin regioisomer (2,3-dihydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl) chlorin from nOe measurements and JPP paper): (8.5 mg, 30%); m.p. 168°C
(decomposed); UV-VIS (CHZCl2) ~.max (relative intensity) 401(0.99), 413 (1.0), (0.08), 536 (0.06), 586 (0.025), 637 (0.20) nm; UV-VIS (CH2C12) (fluorescence) 7~max 639 nm (7~ excitation 412 nm); 8H(270 MHz, 10% MeOH-d4 in CDC13) 9.96 (1H, s, H), 9. 40 ( 1 H, s, I 0-H), 9.18 ( 1 H, d, J =4. 8 Hz, /.3 H), 9. 05 ( 1 H, d, J=4. 8 Hz, ~3 H), 8. 9 8 ( 1 H, d, J = 4. 0, ,~3 H) 8. 92 ( 1 H, d, J = 4. 0 Hz, /.~H), 8 . 74 ( 1 H, d, J = 4. 0 Hz, ~3-H), 8. 5 8 ( 1 H, d, J = 4. 0 Hz, (3-H), 8.13 ( 1 H, d, J = 8. 9 Hz, o Ar), 8. 08 ( 1 H, d, J = 8. 9 Hz, o Ar), 7. 9 5 ( 1 H, d, J = 8 .1 Hz, o ' Ar), 7. 79 ( 1 H, d, J = 8.1 Hz, o '-Ar), 7.
3 6 ( 1 H, d, J = 8 . 9 Hz, nz-Ar), 7. 3 0 ( 1 H, d, J = 8. 9 Hz, m Ar), 7.11 ( 1 H, d, J = 8.1 Hz, n2 ' Ar), 7.05 ( 1 H, d, J =
8 .1 Hz, ni '-Ar), 6. 42 ( 1 H, d, J = 6. 5 Hz, 7-H), 6. 09 ( 1 H, d, J = 6. 5 Hz, ~-H), 4.11 (3 H, s, CH;), (NH'.s exchanged), (OH's not observed); MS (MALDI) m/z = 642.2 (100%, (M+1 )T).
17,18-1)ihydrowy-~-(4-isotlaiocycttcatophenyl)-1~-(4 tnetho~yplaenyl)chloritt (higherRf regioi,sosoer) To a stirred solution of l, l'-thiocarbonyldi-2(1 H)-pyridone (1.07 eq., 7.6 mg, 43.5 mmol) in DCM (25 ml), (dried via passage through an activated alumina column) was added a solution of 17,18-dihydroxy-5-(4-methoxyphenyl)-15-(4-aminophenyl)chlorin (17.5 mg, 23.2 Omol) in DCM (10 ml). The reaction flask was covered with aluminium foil to exclude light and left to stir under NZ for 2 h, at which time TLC
indicated complete loss of starting material. The reaction mixture was then washed with water (2 x 50 ml) and saturated brine (50 ml) then dried (anhyd. Na2S0:~). The organic extract was then filtered and concentrated on to 10 ml flash silica-gel and chromatographed on flash silica-gel ( 100 ml), eluting with 1 % methanol in DCM to elute the required isothiocyanato chlorin diol (NB. traces~of all TDP must be removed prior to concentration of product from column chromatography otherwise some decomposition to 3 higher Rf byproducts occurs. These have not been identified at this time). The title compound was isolated as a browny-purple crystalline solid (17 mg, 90%); m.p. 155°C
(decomposed);
UV-VIS (CHZCl2) a,may (relative intensity) 410 (1.0) 505 (0.09), 534 (0.06), 586 (0.04), 637 (0.18) nm; UV-VIS (CHZC12) (fluorescence) ~,ma~ 639 nm (~, excitation 412 nm);
bH(270 MHz, 10% MeOH-d~ in CDC13) 10.0 (1H, s, I D-H), 9.45 (1H, s, 20-H), 9.20 (1H, d, J =4. 8 Hz, ,(3-H), 9. 06 ( 1 H, d, J=4. 0 Hz, ~3-H), 9.02 ( 1 H, d, J = 4 . 8 Hz, ~3 I~ 8 . 84 ( 1 H, d, J = 4. 8 Hz, ,Q-H), 8. 64 ( 1 H, d, J = 4. 0 Hz, ,!1--I~, 8 . 5 5 ( 1 H, d, J = 4. 8 Hz, ,Q H), 8. 21 ( 1 H, d, J = 8.1 Hz, v Ar), 8.15 ( 1 H, d, J = 8 .1 Hz, o-Ar), 8. 05 ( 1 H, d, J = 8. 9 Hz, o '-Ar) 7.93 (1H, d, J = 8.9 Hz, a' An), 7.65 (2H, m, »z-AY), 7.24 (2H, m, »~' Ar), 6.43 (1H, d, J =
6.5 Hz, 17-H), 6.04 (1H, d, J = 6.5 Hz, 18-I~, 4.08 (3H, s, CH;), (NH's exchanged), (OH'.s not observed); MS (MALDI) m/z = 583.7 (100%, M+); HRMS calcd. for C~:~HZ~N;03S: 584.1757. Found: 584.1756 ((M+1)*).
7, 8,17.18-Tetrahydrowy-~-(4-f luoretzomethyla»zinophenyl)-1 ~-(4-nzetlzovyplaetzyl) b~ccteriochloritc (cisltratzs stereoisotners) 5-(4-Fluorenomethylaminophenyl)-15-(4-methoxyphenyl)porphyrin (35 mg, 48.0 ~mol) was converted to a mixture of bacteriochlorin stereoisomers using the general bacteriochlorin formation procedure given earlier. The crude reaction mixture was then chromatographed on flash silica-gel (200 ml), (dry loaded on to 20 ml flash silica-gel from DCNI and a little methanol to ensure complete solubility) eluting initially with 1%
methanol in DCM to elute the higher Rf chlorin byproducts, then 2% methanol/
DCM to elute separately the two stereoisomeric bacteriochlorins. The higher R~-tnafi,s bacteriochlorin isomer was isolated as a pinky-green crystalline solid, (6 mg, 15%); m.p.
142"C (decomposed); UV-VIS (CH2C12) ~.ma;; (relative intensity) 374 (1.0) 512 (0.23), 702 (0.52) nm; UV-VIS (CHZC12) (fluorescence) ~nlax 708 nm (~, excitation 512 nm);
8H(270 MHz, 10 % MeOH-da in CDC13) 9.20 (2H, s, 10-H, 20-I~, 8.78 (2H, d, J
=4.0 Hz, (3-I~, 8.36 (2H, d, J = 4.0 Hz, ,(3 H), 7.95 (2H, m, o-Aj~), 7.85 (2H, d, J = 7.3 Hz, .flure~r~ern~-Ar), 7.79 (2H, m, o'-Ar), 7.65 (2H, m, na'-An), 7.47-7.38 (6H, m,.fhaoretzo-Ar), 7.24 (2H, m, rn-Ar), 6.27-6.24 (2H, 2 x d (overlapping), J = 6.5 Hz, 7-H, 17-I~, 5.85 (2H, d, J = 6.5 Hz, 8-H, 18-I~, 4.65 (2H, d, J = 7.2 Hz, CHI), 4.39 (1H, t, J
= 7.2 Hz, C.I~, 4.06 (3H, s, CH;), -1.94 (2H, br. s (partly exchanged), NH), (OH's not observed);
MS (MALDI) m/z = 800.4 (100%, (M+1)+).
The lower Rt~ ci.s-bacteriochlorin isomer was isolated as a pinky-green crystalline solid, (8.5 mg, 21%); m.p. 148°C (decomposed); UV-VIS (CH2C12) ?~max (relative intensity) 374 (1.0) 512 (0.24), 703 (0.54) nm; UV-VIS (CHZC12) (fluorescence) ~,max 708 nm (~, excitation 512 nm); bH(270 MHz, 10 % MeOH-d4 in CDCl3) 9.12 (2H, s, 10-H, 20-H), 8.76 (2H, d, J =4.8 Hz, (3-HJ, 8.34 (2H, 2 x d (overlapping), J = 4.8 Hz, ,(3 I~, 8.02 (2H, m, o-Ar), 7.85 (2H, d (obscurred), J = 8.0 Hz, o' Ar), 7.83 (2H, d, J = 7.3 Hz,, fZuorefao-Ar), 7.76 (2H, d, J = 8.0 Hz, na'-An), 7.50-7.38 (6H, m, fluof~er2o AY), 7.24 (2H, m, m At~), G.27-6.23 (2H, 2 x d (overlapping), J = 6.5 Hz, 7-H, 17-H), 5.85-5.82 (2H, 2 x d (overlapping), J = 6.5 Hz, 8-H, 18-H), 4.65 (2H, d, J = 7.2 Hz, CHI), 4.39 ( 1H, t, J = 7.2 Hz, CH), 4.05 (3H, s, CH3), -1.88 (2H, br. s (partly exchanged), NH), (OH's not observed); MS (MALDI) m/z = 800.4 (100%, (M+1)+).
7, 8.17.18-Tetralzydroxy-S-(4-isothiocytcnatoplzenyl)-1 ~-(4-rnethoxyplzenyl) bacterioclzlorin (lower Rf cis stereoisomer) ~1 solution of 7,8,17,18-tetrahydroxy-5-(4-fluorenomethyaminophenyl)-15-(4-methoxyphenyl) bacteriochlorin (lower Rf cis stereoisomer), (8.5 mg, 10.7 p,mol) in 25%
methanol in DCM (1.25 ml) was treated with piperidine (~0 eq., 53 p,l , 0.53 mmol) and left to stir for a period of 3 h. at room temperature under NZ with the light excluded. The reaction mixture was concentrated irmcrcuo to remove all traces of piperidine (high vacuum needed). To a stirred solution of 1,1'-thiocarbonyldi-2(1 H)-pyridone (1.07 eq., 7.6 mg, 43.5 mmol) in DCM (25 ml), (dried vicr passage through an activated alumina column) was added a solution of 2,3,12,13-tetrahydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl)bacteriochlorin (6.1 mg, 10.7 ymol) in DCM (10 ml). The reaction flask was covered with aluminium foil to exclude light and left to stir under NZ for 2 h, at which time TLC indicated complete loss of starting material. The reaction mixture was then washed with water (2 x 50 ml) and saturated brine (50 ml) then dried (arzhyd.
Na~SO:~). The organic extract was thenfiltered and concentrated on to 10 ml flash silica-gel and chromatographed on flash silica-gel (100 ml), eluting with 2% methanol in DCM
to elute the required isothionato bacteriochlorin tetrol (NB. traces of all TDP must be removed prior to concentration of product from column chromatography otherwise some decomposition occurs). The Lower Rf cis-bacteriochlorin isomer was isolated as a pinky-green crystalline solid, (5.0 mg, 76%); m_p. 132°C (decomposed); UV-VIS
(CHzCl2) ?~max (relative intensity) 375 (1.0) 516 (0.22), 702 (0.48) nm; UV-VIS (CHzCl2) (fluorescence) ~,",as 709 nm (~, excitation 516 nm); 8H(270 MHz, 10 % MeOH-d;~ in CDC13) 9.20 (1H, s, n~esn-H), 9.18 ( 1 H, s, me.so '-H), 8. 77 (2H, d, J =4. 8 Hz, /3-H), 8.40 ( 1 H, d, J = 4. 8 Hz, ,(I-H), 8.34 ( 1H, d, J = 4.8 Hz, ~-H), 8.14 (2H, m, c~-Ar), 8.05 (2H, m, o' An), 7.42-7.08 (4H, m, .5~-1.5-n? Ar), 6.20 (2H, 2 x d (overlapping), J = 6.5 Hz, 7-H, 17-H), 5.98 (1H, d, J
= 6.5 Hz, 8-H), 5.93 (1H, d, J = 6.5 Hz, 18-H), 4.04 (3H, s, CH3), -1.80 (2H, br. s (partly exchanged), NH), (pH's not observed); MS (MALDI) m/z = 618.9 (100%, (M+1)T);
HRMS calcd. for C3~IIZgNsOSS: 618.1815. Found: 618.1810 ((M+1)''-).
Further synthetic protocols and methodology protocols are also described in Sutton et al, Por~h~ Chlorin and Bacteriochlorin I~~th;~~yanates Synthesis and Potential Applications in Fluorescence Ima~in,g and Photod;rnamic Ther~v (Journal of Phthalocyaniraes ~ Photosensitisers - in press) and in Oliver J Clarke, Isothioc ay nato P r h. rip f r i n' i n h n i i h n ~.
fluorescence imagi~r~(PhD thesis, April 2001, University ofEssex); the entire contents of each of which are incorporated herein by reference.
Methodology Description 1 ~ General Bioconjug~,ation rotocol Hexahydroxy PITC + Antibody A stock solution of hexahydroxy PITC in DMSO was prepared to a molarity of 0.027, this solution was desiccated and stored at 0°C until required. A
solution of antibody was extensively dialysed against sterilised PBS to remove any trace of azide.
The dialysed antibody solution was then adjusted to a concentration of 10 mg/mL via centrifugal concentration and separated into 250 ~,L aliquots.
A 1 M solution of sodium bicarbonate was prepared and adjusted to pH 9.0 with M sodium hydroxide.
To a 250 p,L aliquot of antibody was added 30 pL of 1 M sodium bicarbonate. A
predetermined volume of hexahydroxy PITC stock solution was then added to give a desired molar ratio (MR) of porphyrin to antibody. For example an MR of 20 was achieved via the addition of 10 p.L of stock solution to 250 p.L of antibody at 10 mg/mL.
In order to maintain a constant concentration of DMSO in the bioconjugation reaction mixture, all aliquots of stock solution were diluted to 25 ~.L with further portions of DMSO.
DesiredVol. of (C] of Vol, of Vol. of Vol.
1 M of MR antibody antibody sodium PITC stockextra solution solution bicarbonatesolution DMSO
2 0 25 0 p,L 10 mg/mL 3 0 p,L 10 p,L 15 p,L
250 ~.L 10 mglmL 30 ~,L 5 ~L 20 p.L
25 0 p,L 10 mg/mL 3 0 p,L 2. 5 ~L 22.
S
~,L
250 yL 10 mglmL 30 yL 1.25 p,L 23.75 ~,L
Table 1.0 Quantities of reagents for bioconjugation Following addition of PITC the bioconjugation reaction was agitated gently for hour at 25°C. After 1 hour the crude bioconjugation reaction mixture was loaded directly onto the top of a prepacked PD10 size exclusion column pre-equilibrated with sterile PBS
(25 mL). The column was eluted with sterile PBS. Antibody-porphyrin conjugate was eluted in the first coloured band/fraction. The antibody-porphyrin conjugate concentration following dilution during chromatography was determined as 1.25 mg/mL.
The degree of labelling (DOL) of porphyrin to antibody was calculated via standard spectroscopic methods using known constants of molar absorptivity for both porphyrin and protein.
Antibody-porphyrin conjugates were stored, without further concentration, in PBS
+ azide at 0°C unless otherwise stated.
1V lVlethylpyridinium chloride PITC + Antibody A stack solution of N methylpyridinium chloride PITC in DMSO was prepared to a molarity of 0.027, this solution was desiccated and stored at 0°C
until required. A
solution of antibody was extensively dialysed against sterilised PBS to remove any trace of azide. The dialysed antibody solution was then adjusted to a concentration of 10 mg/mL vicr centrifugal concentration and separated into 250 1.~L aliquots.
A 1 NI solution of sodium bicarbonate was prepared and adjusted to pH 9.0 with M sodium hydroxide.
To a 250 ~,L aliquot of antibody was added 250 p,L of sterile PBS then 60 yL
of 1 M sodium bicarbonate. A predetermined volume of N methylpyridinium chloride PITC
stock solution was then added to give a desired molar ratio (MR) of porphyrin to antibody. For example an MR of 20 was achieved via the addition of 10 p,L of stock solution to 500 p,L of antibody at 5 mg/mL. In order to maintain a constant concentration of DMSO in the bioconjugation reaction mixture, all aliquots of stock solution were diluted to 25 p,L with further portions of DMSO, DesiredVol. of [C] of Vol. of Vol. of Vol.
1 M of MR antibody antibody sodium PITC stockextra solution solution bicarbonatesolution DMSO
30 500 l.~L 5 mg/mL 60 ~.L 10 ~,L 15 p,L
500 ~.L 5 mg/mL 60 ~.L 5 p,L 20 p,L
5 500 p.L 5 mg/mL 60 p.L 2.Sp.L 22.5 ~,L
2.5 500 1~L 5 mg/mL 60 yL 1.25 yL 23.75 ~,L
Table 2.0 Quantities of reagents for bioconjugation Following addition of PITC the bioconjugation reaction was agitated gently for hour at 25°C. After 1 hour the crude bioconjugation reaction mixture was loaded directly onto the top of a prepacked PD10 size exclusion column pre-equilibrated with sterile PBS
(25 mL). The column was eluted with sterile PBS. Antibody-porphyrin conjugate was eluted in the first coloured band/fraction. The antibody-porphyrin conjugate concentration following dilution during chromatography was determined as 1.25 mg/mL.
The degree of labelling (DOL) of porphyrin to antibody was calculated via standard spectroscopic methods using known constants of molar absorptivity for both porphyrin and protein.
Antibody-porphyrin conjugates were stored, without further concentration, in PBS
+ azide at 0°C unless otherwise stated.
Methodology Description 2 ~ Standard Photocytotoxi i~Y
Cells are grown to confluence or appropriate density then washed 2 times with PBS
(phosphate buffered saline) to eliminate all trace of FBS (foetal bovine serum). Cell density is adjusted to 1.5x106 cells/ml in medium without FBS and these are then incubated for 1 hour in the dark (37 degrees C, 5% C02 ) with a range of photosensitiser/conjugate concentrations. Post incubation, cells are washed further with medium (without FBS )to eliminate unbound photosensitiser, then resuspended and seeded in 96 wells plates (1x10' cells/well) in quadruplate.Plates are then either irradiated (3.GJ/cm2 of filtered red light 0600nm ) or left in the dark as "dark toxicity controls" for the same period of time (~14 minutes).Five microliters (5%/well) of FBS is added after the irradiation/dark period and the plates are returned to the incubator overnight. Twenty to 24 hours after treatment, 10 pl of MTT solution (Sigma Thiazolyl blue, 4.8x10-4M in PBS)is added per well and the plates are returned to the incubator until color develops (between 1 and 4 hours). A solution of acid-alcohol (100p1/well of 0.04N HCL
in isopropanol) is the added and mixed thoroughly to dissolve the dark blue crystals. Plates are then read at 570nm in a microplate reader and the % cell survival calculated against controls.
Methodology Description 3 : Initial Flow~vtometrY Chromouhore Anal, i~
The two fluorochromic probes were generated from separate reactions of 2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-isothiocyanatophenyl)chlorin (higher Rf regioisomer) and 2,3,12,13-tetrahydroxy-5-(4-isothionatophenyl)-15-(4-methoxyphenyl) bacteriochlorin (lower Rf ci.r stereoisomer) with avidin under the standard bioconjugation protocols given earlier. An initial flow experiment has been undertaken utilising these separate avidin conjugates with RAJI cells and biotin monoclonal antibodies (HLA-DR1, L243), (laser excitation 488 nm, collecting emissions at < 640 nm (FL2) > 670 nm (FL3)). Data indicated that the signals from the DPBC samples were much higher due to good match to emission filter (FL3). Samples containing avidin DPCH or. DPBC
conjugates with L243 antibodies indicated modest increases in fluorescence compared to controls. Using higher concentrations of avidin-DPCH/DPBC the peak fluorescence increased, which may either be due to the initial concentrations of conjugates being too Low to saturate receptors or to a lesser extent to some non-covalent binding.
Control samples with avidin-DPCH/DPBC (no antibody) showed some background fluorescence in the absence of L243 antibodies, suggesting that some non-specific binding of the conjugates to the RAJI cells had occurred or that a small quantity of non-covalently bound fluorophore had transferred from the protein to the cell surface. A FITC-avidin control indicated that a slightly higher signal was present in FL2 which appears also in FL3 due to a broad emission band. In the presence of L243 antibody the mean signal increased by 150%. This indicates that non-covalent binding is less significant with FITC-avidin conjugates.
Experiments have been undertaken to determine the level of non-covalent binding of fluorophore to the protein surface (BSA and avidin). 'Blank' bioconjugations using mixtures of the unreactive DPCH and DPBC derivatives 2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-acetomidophenyl)chlorin (higher Rf regioisomer) and 2,3,12,13-tetrahydroxy-5-(4-acetomidophenyl)-15-(4-methoxyphenyl) bacteriochlorin (higher Rr trar~s stereoisomer) with both BSA and avidin have been carried out and the resultant protein solutions have been purified by gel filtration (PD-10) as described for the reactive probes described earlier. UV analysis indicated that approximately similar amounts of unreactive probes non-covalently bind to the proteins. For BSA or avidin, 1 unreactive DPCH binds to each protein molecule, whereas DPBC is less than 1 due probably to its increased polarity and non-amphiphilic nature.
Initial studies have been undertaken to remove non-covalently bound fluorophore from the protein (BSA and avidin) using SDS-PAGE. When the 'blank' bioconjugation mixtures were subjected to SDS-PAGE separation of all non-covalently bound fluorophore was achieved (UV/fluorescence of a solubilised gel segment at 66000 D for BSA and 16500 D for avidin monomer indicated no signal). Further to these investigations, we have been able to show that fluorophore which is non-covalently bound to BSA (or avidin) transfers to the surface of HeLa cells. When HeLa cells were added to solutions of the non-covalent fluorophore-protein complexes, and incubated for 20 min, fluorescence was removed from the solution with removal of the HeLa cells. This effect was much more marked with 2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-acetomidophenyl)chlorin (higher Rf regioisomer) than with 2,3,12,13-tetrahydroxy-5-(4-acetomidophenyl)-15-(4-methoxyphenyl) bacteriochlorin (higher Rt trar2s stereoisomer).
Re-suspension of the cells and measurement of the fluorescence indicated a 10-fold increase in fluorescence in the case of the DPCH, whereas the DPBC only showed a modest increase. These measurements suggest that there is significant fluorescence quenching of both DPCH and DPBC by the protein and that the DPCH's amphiphilic nature has allowed incorporation into the HeLa cell membrane resulting in restoration of almost complete fluorescence. The DPBC, being non-amphiphilic, may complex to the surface of the HeLa cell in a similar manner as it does to the protein resulting in similar fluorescence quenching.
Since the fluorophore conjugates can be purified by SDS-PAGE we have investigated the use of preparative electrophoresis as a technique for removal of non-covalently bound fluorophore. To this end we have used a Centrilutor~ micro-electroeluter bought from Millipore. This device has allowed recovery of pure protein fluorophore conjugates from SDS gels.
VIethodologv Description 4 : Elution of Conjugates from SDS PAGE Utili ing Micro-Electroeluter ~ Working in greatly subdued lighting, the SDS-PAGE of the required protein conjugate was cut into small strips and added to the centrilutor sample tubes and the tops closed (no more than half full, 3-4 sample tube used).
~ The lower buffer chamber of the electroeluter was filled with degassed SDS
running buffer up to the level of the first electrode.
~ 3 to 4 Centricon~ centrifugal devices ( -30 used for BSA conjugates and YM-33 for avidin conjugates) from Millipore were inserted firmly into the holes in the upper buffer chamber rack of the electroeluter from below (with filter membrane lowest) and the vacant holes of the rack were stoppered with stoppers provided, from the underside of the rack.
~ The upper buffer chamber was placed into the lower buffer chamber with both electrodes aligned on the same side of the electroelutor.
~ The upper buffer chamber was then filled with degassed SDS running buffer (as before) until all Centricon~ unit tops were completely immersed. If no leaks were detected the air bubbles trapped below the Centricon~ units were removed vicz an angled plastic pipette(reinforced with paper clip).
~ The centrilutor sample tubes were then placed into the top of the Centricon~
units, ensuring the sample tube fitted snugly and filled completely with sample buffer (air bubbles were removed as described earlier).
~ The safety cover of the electroelutor was added and the power supply connected (200 V, 50 mA used).
~ After a period of 2-3 h. the power supply was removed and the Centricon~
filter extracted from the upper buffer chamber of the electroelutor.
~ The filtrate vial was added to the filter unit and a retentate top added.
The excess buffer was then removed by centrifugation at SOOOG (BSA) and 7,SOOG (avidin) for 2 h. Fresh 0.5 M phosphate buffer (pH 7.0) was added to the Centricon~ unit and the procedure was repeated to ensure all SDS was removed.
~ The concentrated purified conjugates were then collected in the retentate vials of the filter units by inversion and centrifugation. Sodium azide (2 M, 20 ml) was added and the conjugates were stored at 4°C.
Methodolo~,y Descri~ion 5 ~ FACS Conjugate Bindin"
a Protocol Wash flask of cells with phosphate buffered saline (PBS) pH 7.3. Treat with SmM EDTA in PBS for 10 min at 37C. Tap flask to dislodge cells, place in SOmL
polypropylene tube and pellet at 400g 3 min. Resuspend in 10 mL PBS and count cells.
Place 2 x 10' in FRCS tube (Falcon 2054) and wash with 1mL PBS by centrifugation (4008 3min) and resuspension by agitation Block cells in 500 ~L 2% Marvel milk powder in PBS, 1% BSA 30 min RT
Wash cells in 1 mL PBSBSA/Azide centifuge and resuspend pellet (as above) Add 10 p.L appropriate antibody dilution. Incubate on ice lh Wash cells in 1 mL PBS/BSA/Azide centifuge and resuspend pellet (as above) Add 50 pL Rabbit anti-mouse:FITC (Serotec, 1/100 dilution) and incubate on ice in the dark 1 h Wash cells in 1 mL PBS/BSA/Azide centifuge (as above) and resuspend pellet in 400 pL PBS/BSA/Azide.
Run samples through FACS machine using CellQuest acquisition software to collect data.
PB S/B SA/AZIDE
250 mL PBS
0.6258 BSA
1.56 mL Sodium Azide (1.6M) Methodologw Descrip tion 6 : SDS-PAGE
Separating gel Component % of gel 5 20 Acrylamide/Bis (40% w/v) 1.67mL 6.66mL
I.SM Tris-HCl (pH 8.8) 2.SmL 2.SmL
Water 5.67mL 0.7mL
TEMED 10 pL 10 pL
10% Ammonium persulphate 50 pL 50 pL
SDS 100 ~L 100 pL
For gradient gel 5-20%
a gradient mixer connected to a peristaltic pump is used.
Stacking gel (3%) Component mL
Acrylamide/Bis (40% w/v) 1.3 1M Tris-HC1 (pH 6.8) 1.25 Water 7.4 TEMED 20 pL
10,/ Ammonium persulphate50 ~tL
SDS 100 pL
Running buffer 0.0251VI Tris, 0.192M 0.1% SDS, pH8.3 in water.
glycine, Sample buffer 1M Tris-HC1 pH 6.8 l3mL , 20% SDS 6.SmL
Glycerol 5.2mL
0.5% Bromophenol blue 0.26mL
Biorad Protean 2 equipment was used in accordance with manufacturer's instructions Samples (total volume 15-20 11L containing 1-10 pg sample protein) were loaded onto a gel.
Gels were run at 200V for approximately lh. Gels were then scanned by light, after which they were stained using Coomassie blue stain and subsequently destained using acetic acid/methanol.
Further exemplification of the invention It has been demonstrated in our original work, described inter alia in Sutton, J., Fernandez, N. and Boyle, R.W. (2000) Functionalised Diphenylchlorins and Bacteriochlorins - Their Synthesis and Biocon~L,gation for Targeted Photodynamic Therapy and Tumour Cell Ima,g'~ng, J. Porphyrit~s and Phthalocyanines 4, 655-658; and Clarke, O.J. and Boyle, R.W. (1999) Isothioc, a~~o~~ r~ ins useful intermediates fir the con~iuaation of ~r_phyrins with biomolecules anr~ solid supports. ,L C. S.
Chem.
C:omnaura. 2231-2232, each of which is incorporated herein by reference, that a set of porphyrin, chlorin and bacteriochlorin molecules can be efficiently conjugated to proteins via a stable thiourea bond, and that these conjugates have potential as fluorescence imaging agents.
As exemplification of the present invention, we now describe the use of this method to form conjugates between monoclonal antibodies having high specificity for human cancer cells, and our set of porphyrin based photosensitisers.
Conjugates formed in this way have been assayed for photodynamic activity against the corresponding carcinoma cells, and also for their ability to selectively bind to, and photosensitise, these target cells in the presence of non-target cells. We also demonstrate the specific internalisation of porphyrin-BSA conjugates into HeLa cells.
Our examples utilise 5,10,15-tris(3,5-dihydroxyphenyl)-20-(4-isothiocyanatophenyl) porphyrin (OH6) and 5,10,15-tris(pyridyl)-20-(4-isothiocyanatophenyl)porphyrin (PYR), as we have found from our previous studies that the pattern of hydrophilic substituents around the photoactive porphyrin core of each of these chromophores leads to efficient conjugation with proteins; hydrophilic substituents also minimise non-covalent binding of photosensitiser to protein, often found with more hydrophobic porphyrins. Synthetic protocols for these chromophores are described in Examples 1 and 2 above respectively.
(OH6) (PYR) Example 25 - stable con~iugation to antibodie OHG and PYR were prepared as described in Examples 1 and 2 above respectively. Antibody 17. lA was selected for the bioconjugation procedure.
17. lA is an antibody which reacts specifically with a receptor that is over-expressed on colorectal cancer cells, in particular Colo 320 cells (ECACC, deposit no. 87061205).
However, any antibody which reacts against any antigen that is over-expressed on a suitable cell line may be utilised in accordance with the invention. Examples of such antibodies include Ber-EP4 and MOK-31, each of which is commercially available from DAKO Ltd, Ely, Cambridgeshire, and each of which is reactive against an antigen that is over-expressed on epithelial cells.
To increase the buffer pH of the antibody preparation to approximately pH9, prior to and for the purposes of the bioconjugation procedure, the monoclonal antibody preparation was either buffer-exchanged from a phosphate to an acetate buffer using a Centricon centrifuge or was subjected to dialysis so as to exchange the phosphate buffer for an acetate buffer.
Each of OH6 and PYR was separately conjugated with l7.lA monoclonal antibody in accordance with the method described in Methodology Description 1, to obtain a range of conjugation dilutions having respective MRs of 2.5, 5, 10 and 20..
The acetate-buffered antibody preparation and range of conjugation dilutions obtained therefrom were subjected to SDS-PAGE in accordance with the method described in Methodology Description 6. The results are shown in Figures 1-3 respectively. Figure 1 shows a gel loaded with buffer-exchanged l7.lA antibody (lane 1), and buffer-exchanged antibody/OH6 conjugations at MRs 2.5 (lanes 2, 3), 5 (lanes 4, 5), (lanes G, 7) and 20 (lanes 8, 9) and molecular weight markers (lane 10).
Figure 2 shows a gel loaded with dialysed 17. lA antibody (lane 1), and dialysed antibody/OH6 conjugations at MRs 2.5 (lanes 2, 3), 5 (lanes 4, 5), 10 (lanes 6, 7) and 20 (lanes 8, 9) and molecular weight markers {lane 10). Figure 3 shows a gel loaded with buffer-exchanged 17. lA antibody (lane 1), and buffer-exchanged antibody/PYR conjugations at MRs 2.5 (lanes 2, G), 5 (lanes 3, 7), 10 (lanes 4, 8) and 20 (lanes 5, 9) and molecular weight markers {lane 10).
As seen in these Figures, neither the buffer-exchange nor dialysis procedures disrupt the antibody structure, the light and heavy chains remaining associated with one another and migrating together on each of the gels (lane 1). Conjugation of OH6 and PYR at each of the MRs can also be seen on the;gels (lanes 2-9).
Example 26 - FACS anal FACS analyses were run in accordance with Methodology Description 5.
Figure 4 shows results derived utilising FITC-labelled l7.lA and Colo 320 cells (3 repeats) and indicates that binding of the antibody to the cells has occurred (ie the Colo 320 cells express the antigen specific to 17. lA).
Figure 5 shows results derived utilising OH6/l7.lA conjugate and Colo 320 cells with a FITC-labelled anti-17. lA antibody for detection (3 repeats) and indicates that the OHG/l7.lA conjugate has bound to the cells.
Figure 6 shows results derived utilising PYR/l7.lA conjugate and Colo 320 cells with a FITC-labelled anti-17. lA antibody for detection (3 repeats) and indicates that the PYR/17. lA conjugate has bound to the cells.
Figure 7 shows results derived utilising FITC-labelled OX-34 which is an antibody of the same class (IgG2a) as 17. lA but with a different antigen specificity (3 repeats). The results indicate that OX-34 has not bound to the Colo 320 cells and hence that there are no binding sites for OX-34 on Colo 320 cells.
Example 27 - Photocytotoxicitv experiments Photocytotoxicity tests in accordance with the method described in Methodology Description 2 were performed on Colo 320 cells utilising various antibody conjugates.
Figures 8 and 9 show the results of control experiments performed using OHG/OX-34 and PYR/OX-34 conjugates respectively. As described in Example 16 0X-34 has been found to lack specificity for any antigens expressed on the surface of Colo 320 cells. Accordingly, as expected these control experiments show no photocytotoxicity following irradiation.
Figures 10 and 11 show the results of further control experiments performed using "capped" OHG and PYR respectively. The "capping" procedure involved reacting the NCS group on each chromophore with propylamine, so as to block serum protein conjugation. Figure 10 shows no cytotoxicity in the dark, indicating that OH6 is non-toxic to Colo 320 cells. On irradiation, however, some photocytotoxicity is observed, indicating that an amount of the capped OH6 has been transferred to the surface of the Colo 320 cells. Figure 11 meanwhile shoves some cytotoxicity in the dark, suggesting that PYR is to some extent cytotoxic to Colo 320 cells, and increased photocytotoxicity on irradiation, which again indicates that an amount of the capped PYR has been transferred to the surface of the Colo 320 cells.
In the absence of any antibody, transfer of the capped chromophores to the cell membrane is probably attributable to the amphiphilic nature of the capped chromophores, which possess both hydrophilic groups around the porphyrin core and a hydrophobic propylamine "capping" group. This renders them particularly susceptible to becoming embedded in a lipid membrane such as the Colo 320 cell membrane.
Figures 12 and 13 show results obtained using OH6/l7.lA and PYR/l7.lA
conjugates respectively, at various conjugation dilutions (2.5, 5, 10, 20 for OH6/l7.lA;
and 20 for PYR/17, lA). The results indicate a significant increase in cytotoxicity on irradiation, indicating that the binding of the bioconjugates to the cell surface confers photosensitivity upon the cells. Hence, these species are suitable candidates for PDT.
Example 28 - hotod;~namic theraw in vivo Protocols for performing and assessing photodynamic therapy in vivo, utilising the conjugates of the invention, are variously described in R Boyle et al, Br.
J. Cancer ( 1992) 65:813-817; R Boyle et al, Br. .I. Cancer (1993) 67:1177-1181; R Boyle et al, Br.
.l. Cancer ( 1996) 73 :49-53; and Lapointe et al, .I. Nuclear Medicine, Vol.
40, No. 5 (May 1999) 876-882; the contents of each of which are incorporated herein by reference.
As described in these papers, tumours may be induced or transplanted into animals such as mice, and the animal may then be injected with a quantity of photosensitiser in accordance with the invention conjugated to an antibody with specificity for an antigen which is specifically expressed or over-expressed on the surface of the tumour cells. Thereafter, the animal may be subjected to irradiation, and the effects on the tumour assessed, qualitatively or metrically, with reference to tumour metabolism (as described in Lapointe et al, J: Nuclear Medicine, Vol. 40, No. 5 (May 1999) 876-882). As described in R Boyle et al, Bj-. J. Cancer (1996) 73:49-53, the distribution of the photosensitiser in vivo may also be measured, by biodistribution and/or vascular stasis assays.
Example 29 - Confocal Laser Scanning Microsco~"Y
A preliminary examination of the intracellular localisation of a conjugate of 10,15,20-tris(3,5-dihydroxyphenyl)5-isothiocyanatophenylporphyrin (OH6-NCS) with BSA was carried out using confocal laser scanning microscopy. The readily available epithelial human carcinoma cell line HeLa was selected for incubation with the conjugate. All incubations were performed' in triplicate with sub-confluent cultures of HeLa cells, including a series of control solutions of unlabelled BSA, 10,15,20-tris(3,5-dihydroxyphenyl)5-aminophenylporphyrin porphyrin (OH6-NH2, amino precursor of OH6-NCS), and PBS on its own. Cells were seeded onto coverslips in 35 mm dishes.
Fluorescence images of cells were obtained with a Bio-Rad Radiance2000 confocal laser scanning microscope (Bio-Rad Microscience, Cambridge, MA) on an inverted Olympus IX70 microscope using a 60x (NA 1.4) oil immersion objective lens.
The illumination source was the 514 nm line from a 25 mW argon ion laser.
Porphyrins were visualised with a 514 nm band-pass excitation filter, a 510 nm dichroic mirror, and a 570 nm long-pass emission filter.
Each field of cells was sectioned 3-dimensionally by recording images from a series of focal planes. Movement from one focal plane to another was achieved by a stepper motor attached to the fine focus control of the microscope, the step sizes (in the range 0.5 l.~m to 1.25 ~~m) being chosen with regard to the aperture size being used, so that there would be some overlap between adjacent sections. Enough vertical sections were taken so that the tops and bottoms of all the cells in each field would be recorded.
Each image collected was the average of four scans at the confocal microscope's normal scan rate. During each imaging session calibration images were taken of: (i) a microscope slide containing medium, in order to measure background levels;
(ii) a slide containing ITC porphyrin OH6-NCS dissolved in DMSO; and (iii) a slide bearing only un-probed HeLa cells.
Image data acquisition and remote microscope operation was carried out using the Bio-Rad Lasersharp2000 software. All images were managed using Confocal Assistant version 4.02, (build 101) 1994-1996 Todd Clark Brelje. Artificial colour was applied using standard Bio-Rad look-up tables (LUT).
A preliminary evaluation of the fluorescence of OH6-NCS at each of the excitation laser lines available on the CLSM set-up was carried out for a 0.01 mM
solution of OH6 in DMSO. Figure 14 shows the UV-visible spectrum of OH6-NCS
identifying its principal absorption bands. Unfortunately, no laser line was available in order to excite OH6-NCS at its Soret band ~,max. Figure 15 demonstrates the relative intensities of fluorescence emission for OH6-NCS when excited at 422 nm (optimal), and at the four wavelengths of the argon ion laser, 457, 476, 488, and 514 nm.
It was determined that the intensity of fluorescence emitted by a solution of NCS when excited at 514 nm was roughly three times greater than fluorescence emission at excitation wavelengths of 457, 476, and 488 nm. The UV-visible absorption spectrum of OH6-NCS showed that the 516 nm argon-ion laser line was the only excitation source compatible with OH6-NCS. The three strongest laser lines, 457, 476, and 488 nm all excited in the region between the Soret and first Q band of OH6-NCS, whereas the 514 line overlapped well with the Q band at 516 nm.
Cell cultures separately incubated with conjugate OH6-NCS-BSA and each of the three controls, were subsequently washed and fixed. Coverslips containing the incubated cells were then cautiously mounted onto standard glass microscope slides ready to be imaged. All four argon-ion laser lines were tested, but, as expected satisfactory resolution of fluorescence could only be achieved using the 514 nm laser line.
A Z-series fluorescence image of HeLa cells incubated with OH6-NCS-BSA is shown in Figure 1G (this Figure should be viewed from top left to bottom right).
Consecutive sections were scanned with a 2l.tM step between each focal plane resolved by the microscope, thus enabling three dimensional visualisation of the localisation of the conjugate within the cell. Clearly the conjugate OH6-NCS-BSA had entered the cell, no studies of the nature of cellular uptake were conducted, however it is most likely that uptake had taken place via endocytosis. It can be seen that the conjugate has not entered the nucleus and appears to be largely distributed throughout the cytoplasm.
When imaged, cells incubated with the BSA control or the PBS control, showed only very low, barely detectable levels of fluorescence, attributed to normal levels of cellular autofluorescence. The localisation of OH6-NHZ (unconjugated porphyrin control), is shown in Figure 17, which shows a CLSM image of porphyrin control cells with zoom view. No fluorescence was found to emanate from inside the cells, instead it appeared that the majority of OH6-NH? had become localised on the plasma membrane.
Evidently the BSA component of the conjugate is required in order to facilitate the transport of porphyrin to the interior of the cell.
In summary, it has been shown that the cellular localisation of porphyrin-BSA
conjugates, constructed via the formation of covalent thiourea linkages, can be imaged using conventional CLSM techniques. Unconjugated porphyrin OH6-NH2 was not found to penetrate the cellular membrane, whereas a significant level of fluorescence was detected from inside cells incubated with OH6-NCS-BSA, indicating good conjugate penetration.
~J
= 7.2 Hz, CHI), 4.30 (t, 1H, J = 7.2 Hz, CH), 4.13 (s, 3H, CH3), -3.15 (br. s, 2H, NH); MALD-MS m/z 731.5 ([M+H]+, 100°J°), 508.3 ([M-FMOC+2]~, 50%); ES-HRMS calcd. for C4gH36N5O3 ([M+H]~) 730.2818, found 730.2809.
(13, 14) cis/traps-7,8,17,18-Tetrahydroxy-5-(4-fluorenylmethylaminophenyl)-15-(4-methoxyphenyl) bacteriochtorins Porphyrin 12 (35 mg, 48.0 pmol) was converted into the required mixture of bacteriochlorin stereoisomers by minor modification of the procedure of Sutton et al. (2000 Functionalised diphenylchlorins and bacteriochlorins - their synthesis and bioconjugation for targeted photodynamic therapy and tumour cell imaging J.
Porphyrin arzcl Phthcrlocyarzines 4, 655-658 - incorporated herein by reference) (reaction carried out using 1,4-dioxane (5 mL) to allow dissolution of 12). The crude reaction mixture was chromatographed, eluting initially with 1% MeOH in DCM to remove chlorin by-products. Further elution with 2% MeOH/DCM allowed isolation of both stereoisomeric bacteriochlorin tetrols. The higher R~~trans bacteriochlorin isomer 13 was isolated as a pink-green crystalline solid, (6 mg, 15%), Rf= 0.25 (DCM/MeOH, 19:1), mp 142-145oC
(decomposed); UV-vis (DCM) ~.",:1~ (relative intensity) 374 (1.0) 512 (0.23), 702 (0.52) nm; Fluorescence (DCM) 7~",~, 708 nm (7,, excitation = 512 nm); 1H NMR (270 MHz, 10% CD30D in CDCl3) d 9.20 (s, 2H, 10+?0-H), 8.78 (d, 2H, J = 4.0 Hz, ~3 H), 8.36 (d, 2H, J = 4.0 Hz, ,(3-H), 7.95 (m, ZH, o-Ar), 7.85 (m, 2H, J = 7.3 Hz, fZzcor~erzo-Ar), 7.79 (m, 2H o '-Ar~), 7.65 (m, 2H, rn ' Ar), 7.47-7.3 8 (m, 6H, fZuor°erzo-Ar), 7.24 (m, 2H, rn-Ar"), 6.27-6.24 (m, 2H, 7+17-H), 5.85 (m, 2H, 8+18-H), 4.65 (d, 2H, J = 7.2 Hz, CHz), 4.39 (t, 1H, J = 7.2 Hz, CH), 4.06 (s, 3H, CHj), -1.94 (br s (partly exchanged), 2H, NH), (OH's not observed); MALDI-MS m/z 800.4 ([M+H]+, 100%); ES-HRMS calcd. for C~,RH:,«N;O~ ([M+H]+) 798.2927, found 798.2921.
The lower Rt~ cis-bacteriochlorin isomer 14 was isolated as a pink-green crystalline solid, (8.5 mg, 21%), Rf= 0.2 (DCM/MeOH, 19:1), mp 148-150oC (decomposed); UV-vis (DCM) ~,",:" (relative intensity) 374 (1.0) 512 (0.24), 703 (0.54) nm;
Fluorescence (DCM) ~,",:1~ 708 nm (7~ excitation = 512 nm); 1H NMR (270 MHz, 10% CD30D in CDC13) 8 9.12 (s, 2H, 10+20-H), 8.76 (d, 2H, J = 4.8 Hz, /3-H), 8.34 (d (overlapping), 2H, J = 4.8 Hz, ,(3-H), 8.02 (m, 2H, o-Ar), 7.85 (m (obscured), 2H, J = 8.0 Hz, o' AY), 7.83 (m, 2H, J = 7.3 Hz, fZuoYerzo Ar~), 7.76 (m, 2H, J = 8.0 Hz, rn'-Ar), 7.50-7.38 (m, 6H, f7zcoueroo-Ar~), 7.24 (m, 2H, rn Ar~), 6.27-6.23 (m, 2H, 7+ 17-H), 5.85-5.82 (m, 2H, 8+18-H), 4.65 (d, 2H, J = 7.2 Hz, CHI), 4.39 (t, 1H, J = 7.2 Hz, CH), 4.05 (s, 3H, CH3), -1.88 (br. s (partly exchanged), 2H, NH), (OH's not observed); MALDI-MS mlz 800.4 ([M+H]T, 100%); ES-HRMS calcd. for Ca$H4~N50~ ([M+H]+) 798.2927, found 798.2921.
(15) 5-(3,4,5-Trismethoxyphenyl)dipyrromethane 3,4,5-Trismethoxybenzaldehyde (5.0 g, 25.5 mmol) was dissolved in freshly distilled pyrrole (75 ml) and the solution degassed by bubbling with dry NZ for 10 min.
TFA
(0.075 eq. , 0.15 ml, 1.91 mmol) was added and the mixture stirred under NZ
until no starting aldehyde could be detected by TLC (ca. 10 min). The reaction mixture was concentrated lr2 VaCZlO at water aspirator pressure (evaporator water bath temp 75°C ) then under high vacuum for 16 h to remove excess pyrrole. The crude product was recrystallised from hot ethylacetate/ nHexane and afforded the required dipyrromethane as a white solid, ( 5.41 g, 68%): v",a~ (nujol mull)/ cm i 3378 (br. NH), 1594 (C=C), 1233, 1040; UV-VIS (MeOH) ~.",a~/ (rel. intensity) 222 (1.0), 280 (0.75) nm;
c~H(270 MHz; CDC13) 8.07 (2H, br. s, NH), 7.53 (2H, m, I-H), 6.68 (2H, s, 2'-H), 6.37 (2H, m, ?-H), 5.93 (2H, m, 3-H), 5.38 (1H, s, rr7etharae), 3.80 (3H, s, -~'-OCH;), 3.73 (6H, s, 3 '+~ '-UCH;); bC(68 MHz; CDC13) 152.7 (CH, 2'-C), 137.3 (q, 3'+5'-C), 136.1 (q, 4'-C), 131.8 (q, 4-C), 116.7 (CH, 1-C), 107.9 (CH, 2-C), 106.6 (CH, 3-C), 104.9 (q, 1'-C), 60.3 (CH;), 55.5 (CH;), 43.7 (CH., methane); MS (MALDI) m/e 311.2 (100%, (M-1)+).
(16) 5-(4-Acetomidophenyl)dipyrromethane The dipyrromethane was synthesised using the general procedure detailed above using the same molar quantity of starting aldehyde. The crude reaction mixture was chromatographed on flash silica-gel (350 ml), (dry loaded on to 50 ml flash silica-gel from ethylacetate) and eluted with 40% ethylacetate/ DCM and afforded the pure product as an off white solid, (4.3 g, 50%): vm~,,; (nujol mull)/ cm 1 3409 (NH, amide), 3248 (br.
NH), 1650 (C=O), 1593 (C=C), 1320, 1009; UV-VIS (MeOH) ~,m~;;/ (rel.
intensity) 224 ( 1.0) nm; dH(270 MHz; CDC13) 8.00 (ZH, br. s, NH), 7.40 (2H, d, J = 8.5 Hz, o-Ar ), 7.30 (1H, br. s, NH-acetotnido), 7.13 (2H, d, J= 8.5 Hz, m-Ar), 6.68 (2H, m, I-H), 6.16 (2H, m, ?-I~, 5.90 (2H, m, 3-H), 5.42 (1H, s, rnetharze), 2.14 (3H, s, NH~~); 8C(68 MHz;
CDC13) 168.4 (q, LOCH;), 138.2 (q, 4'-C), 136.5 (q, 2'-C), 132.4 (q, 4-C), 128.9 (CH, 2'-C), 120.3 (CH, 3'-C), 117.2 (CH, 1-C), 108.4 (CH, 2-C), 107.1 (CH, 3-C), 43.4 (CH., methane), 24.5 (CH3); MS (MALDI) m/e 279.4 ( 100%, (M)~).
(17) ~-(4-Methoxyphenyl)dipyrromethane The dipyrromethane was synthesised using the general procedure detailed above using the same molar quantity of starting aldehyde. The crude reaction mixture was chromatographed on flash silica-gel (350 ml), (dry loaded on to 50 ml flash silica-gel from ethylacetate) and eluted with 30% nHexane/ DCM and afforded the pure product as an off white solid, (4.3 g, 50%): vma;; (nujol mull)/ cm 1, 3382 (br. NH), 1598 (C=C), 1300, 1050; UV-VIS (MeOH) 7~",a,~/ (rel. intensity) 224 (1.0) nm; 8H(270 MHz;
CDC13) 7.87 (2H, br. s, NIA, 7.10 (2H, d, J = 8.8 Hz, m-Ar ), 6.83 (2H, d, J = 8.8 Hz, o-An), 6.66 (2H, m, I-I~, 6.14 (2H, m, ?-I~, 5.89 (2H, m, 3-I~, 5.40 (1H, s, rrZethane);
MS (MALDI) m/e 252.4 (100°J°, (M)+).
Example 1 s-(4-Isothiocyanatophenyl)-10,15,20-tris(3,5-dihydroxyphenyl)porphyrin H
H~
To a stirred solution of 3 (100 mg, 0.137 mmol) in freshly distilled THF (25 mL) was added 1,1'-thiocarbonyldi-2(ll~-pyridone (64 mg, 0.276 mmol). The reaction was allowed to proceed under argon for 4 hours at room temperature. Excess solvent was evaporated lf7 VClCZlO to yield a crude purple solid. The solid was dissolved in a minimal amount of chloroform/methanol (9:1) and purified by flash chromatography (silica, eluent: CHC13/MeOH, 9:1). Relevant fractions were combined, dried (Na2S0a) and evaporated irZ ocrcuo to yield the above compound as a purple solid (67.5 mg, 63.8%); Rf = 0.29 (silica, CHCl3/MeOH, 9:1); mp >350 °C decomp.; 1H NMR [270 MHz, CDC13/CD30D, 3:1] 86.77 (3H, s, 10, 15, 20-Ar-4-H), 7.12 (6H, s, 10, 15, 20-Ar-2,6-H), 7.64 (2H, m, .I* = 8 Hz, 5-Ar-3,5-H), 8.19 (2H, m, J* = 8 Hz, S-Ar-2,6-H), 8.76-9.0 (8H, m, (3-H); 13C NMR [67.5 MHz, CDC13/CD30D, 3:1] 8101.9, 107.1, 114.7, 117.6, 119.9, 120, 120.1, 123.9, 130.9, 134, 135.2, 136.1, 141.2, 142, 143.6, 155.8; UV-vis (MeOH) w vn ~.",~"422, 516, 552, 592, 648 nm; HRMS (ES) m/z calc'd for C45Hz9N5OsS [M+H]+
768.1914, found 768.1908.
Example 2 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-pyridyl)porphyrin To a stirred solution of 5 (100 mg, 0.158 mmol) in freshly distilled dichloromethane (20 mL) was added l,1'-thiocarbonyldi-2(11-pyridone (320 mg, 1.38 mmol). The reaction was allowed to proceed under argon for 4 hours at room temperature. Excess solvent was evaporated in vacuo to yield a crude purple solid. The solid was dissolved in a minimal amount of chloroform and purified by flash chromatography (silica, eluent: CHCl3/MeOH, 49:1). Relevant fractions were combined, dried (NazSO:~) and evaporated in vacuo to yield the above compound as a purple solid ( 104 mg, 97.5%); Rf= 0.57 (silica, CHCI3IMeOH, 49:1); mp >350 °C
decomp.; 1H NMR
[270 MHz, CDC13] 8-2.91 (2H, br s, NH), 7.65 (2H, m, J* = 8 Hz, 5-Ar-3,5-H), 8.15-8.21 (8H, m (overlapping), 10, 15, 20-Py-2,6-H & 5-Ar-2,6-H), 8.67 (8H, br s, (3-H), 9.06 (6H, m, J* = 5 Hz, 10, 15, 20-Py-3,5-H); 13C NMR [67.5 MHz, CDCl3] 8117.4, 117.6, 119.7, 124.7, 129.3, 131.6, 135.4, 136.9, 140.6, 148.4, 149.8; UV-v15 (CHZCIz) a,max 417, 514, 548, 587, 643 nm; HRMS (ES) m/z calc'd for C4zHz6NsS (M+H) 675.2079, found 675.2078.
Example 3 5-(4-Isothiocylnatophenyl)-10,15,20-tris(3-pyridyl)porphyrin (160) To a stirred solution of 7 (200 mg, 0.316 mmol) in freshly distilled dichloromethane (40 mL) was added l,1'-thiocarbonyldi-2(lf~-pyridone (640 mg, 2.76 mmol). The reaction was allowed to proceed under argon for 17 hours at room temperature. Excess solvent was evaporated in vacz.ro to yield a crude purple solid. The solid was dissolved in a minimal amount of chloroform and purified by flash chromatography (silica, eluent: CHCl3/MeOH, 49:1). Relevant fractions were combined, dried (Na2S0:,) and evaporated irz vacuo to yield the above compound as a purple solid ( 171 mg, 80.3%); Rf= 0.55 (silica, CHCl3/MeOH, 49:1); mp >350 °C
decomp.; 1H NMR
[270 MHz, CDC13] 8-2.83 (2H, br s, NH), 7.65 (2H, m, J* = 8 Hz, 5-Ar-3,5-H), 7.78 (3H, m, 10, 15, 20-Py-5-H), 8.20 (2H, m, J* = 8 Hz, 5-Ar-2,6-H), 8.54 (3H, m, 10, 15, 20-Py-6-H), 8.83-8.88 (8H, m, (3-H), 9.07 (3H, m, 10, 15, 20-Py-4-H), 9.07 (3H, s, 10, 15, 20-Py-2-H); 13C NMR [67.5 MHz, CDCl3] 8116.6, 122.1, 124.2, 131.5, 135.5, 137.7, 140.8, 140.9, 149.2, 153.5; UV-vis (CHZCIz) a,mah 421, 513, 547, 587, 657 rim;
MS
(MALDI-TOF) nZ~s 674 (MT, 100%).
=~6 Example 4 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-N methylpyridiniumyl) porphyrin triiodide I Me- -Me I
N
I
Me I
To a solution of Example 2 (50 mg, 0.074 mmol) in anhydrous DMF (10 mL, distilled from CaHz, 0.1 torr) was added iodomethane (1 mL, 0.016 mol). The reaction was stirred under argon for 3 hours at room temperature, monitored by TLC
(normal phase silica) in a water/saturated aqueous potassium nitrate/acetonitrile (1:1:8) solvent system. Upon reaction completion excess DMF was evaporated in vacuo (0.1 torr) at 30-40 °C to yield the above compound as a lustrous purple solid (77 mg, 95%); Rf = 0.32 (silica, H20/sat.aq. KN03/MeCN, 1:1:8); mp >350 °C decomp.; 1H NMR [270 MHz, (CD3)zS0] 8-3.03 (2H, br s, NH), 4.74 (9H, br s, N CH3-pyridine), 7.96 (2H, m, J* = 8 Hz, 5-Ar-3 , 5-H), 8. 3 2 (2H, m, J* = 8 Hz, 5-Ar-2, 6-H), 9. 03 (6H, m, J* =
6 Hz, 10, 15, 20-Py-2,6-H), 9.16 (8H, m, (3-H), 9.50 (6H, m, J* = 6 Hz, 10, 15, 20-Py-3,5-H); 13C
NMR [67.5 MHz, (CD3)zSO] X47.9, 114.7, 115.3, 121.1, 124.8, 130.6, 132, 134.7, 135.4, 139.7, 144. l, 156.3, 156.4; UV-vis (Hz0) ~,m;~X 423, 520, 585 nm; MS (FAB) nalz 719 (MT, 100%), 704 (M-CH3, 26%), 689 (M-2CH3, 20%), 674 (M-3CH3, 5%); HRMS (ES) nz/z calc'd for C:~;H35N8S (M+H) 719.2705, found 719.2686.
E~cample 5 5-(4-Isothiocyanatophenyl)-10,15,20-tris(3-N methylpyridiniumyl) porphyrin triiodide I
~e ME
I
me I
To a solution of Example 3 (50 mg, 0.074 mmol) in anhydrous DMF (5 mL, distilled from CaH, 0.1 torr) was added iodomethane (1 mL, 0.016 mol). The reaction was stirred under argon for 4 hours at room temperature, monitored by TLC
(normal phase silica) in a water/saturated aqueous potassium nitrate/acetonitrile (1:1:8) solvent system. Upon reaction completion excess DMF was evaporated irt mcuo (0.1 torr) at 30-40 "C to yield the above compound as a lustrous purple solid (72 m~, 89%); Rf = 0.46 (silica, H~O/sat.aq. KN03/MeCN, 1:1:8); mp >350 °C decomp.; iHNMR [270 MHz, (CDs)ZSO] ~-3.07 (2H, br s, NH), 4.69 (9H, br s, N CH3-pyridine), 7.97 (2H, m, ,l* = 8 Hz, 5-Ar-3,5-H), 8.31 (2H, m, J* = 8 Hz, S-Ar-2,6-H), 8.64 (3H, m, 10, 15, 20-Py-5-H), 9.03-9.25 (8H, m, (3-H), 9.35 (3H, m, 10, 15, 20-Py-6-H), 9.57 (3H, m, 10, 15, 20-Py-4-H), 10.03 (3H, s, 10, 15, 20-Py-2-H); 13C NMR [67.5 MHz, (CD3)ZSO] 848.3, 112.3, 112.9, 120.7, 124.8, 126.3, 126.4, 126.6, 130.6, 132.1, 132.3, 132.4, 132.6, 132.8, 133.1, 133.4, 134.7, 135.4, 139.8, 139.9, 140, 145.5, 145.6, 147.4, 147.5, 147.8, 147.9, 148.5, 155.9; UV-vis (H20) ~,",<«419, 516, 552, 581, 637 nm; MS (MALDI-TOF) m%z 689 ([M-2CH~]T, 100%).
Example 6 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-N methylpyridiniumyl) porphyrin trichloride Ci Me- ~ Me Cl Me To a solution of Example 4 (30 mg, 0.027 mmol) in anhydrous methanol (30 mL) was added Amberlite° IRA 400 (lg) and the mixture stirred for 1 hour at room temperature. Amberlite° IRA 400 resin was filtered under vacuum and the porphyrin filtrate recovered, dried (Na2S0~) and evaporated i~z vacuo to yield the above compound as a water soluble purple solid (22 mg, 96.4%). Porphyrins of Examples 4 and 6 were distinguished only by their respective solubility in water.
Example 7 5-(4-Isothiocyanatophenyl)-10,15,20-tris(4-N methylpyridiniumyl) porphyrin trichloride 49 =
CI
~e Me Cl IVIC
CI
To a solution of 5 (30 mg, 0.027 mmol) in anhydrous methanol (30 mL) was added Amberlite° IR.A 400 (lg) and the mixture stirred for 1 hour at room temperature.
Amberlite° IRA 400 resin was filtered under vacuum and the porphyrin filtrate recovered, dried (NaZS04) and evaporated ifZ vacuo to yield the above compound as a water soluble purple solid (21 mg, 92.0%). Porphyrins of Examples 5 and 7 were distinguished only by their respective solubility in water.
Example 8 17,18-Dihydroxy-5-(4-isothiocyanltophenyl)-15-(4-methoxyphenyl)chlorin, The higher Rt~regioisomeric chlorin 10 (17.5 mg, 23.2 p.mol) was converted into the corresponding isothiocyanate according to the following method. To a stirred solution of ( 1 ec~., 50 mg, 0.099 mmol) in freshly distilled DCM (20 mL) was added 1,1'-thiocarbonyldi-2(11~-pyridone (2 eq., 46 mg, 0.198 mmol). The reaction was allowed to stir under argon for 2 h at room temperature, after which the reaction mixture was filtered, and concentrated then chromatographed, eluting with 1% MeOH in DCM
to afford the title compound. The title compound was isolated as a brown-purple crystalline solid, (17 mg, 90%), Rf= 0.36 (DCM/MeOH, 19:1), mp 155-158°C
(decomposed); UV-vis (DCM) ~.",,1~ (relative intensity) 410 (1.0) 505 (0.09), 534 (0.06), 586 (0.04), 637 (0.18) nm; Fluorescence (DCM) 7~",~~ 639 nm (~, excitation = 412 nm); 1H NNiR
(270 MHz, 10% CD30D in CDC13) 8 10.0 (s, 1H, 10-I~, 9.45 (s, 1H, 20-I~, 9.20 (d, 1H, J =
4.8 Hz, ,C~H), 9.06 (d, 1H, J = 4.0 Hz, ~ H), 9.02 (d, 1H, J = 4.8 Hz, ~3 H) 8.84 (d, 1H, J =
4.8 Hz, ,C~H), 8.64 (d, 1H, J = 4.0 Hz, ~3 H), 8.55 (d, 1H, J = 4.8 Hz, ~3 H), 8.21 (m, 1H, J
= 8.1 Hz, ~-o-Ar), 8.15 (m, 1H, J = 8.1 Hz, ~-o An), 8.05 (m, 1H, J = 8.9 Hz, 1.5-o-Ar~) 7.93 (m, 1H, J = 8.9 Hz, !~-o-Af~), 7.65 (m, 2H, ~-n~-An), 7.24 (m, 2H, l.iayz-Ar), 6.43 (d, 1H, J = 6.5 Hz, 17-H), 6.04 (d, 1H, J = 6.5 Hz, 18-H), 4.08 (s, 3H, CH;), (NH's exchanged & OH's not observed); MALDI-MS m/z 583.7 ([M=H]+, 100%); ES-HRMS
calcd. for C3aH2~N;03S ([M+H]t) 584.1757, found 584.1756.
Example 9 cis-7,8,17,18-Tetrahydroxy-5-(4-isothiocyanatophenyl)-15-(4-methoxyphenyl)bacteriochlorin The ci.s-bacteriochlorin 14 (8.5 mg, 10.7 p.mol) in 25% MeOH in DCM (1.25 mL) was treated with piperidine (.SO eq., 53 p.l , 0.53 mmol) and left to stir for a period of 3 h at room temperature under N2 with light excluded. The reaction mixture was concentrated ira vcrc~ro (0.1 torr) to remove all traces of piperidine. The crude amine was then converted into the reduired isothiocyanate following the procedure described above The cis-bacteriochlorin_isothiocyanate was isolated as a pink-green crystalline solid (5.0 mg, 76%), Rf~= 0.40 (DCMIMeOH, 19:1), mp 132-135°C (decomposed); UV-vis (DCM) ~,max (relative intensity) 375 (1.0) 516 (0.22), 702 (0.48) nm; Fluorescence ~,max 709 nm (~, excitation = 516 nm); 1H NMR (270 MHz, 10% CD30D in CDC13) 8 9.20 (s, 1H, meso-H), 9.18 (s, 1H, n2eso-H), 8.77 (d, 2H, J = 4.8 Hz, ,l3-H), 8.40 (d, 1H, J =
4.8 Hz, ,<3 H), 8.34 (d, 1H, J = 4.8 Hz, ,Q-H), 8.14 (m, 2H, o Af~), 8.05 (m, 2H, o' An), 7.42-7.08 (m, 4H, ~+l~-m-Ar), 6.20 (m, 2H, 7+17-H), 5.98 (m, 1H, 8-H), 5.93 (m, 1H, 18 I~, 4.04 (s, 3H, CH;), -1.80 (br s, 2H, partly exchanged-NH), (OH's not observed); MALDI-MS m/z 618.9 ([M+H]+, 100%); ES-HRMS calcd. for C3~IZgN;OSS ([M+H]+) 618.1815, found 618.1810.
Examples 10, 11, 12, 13 17,18-Dihydroxy-5-(4-acetamidophenyl)-15-(4-methoxyphenyl)chlorinl7,8-dihydroxy-5-(4-acetamidophenyl)-15-(4-methoxyphenyl)chlorin regioisomers, and cis/trap.s-7,8,17,18-tetrahydroxy-5-(4-acetamidophenyl)-15-(4-methoxyphenyl)bacteriochlorin stereoisomers, Porphyrin 8 (100 mg, 0.18 mmol) was converted, in a single reaction, to a mixture of chlorin diols/bacteriochlorin tetrols following the procedure of Sutton et al.
After 38 h the reaction was stopped. The crude reaction mixture was then chromatographed, eluting with 2% MeOH in DCM to give first, some un-reacted starting material then the higher Ri~ chlorin isomer of Example 10 as a brown-purple crystalline solid (5 mg, 5%). The lower Rt~ isomer of Example 11 was obtained by further elution with 3.5% MeOH
in DCM and gave also a brown-purple crystalline solid (7.0 mg, 7%). Further elution with 5% MeOH in DCM afforded the required tj~ar~sicis-bacteriochlorin tetrols of Examples 12 and 13 respectively as pink/green solids (5.0 mg, 5%) and (7.0 mg, 7%) respectively.
High Rt~ chlorin regioisomer of Example 10 (17,18-dihydroxy-15-(4-methoxyphenyl)-5-(4-acetamidophenyl) chlorin assigned on the basis of past data)(~6) R~= 0.40 (DCM/MeOH, 37:3), mp 186-188°C (decomposed); UV-vis (DCM) ~,max (relative intensity) 410(1.0), 505.5 (0.12), 535 (0.08), 585.5 (0.05), 637 (0.18) nm;
Fluorescence (DCM) 7~",;,~ 639 nm (~, excitation = 410 nm); 1H NMR (270 MHz, CDCl3) 8 9.97 (s, 1H, 10-I~, 9.42 (s, 1H, 20-H), 9.19 (d, 1H, J = 4.0 Hz, ~3-H), 9.03 (d, 1H, J =
4.0 Hz, ,(3-H), 8.98 (d, 1H, J = 4.8 Hz, /3-H) 8.89 (d, 1H, J = 4.0 Hz, ,~3-H), 8.70 (d, 1H, J
= 4.8 Hz, /3 H), 8.52 (d, 1H, J = 4.8 Hz, ,(3-H), 8.14-8.10 (m, 3H, S-olna At~), 7.96-7.82 (m, 3H, ~+IS-o%jn-Ar), 7.50 (s, 1H, NH), 7.34 (m, 2H, IS-na Af°), 6.48 (m, 1H, 17-H), 6.20 (m, 1H, I~-H), 4.08 (s, 3H, CH;), 2.38 (s, 3H, CH;), -1.89, -2.20 (s, 2H, NH); MALDI-MS
miz 582.6 ([M+H]~, 100%); ES-HRMS calcd. for C3sHzsNsOa ([M+H]+) 582.2141, found 582.2137.
Low Rt~ chlorin regioisomer of Example 11 (7,8-dihydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl)chlorin) Rf= 0.35 (DCM/MeOH, 37:3), mp 182-185°C
(decomposed);
UV-vis (DCM) ~,",a,; (relative intensity) 410(1.0), 505.5 (0.1), 535 (0.07), 585 (0.04), 636 (0.19) nm; Fluorescence (DCM) ~,",ax 639 nm (~, excitation = 410 nm); 1H NMR
(270 MHz, 10% DMSO-d~ in CDC13) 8 9.96 (s, 1H, 10 ~, 9.92 (s, 1H, NH), 9.42 (s, 1H, H), 9.22 (m, 1H, ~H), 9.02 (d, 1H, J = 4.8 Hz, ,(3-H), 9.00 (m, 1H, ,l3-I~
8.92 (m, 1H, ,l3 H), 8.70 (d, 1H, J = 4.8 Hz, ,(3-FI), 8.53 (m, 1H, ,(3 I~, 8.18-7.91 (m, 6H, 5+1.5-olm Ar), 7.33-7.28 (m, 2H, L5-n~ Ar), 6.36 (m, 1H, 7-H), 5.96 (m, 1H, 8 II), 4.10 (s, 3H, CHj), 2.30 (s, 3H, CH;), -1.74, -2.17 (s, 2H, NH); MALDI-MS m/z 582.6 ([M+H]+, 100%). ES-HRMS calcd. for C35H28N;Oa ([M+H]+) 582.2141, found 582.2135.
High Rt~trccrts bacteriochlorin of Example 12; Rf= 0.29 (DCM/MeOH, 37:3:1), mp 155°C (decomposed); UV-vis (DCM) ~.max (relative intensity) 373.5 (1.0) 514 (0.25), 702 (0.49) nm; Fluorescence (DCM) ~,max 708 nm (~, excitation = 514 nm); 1H NMR
(270 MHz, DMSO-d~) 8 10.27 (s, 1H, NH), 9.16 (s, 2H, 10+20-H), 8.96 (d, 2H, J = 4.0 Hz, ~
H), 8.24 (d, 2H, J = 4.0 Hz, /.~H), 7.99-7.89 (m, 6H, 5+1 S-olm Ar), 7.25 (m, 2H, I S-m-An), 6.30 (m, 2H, 7+17-H), 6.15 (m, 2H, 8+18 l~, 5.63 (m, 2H, Ol~, 5.32 (m, 2H, OH), 3.99 (s, 3H, CH3), 2.20 (s, 3H, CH3), -1.87 (br s, 2H, NH); MALDI-MS m/z 616.3 ([M+H]1, 100%). ES-HRMS calcd. for C35H3oNsOs ([M+H]+) 616.2196, found 616.2192.
Low Rt~ cis-bacteriochlorin 13; Rf= 0.24 (DCM/MeOH, 19:1), mp 148-151°C
(decomposed); UV-vis (DCM) ~,maX (relative intensity) 373.5 (1.0) 514.5 (0.24), 703 (0. SO) nm; Fluorescence (DCM) ~,max 708 nm (~, excitation = 514 nm); 1H NMR
(270 MHz, 20% CD30D in CDC13) 8 9.20 (s, 2H, 10+20-H), 8.78 (m, 2H, ,Q H), 8.35 (m, 2H, /.3 H), 8.05 (m, 2H, 5-~ AY), 7.89-7.86 (m, 3H, 5+IS-olm Ar), 7.75 (m, 1H, IS-o Ar), 7.20-7.17 (m, 2H, 15-m Ar), 6.25 (m, 2H, 7+17-F~, 5.86 (m, 2H, 8+18-H), 4.06 (s, 3H, C:H;), 2.31 (s, 3H, CHj), (NH's exchanged); MALDI-MS m/z 616.4 ([M+H]+, 100%).
ES-HRMS calcd. for C35H30N506 ((M+H]~) 616.2196, found 616.2192.
Example 16 5-(4-Isothiocyanatophenyl)-10,15,20-tri(4-methylphosphoniumphenyl)- porphyrin and 5-(4-isothiocyanatophenyl)-15-(4-methylphosphoniumphenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(4-aminophenyl)-10,25,20-tri-(4-carbomethoxyphenyl) porphyrin and 5-(4-aminophenyl)-15-(4-carbomethoxyphenyl) porphyrin were synthesised by mixed condensation using Lindsey conditions (Lindsey, J.S., Schreiman, LC., Hsu, H.C., I~earney, P.C., Marguerettaz, A.M. (1987) .I. Org. Che»a. 52, 827) or by 2+2 condensation methodology via the appropriately substituted 5-phenyldipyrromethanes as described by Boyle et al (Boyle, R.W., Bruckner, C., Posakony, J., James, B.R., Dolphin, D. ( 1999) Ongarzic Sy~ztheses. 76, 287 - incorporated herein by reference) respectively.
The (4-carbomethoxyphenyl) groups on these porphyrins were then converted to (4-(1-bromomethyl)phenyl) groups using the following standard procedure: the porphyrin (0.2 53 =
mmol) was dissolved in dry THF (25 ml) at 0°C and stirred under argon for 10 minutes.
Lithium aluminium hydride (0.7 mmol) was added and the stirring continued for hours. The reaction was monitored by TLC and, when the reaction was complete ethyl acetate (2 ml) was added and the mixture washed with aqueous HCl (0.2 M, 20 ml), saturated sodium bicarbonate solution (30 ml) and finally, brine (20 ml). The organic layer was dried (MgSO~) and evaporated to dryness to yield the corresponding (4-(1-hydroxymethyl)phenyl) substituted porphyrins, bearing three or one reduced carbomethoxy groups respectively. (4-(1-Hydroxymethyl)phenyl) substituted porphyrins (0.2 mmol) were dissolved in dry chloroform (40 ml) and stirred under argon while triphenylphosphine (1.0 mmol) and carbon tetrabromide (1.6 mmol) were added.
The reaction was stirred, in the dark, for 24 hours and then monitored by TLC.
Once all the hydroxymethyl groups had been converted to bromomethyl groups the reaction mixture was diluted with dichloromethane (40 ml), washed with saturated sodium bicarbonate (2 x 20 ml) then brine (2 x 20 ml) and the organic layer dried (MgSO~,). Removal of solvent by evaporation in vacuo afforded the corresponding bromomethyl porphyrins as purple crystalline solids.
Boc N-protected 5-(aminophenyl)-10,25,20-tri-(4-bromomethylphenyl) porphyrin and 5-(aminophenyl)-15-(4-bromomethylphenyl) porphyrin (0.75 mmol) were dissolved in dry dichloromethane (50 ml) under an atmosphere of argon at 25°C. Triaryl or trialkylphosphine (7.5 mmol) dissolved in dry dichloromethane (10 ml) was injected by syringe and the progress of the reaction was followed by TLC. Upon completion the solvent was evaporated from the reaction in vacuo and the crude product was purified by flash column chromatography (silica; gradient elution: dichloromethane to methanol) to give the required Boc-N-protected-5-(aminophenyl)-methylphosphonium-meso-aryl porphyrins as lustrous purple crystalline solids. The Boc protecting group was removed by dissolution of the porphyrin in chloroform or acetonitrile, depending upon solubility, and addition of trimethylsilyl iodide (5.0 equivalents), after 30 minutes the reaction was quenched with methanol (10 ml). Removal of solvent by evaporation, followed by purification by flash column chromatography (silica; gradient: dichloromethane to methanol) gave the 5-(aminophenyl)-methylphosphonium-meso-aryl porphyrins which were converted to the required mono-4-(isothiocyanatophenyl) compounds by treatment ~4 --with 1,1'-thiocarbonyldi-2(1H)-pyridone using standard procedures (Clarke, O.J. and Boyle, R.W. (1999.LC.S. Chem. Cornmicn. 2231).
Example 17 5-(4-Isothiocyanatophenyl)-10,15,20-tri((4-methylphosphono-di-ethoxy)phenyl)-porphyrin and 5-(4-isothiocyanatophenyl)-15-((4-methylphosphono-di-ethoxy)phenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(4-aminophenyl)-10,15,20-tri-(4-bromomethylphenyl) porphyrin and 5-(aminophenyl)-15-(4-bromomethylphenyl) porphyrin (0.75 mmol) were dissolved in a mixture of triethyl phosphite (15 mmol) and dry acetonitrile (50 ml). A reflux condenser was fitted and the reaction was refluxed under argon. The reaction was followed by TLC
and upon completion was washed with saturated sodium bicarbonate (2 x 20 ml), water (2 x 20 ml) and brine (2 x 20 ml). The organic layer was then dried (MgSO:~) and the solvent evaporated in vacuo. The crude product was then purified by flash column chromatography (silica; gradient elution:
dichloromethane to ethyl acetate) to give the title compounds as purple crystalline solids. The methylphosphono-di-ethoxy groups were then deprotected to either methylphosphono-mono-ethoxy sodium groups by sonication in aqueous sodium hydroxide for 1 hour followed by reversed phase medium pressure chromatography (C18; gradient elution 0.1%
aqueous TFA to methanol) (Boyle, R.W. and van Lier, J.E. (1993) Synlett 351), or to the fully deprotected methylphosphonic acids by treatment with bromotrimethylsilane (2 equivalents per methylphosphono-di-ethoxy group) for 2 hours followed by reversed phase chromatographic purification chromatography (CIB; gradient elution 0.1%
aqueous TFA to methanol) (McI~enna, C.E., Higa, M.T., Cheung, N.H., McI~enna, M-C.
(1977) 2, 155). Boc deprotection (see above) followed by conversion of the unmasked 4-(aminophenyl) group to its isothiocyanato analogue was performed using standard procedures (Clarke, O.J. and Boyle, R.W. (1999 J. C. S. Chena. Com~rrura.
2231)_ Example 18 5-(4-Isothiocyanatophenyl)-10,15,20-tri((4-methylphosphonato-di-ethoxy)phenyl)-porphyrin and 5-(4-isothiocyanatophenyl)-15-((4-methylphosphonato-di-ethoxy)phenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(aminophenyl)-10,15,20-tri-(4-hydroxymethylphenyl) porphyrin and 5-(aminophenyl)-15-(4-hydroxymethylphenyl) porphyrin (0.75 mmol) were dissolved in a mixture of dry dichloromethane and pyridine (4:1) under an atmosphere of argon.
Diethyl chlorophosphate (2 equivalents per hydroxymethyl group) was injected and the mixture was stirred for 16 hours. Evaporation of solvent from the reaction mixture followed by chromatographic purification gave the corresponding tri or mono ((4-methylphosphonato-di-ethoxy)phenyl) porphyrins. Treatment with aqueous sodium hydroxide ( 1M) gave the sodium salts of tri or mono ((4-methylphosphonatoethoxy)phenyl) porphyrins (Boyle, R.W. and van Lier, J.E.
(1995) Synthesis 1079). Boc deprotection and generation of the isothiocyanato group were performed as described above.
Example 19 5-(4-Isothiocyanatophenyl)-10,15,20-tri((4-methylpyridiniumyl)phenyl)- porphyrin and 5-(4-isothiocyanatophenyl)-15-((4-methylpyridiniumyl)phenyl)- porphyrin - General Synthetic Procedure Boc N-protected 5-(aminophenyl)-10,25,20-tri-(4-bromomethylphenyl) porphyrin and 5-(aminoophenyl)-15-(4-bromomethylphenyl) porphyrin (0.75 mmol) were dissolved in dichloromethane (50 ml) and pyridine (15 mmol), or substituted pyridine (15 mmol), as required, were added. A reflux condenser was fitted and the reaction was refluxed under argon. The reaction was followed by TLC and, upon completion, was evaporated to dryness in vacuo. The residue was purified by reversed phase medium pressure chromatography (C1R; gradient elution 0.1% aqueous TFA to methanol) to yield the N-Boc protected 4-aminophenyl compounds. Deprotection of the aminophenyl groups) and conversion to the isothiocyanato analogues) were conducted using the standard protocols (see above).
~6 =
Example 20 5-(4-Isothiocyanatophenyl)-15-axyl-10,20-(1,2-dihydroxyethyl)-porphyrin - General Synthetic Procedure The Fmoc protected 5-(4-aminophenyl)-15-aryl porphyrin (0.8 mmol) was dissolved in dry chloroform (300 ml) under an atmosphere of argon. Freshly recrystallised N-bromosuccinimide (1.8 mmol) in dry chloroform (20 ml) was injected by syringe and the mixture was stirred for 30 min. The solvent was then evaporated in vacuo and the crude product purified by flash column chromatography (silica; gradient elution:
hexane to ethyl acetate) to give the required 5, 15-dibromo-10, 20-diarylporphyrin as a purple crystalline solid. The product was then metallated by refluxing in a chloroform/methanol (9:1 ) solution of zinc acetate dihydrate (80 mmol). The metallation was followed by visible spectroscopy and, upon completion, was passed through a short column of neutral alumina to remove uncoordinated zinc. The zinc 5,15-dibromo-10, 20-diarylporphyrin (0,6 mmol) was dissolved in dry THF to which had been added tetrakis(triphenylphosphine)-palladium(0) (0.6 mmol) and vinyltributyltin (1.4 mmol).
The mixture was refluxed under nitrogen for 48 hours after which the solvent was evaporated in vacuo and the residue chromatographed by flash column (silica;
gradient elution: dichloromethane to ethyl acetate) to give zinc 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin as a purple crystalline solid. Zinc 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin was demetallated by dissolution in a solution of trifluoroacetic acid in dichloromethane (1% vlv) to give 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin after extracting with water and evaporation of solvent from the organic layer in vacuo. Finally the 10 and 20 ethenyl groups were hydroxylated by osmium tetroxide as described (Sutton J, Fernandez N, Boyle RW (2000) J.
Porphyrins and Phthalocyanines 4, 655), however due to the rapidity of the reaction between the ethenyl groups and osmium tetroxide it was possible to selectively hydroxylate these groups by control of reaction time and stoichiometry. In a typical set of conditions the 5-(Fmoc aminophenyl)-15-aryl-10,20-diethenyl porphyrin, when treated with osmium tetroxide (5 equivalents) in 10°f° pyridine/chloroform for 24 -48 hours, gave the desired 5-(Fmoc aminophenyl)-15-aryl-10,20-bis(1,2-dihydroxyethyl) porphyrin, while if longer reaction times (72 hours) and higher molar ratios of osmium tetroxide (7.5 or equivalents) are used under the same conditions 5-(Fmoc aminophenyl)-15-aryl-10,20-bis( 1,2-dihydroxyethyl) 7,8-dihydroxychlorin and 5-(Fmoc aminophenyl)-15-aryl-10,20-bis( 1,2-dihydroxyethyl) 7,8,17,18-tetrahydroxybacteriochlorin respectively are obtained.
All the above products are converted cleanly to the corresponding isothiocyanates upon piperidine mediated deprotection of the amino group (see above) and treatment with l, l'-thiocarbonyldi-2(1H)-pyridone using standard procedures (Clarke, O.J. and Boyle, R.W.
( 1999 ,I. C. S. Chena. Common. 2231 ).
Example 21 5-(4-Isothiocyanatophenyl)-15-phenyl-10,20-(diaryl)-porphyrins -Synthesis from 5,15-diphenyl porphyrins by Pd° mediated Suzuki coupling Boc N-protected 5-(aminophenyl)-15-phenyl porphyrin was brominated at the 10 and 20 meso positions as described above. The meso-10,20-dibrominated product (0.75 mmol) was dissolved in dry THF (50 ml) or toluene (50 ml), depending upon the boronic acid used in the coupling reaction, tetrakis-(triphenylphosphine) palladium (0) (0.75 mmol) and anhydrous potassium phosphate (0.75 mmol) were added, a reflux condenser was then fitted to the flask and the whole apparatus was placed under an atmosphere of argon.
The required aryl or heterocyclic boronic acid was then added as a solution in the appropriate solvent (10 ml) by injection. The reaction was brought to reflux and followed to completion by TLC. On completion the crude reaction mixture was diluted with dichloromethane (100 ml) and extracted with saturated sodium bicarbonate (2 x 50 ml), water (2 x 50 ml) and brine (2 x 50 ml). The organic phase was dried (Mg SOa) and concentrated by evaporation in vacuo. Finally, the residue was purified by flash column chromatography (silica; gradient elution: dichloromethane to methanol) to give the Boc N-protected 5-(aminophenyl)-15-phenyl-10,20-(diaryl)-porphyrin as a purple crystalline solid. The Boc protecting group was removed by dissolution of the porphyrin in chloroform or acetonitrile, depending upon solubility, and addition of trimethylsilyl iodide (1.2 equivalents), after 30 minutes the reaction was quenched with methanol (10 ml). Removal of solvent by evaporation followed by purification by flash column chromatography (silica; gradient: dichloromethane to methanol) gave the 5-(aminophenyl)-15-phenyl-10,20-(diaryl)-porphyrin which was converted to the title compound by treatment with 1,1'-thiocarbonyldi-2(1H)-pyridone using standard procedures (Clarke, O.J. and Boyle, R.W. (1999 J. C. S. Chem. Conamun. 2231).
58 _ Example 22 5-(4-lsothiocyanatophenyl)-10,15,20-tri(4-glycosylphenyl)-porphyrin and 5-(4-isothiocyanatophenyl)-15-(4-glycosylphenyl)- porphyrin - General Synthetic Procedure 4-(2',3',4',6'-tetra-O-acetyl-(3-D-glucopyranosyloxy)benzaldehyde was condensed with 4-nitrobenzaldehyde and pyrrole using Lindsey conditions (Sol, V., Blais, J.C., Carre, V., Granet, R., Guilloton, M., Spiro, M., I~rausz, P. (1999) J. Org. Chenz. 64, 4431) and the crude reaction mixture purified by flash column chromatography to give 5-(4-nitrophenyl)-10,15,20-tris[4-(2',3',4',6'-tetra-O-acetyl-(3-glucopyranosyloxy)phenyl]
porphyrin. Alternatively, 4-(2',3',4',6'-tetra-O-acetyl-(3-D-glucopyranosyloxy)benzaldehyde was used to synthesise 5-(4-(2',3',4',6'-tetra-O-acetyl-(3-D-glucopyranosyloxy)phenyl) dipyrromethane using the method of Boyle (Boyle, R.W., Bruckner, C., Posakony, J., James, B.R., Dolphin, D. (1999) Organic Syntheses.
76, 287) which was then condensed to give 5-(4-nitrophenyl)-15,-[4-(2',3',4',6'-tetra-O-acetyl-[i-glucopyranosyloxy)phenyl] porphyrin. Reduction of the nitro group of these porphyrins was performed by dissolution in THF and addition of 10% palladium on carbon. Stirring of the mixture under HZ for 5 hours followed by filtration through Celite and purification by flash column chromatography gave the corresponding amino porphyrins, which were N-protected by reaction with Fmoc chloride (2 equivalents) in anhydrous 1,4-dioxane in the presence of sodium bicarbonate (6 equivalents) under argon. The reaction was monitored by TLC and, upon completion, diluted with dichloromethane and washed with water then brine before drying the organic layer (MgSO~). Purification by flash column chromatography gave the Fmoc N-protected 5-(4-aminophenyl)-10,15,20-tris[4-(2',3',4',6'-tetra-O-acetyl-(3-glucopyranosyloxy)phenyl]
porphyrin or 5-(4-aminophenyl)-15,-[4-(2',3',4',6'-tetra-O-acetyl-(3-glucopyranosyloxy)phenyl] porphyrin. N and O protecting groups were removed by dissolution of the porphyrin in dichloromethane/morpholine (1:1) and stirring for 1 hour.
Removal of solvent by evaporation in vacuo was followed by redissolution of the residue in a mixture of dichloromethane and methanol (4:1). Sodium methanolate in dry methanol(1.5 equivalents per OAc group) was added and the mixture stirred for 1 hour.
The fully deprotected porphyrin was recovered by precipitation with hexane.
Finally, the 59 =
5-(4-aminophenyl) porphyrin was dissolved in dry methanol and l, l'-thiocarbonyldi-2(1H)-pyridone (2 equivalents) was added. The reaction was stirred under argon for 2 hours and monitored by TLC, upon completion, solvent was evaporated in vacuo~and the crude product was purified by preparative medium pressure reversed phase chromatography (Clg;gradient elution: 0.1% aqueous TFA to methanol).
Example 23 : Symmetrical Porphyrin/ Chlorin Diol/ Bacteriochlorin Tetrol Series ~,1~-(3,4,~-Tris»zetlzoxyphenyl)porphyrin (,general procedure) To a 3 L round bottom flask was added 5-(3,4,5-trismethoxyphenyl)dipyrromethane (1.86 g, 6 mmol), then DCM (1L) under NZ. To this stirred solution was added trimethylorthoformate (48 ml, mmol). A pressure equalizing dropping funnel containing a solution of trichloroacetic acid (23.0 g, mmol) in DCM (500 ml) was then fitted to the flask and the solution added dropwise to the reaction mixture over a period of 10 min.
The reaction vessel was covered in aluminium foil to exclude light and allowed to stir under NZ for a period of 3.5 h. Pyridine was then added to the reaction mixture, rapidly with stirring, and the reaction allowed to stir for a further 16 h. at room temperature under NZ with the light excluded. The aluminium foil was removed and air was bubbled through the solution for a period of 20 min. After this the reaction was left to stir unstoppered for a further period of 3 h. at room temperature with the aluminium foil removed.
The reaction mixture was then concentrated in vacuo to remove DCM and remaining pyridine by evaporator, then high vacuum. The crude reaction mixture was then chromatographed on flash silica-gel (250 ml), (dry loaded on to 50 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting with chloroform . The title compound was obtained as purple crystalline solid (347 mg, 18%); ~,max/
(relative intensity) 410 (1.0), 502 (0.04), 538 (0.02), 578 (0.015), 630 (0.01) nm; UV-VIS
(CH~CIz) (fluorescence) 7~""t, = 634 nm (7~ excitation = 408 nm); (270 MHz, CDCl3) 10.32 (2H, s, I Q-H, ?D-H), 9.40 (4H, d, J = 4.8 Hz, ~3 H), 9.18 (4H, d, J =
4.8 Hz, ,(3 H), 7.52 (4H, s, o An), 4.20 (6H, s, CHj), 4.00 (12H, s, CHj), -3.10 (2H, br. s, NH); MS
(MALDI) m/z = 643.4 (100%, M+).
7, 8-Dihplroxy ~,1 ~-(3, 4, ~-trismethoxyphenyl) clzlorin (A General procedure) To a stirred solution of 5,15-(3,4,5-trismethoxyphenyl)porphyrin (50 mg, 77.8 p.mol) in HPLC grade chloroform (5.0 ml) was added a solution, in anhydrous pyridine (0.5 ml), of osmium tetroxide (~..5 eq., 0.195 mmol, 49 mg). The reaction vessel was flushed with NZ
and sealed with a lightly greased glass stopper, then covered in aluminium foil to exclude the light and left to stir for 72 h at room temperature. After this period the reaction vessels glass stopper was replaced With a plastic stopper and a continuous stream of hydrogen sulfide gas was bubbled through the reaction mixture for 5 min., (a gas outlet needle was attached and allowed excess hydrogen sulfide gas to escape into a series of Dreshel bottles filled with mineral oil and a bleach solution respectively).
After this time the reaction mixture was filtered through Celite~ and then concentrated in vacuo. Any excess pyridine was removed under high vacuum. The crude reaction mixture was then chromatographed on flash silica-gel (100 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting with 1%
methanol in DCM. Some starting material was recovered (15%) and the title compound was obtained as browny-purple crystalline solid , (26 mg, 50%); m.p. 170 °C
(decomposed);
UV-VIS (CHZC12) 7~ma~ (relative intensity) 410 (1.0) 504 (0.09), 534 (0.06), 582 (0.04), 636 (0.18) nm; UV-VIS (CHZC12) (fluorescence) ~,max 639 nm (~, excitation 410 nm);
SH(270 MHz, CDC13) 9.98 (1H, s, 10-H), 9.42 (1H, s, ?0-H), 9.20 (1H, m,,QH), 9.04 ( 1 H, d, J = 4. 0 Hz, /.3 I~, 8 . 99 (2H, s, ~3 H), 8. 79 ( 1 H, d, J = 4. 0 Hz, ,(3 H), 8. 66 ( 1 H, m, ,~i H), 7.45 (1H, d, J = 1.6 Hz, l~-o Ar), 7.42 (1H, d, J = 1.6 Hz, l.i-o-Ar), 7.40 (1H, d, J =
1.6 Hz, ~-o Ar), 7.19 ( 1 H, d, J = 1.6 Hz, 15-o Ar), 6.49 ( 1 H, d, J = 7. 3 Hz, 7-H), 6.23 (1H, d, J = 7.3 Hz, 8-H), 4.17 (3H, s, GH;), 4.15 (3H, s, CH3), 4.04 (3H, s, CH3), 4.00 (3H, s, CHI), 3.98 (3H, s, CH3), 3.91(3H, GH3), -1.80 (1H, br. s, NH), -2.19 (1H, br. s, NH), (OH'.s not observed); MS (MALDI) m/z = 677.3 (100%, M+); HRMS calcd. for C3RH~~N:~Og: 676.2533. Found: 676.2587.
7,8,17,18-Tetrahydroxy~,l~-(3,4,x-trismethoxyphenyl) bacteriochlorin ( n r 1 r ce ure) To a stirred solution of 5,15-(3,4,5-trismethoxyphenyl)porphyrin (50 mg, 77.8 pmol) in HPLC grade chloroform (5.0 ml) was added a solution, in anhydrous pyridine (0.5 ml), of osmium tetroxide (~.0 ed., 0.39 mmol, 49 mg). The reaction vessel was flushed with NZ
and sealed with a lightly greased glass stopper, then covered in aluminium foil to exclude the light and left to stir for 72 h at room temperature. After this period the reaction vessels glass stopper was replaced with a plastic stopper and a continuous stream of hydrogen sulfide gas was bubbled through the reaction mixture for 5 min., (a gas outlet needle was attached and allowed excess hydrogen sulfide gas to escape into a series of Dreshel bottles filled with mineral oil and a bleach solution respectively).
After this time the reaction mixture was filtered through Celite~ and then concentrated in vcrcuo. Any excess pyridine was removed under high vacuum. The crude reaction mixture was then chromatographed on flash silica-gel (100 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting initially with 1%
methanol in DCM to elute chlorin by-product then 2.5 % methanol in DCM to elute the major bacteriochlorin isomer (assumed as tr~ans form Bruckner et cal (1995) Tetrahedron Lett. 3G, 9425). The title compound was obtained as a greeny-pink crystalline solid, (20 mg, 3G%); m.p. 135°C (decomposed); UV-VIS (CH2Clz) ~.max (relative intensity) 374 (1.0) 512 (0.23), 702 (0.52) nm; UV-VIS (CHZCIz) (fluorescence) 7~,na,; 708 nm (~, excitation 512 nm); 8H(270 MHz, CDCl3) 9.23 (2H, s, 10-H, 20-H), 8.79 (2H, d, J = 3.2 Hz, ~3-H), 8.44 (2H, d, J = 3.2 Hz, ,~ 1~, 7.37 (2H, s, 5+15-o-Ar), 7.13 (2H, s, S + 15-0-Ar~), G.31 (2H, d, J = 6. 5 Hz, 7-H, 17-H), 6.01 (2H, d, J = 6.5 Hz, ~-H, I ~-H), 4.12 (6H, s, CH;), 3.92 (GH, s, CH;), 3.89 (6H, s, CH3), -1.97 (2H, br. s, NH), (OH's not observed);
MS (1VIALDI) m/z = 712.4 (100%, (M+1)~'); HRMS calcd. for C3gH36N~O1~:
710.2590.
Found: 710.2607.
Example 24 : Unsymmetrical Porphyrin/ Chlorin Diol/ Bacteriochlorin Tetrol Fluorochrome Sets for Bioconjugation ~-(4-AcetomidoplZenyl)-1 ~-(4-naetlaoxyplzenyl)porplZyrin The required unsymmetrical diphenylporphyrin was synthesised using the general procedure outlined earlier, but with only slight modification. In this example a mixture of dipyrromethanes were used. Due to the different reactivities of the respective dpyrromethanes, the amounts needed for optimisation of mixed porphyrin were different.
For the same scale reaction 5-(4-methoxyphenyl)dipyrromethane (505 mg, 2 mmol) and 5-(4-acetomidophenyl)dipyrromethane (838 mg, 3 mmol) were used. The porphyrin mixture was chromatographed on silica-gel (400 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting initially with DCM ( 1 glass pipette full of triethylamine was added to 500 ml of eluent to aid elution) to remove 5,15-(methoxyphenyl)porphyrin byproduct. After separation of this component the elution was continued with chloroform to allow 5-(4-Acetomidophenyl)-15-(4-methoxyphenyl)porphyrin collection. The desired porphyrin was obtained as purple crystals; (150 mg, 12%); 7~r"~,/ (relative intensity) 410 (1.0), 502 (0.04), 538 (0.02), 578 (0.015), 630 (0.01) nm; 8H(270 MHz, CDC13) 10.35 (2H, s, 10-H, 20-H), 9.43 (4H, d, J =
4. 8 Hz, ,(3-H), 9.14 (4H, d, J = 4. 8 Hz, f3 H), 8.65 (2H, d, J = 7.2 Hz, 5-»a-Ar), 8.22-8.12 (4H, d (overlapping), J= 8.1 Hz, .5-o Ar+IS-o Ar), 7.56 (2H, d, J= 8.1 Hz, IS-rrz Ar), 4.14 (3H, s, C:H;), -3.00 (2H, br. s, NH); MS (MALDI) m/z = 550.3 (100%, M~).
~-(4-Anzinophenyl)-1 ~-(4-i~iethoxyphenyl)porphyrin 5-(4-Acetomidophenyl)-15-(4-methoxyphenyl)porphyrin (100 mg, 0.182 mmol) was treated with 18% hydrochloric acid (200 ml) and fitted with an air condenser.
The green solution was left to warm to 85oC for a period of 3 h. Prior to cooling, the reaction mixture was concentrated irz vacuo (water aspirator; evaporator water bath at 75°C) to remove excess hydrochloric acid then treated carefully with a solution of triethylamine (50 ml) in DCM. The organic extract was washed with water (100 ml) then saturated brine ( 100 ml) prior to drying (arzhyd. Na2S0~), filtering via Buckner funnel and finally concentration ifz vacuo. The required porphyrin was obtained by chromatography on silica-gel (100 ml), (liquid loaded in 10 ml DCM) eluting with DCM (1 glass pipette full of triethylamine was added to 500 ml of eluent to aid elution). The desired porphyrin was obtained as purple crystals; (150 mg, 12%); ~,",a,I (relative intensity) 410 (1.0), 503 (0.045), 538(0.02), 578 (0.015), 630 (0.005) nm; UV-VIS (CHZC12) (fluorescence) ~,m~X=
634 nm (~, excitation = 410 nm); dH(270 MHz, CDC13) 10.30 (2H, s, 10-H, 20-H), 9.39 (4H, d, J = 4.9 Hz, ,l3-H), 9.17 (2H, d, J = 4.9 Hz, ,(3 H), 9.10 (2H, d, J =
4.9 Hz, ,l3 H), 8.19 (2H, d, J = 8.8 Hz, LS-o Ar), 8.07 (2H, d, J = 8.1 Hz, 5-o Ar), 7.35 (2H, d, J = 8.8 Hz, I~-na Ar), 7.14 (2H, d, J = 8.1 Hz, S-m Ar), 4.13 (3H, s, CH3), 4.08 (2H, br. s, NH), -3.06 (2H, br. s, NH); MS (MALDI) m/z = 508.3 (100%, (M+1)~).
~-(~-Fluorenonzetlzylanzinoplzenyl)-I'-(9-nze'tlzoxyphenyl)porphyrin To a stirred solution of 5-(4-aminophenyl)-15-(4-methoxyphenyl)porphyrin (28 mg, 55 ymol) in anhydrous 1,4-dioxane (2.5 ml) was added solid sodium hydrogen carbonate (6 ed., 28 mg, 0.33 mmol). To this mixture was then added a solution of 9-fluorenomethylchloroformate (2 eq., 0.11 mmol, 28.5 mg) in 1,4-dioxane (0.5 ml) under N~. The reaction flask was covered with aluminium foil to exclude light and stirred at room temperature for a period of 3 h. At this time the reaction had gone to completion (as monitored by TLC). The 1,4-dioxane was removed irz-vacuo and the residue partitioned between water (25 ml) and DCM (2 x 25 ml). The combined organic extracts were washed with saturated brine (25 ml) then dried (anlzyd. Na2S04), filtered and concentrated irmacuo. The required porphyrin was obtained by chromatography on silica-gel ( 100 ml), (dry loaded on to 10 ml flash silica-gel from DCM and a little methanol for solubility) eluting with DCM. The desired porphyrin was obtained as purple crystals; ( 38 mg, 95%); 7~",a,I (relative intensity) 410 (1.0), 505 (0.042), 541 (0.02), 578 (0.015), 633 (0.01) nm; UV-VIS (CH2C12) (fluorescence) 7~",ax = 635 nm (~, excitation =
410 nm); bH(270 MHz, CDC13) 10.35 (2H, s, I D-H, 20-H), 9.69 (1H, br. s, NH), 9.44 (4H, d, J = 4. 8 Hz, ,(3-H), 9.12 (4H, d, J = 4.8 Hz, /3 H), 8.20-8.17 (4H, 2 x d (overlapping), J = 8.1 Hz, 5+I~-o Ar), 7.85 (4H, m, 5+15-»z Ar), 7.76-7.66 (2H, m, fTll()7'E'll0-Ar), 7.51-7.30 (6H, m, fZurerzo Ar), 4.69 (2H, d, J = 7.2 Hz, CH2), 4.30 (1H, t, J
= 7.2 Hz, CH), 4.13 (3H, s, CH3), -3.15 (2H, br. s, NH); MS (MALDI) mlz =
731.5 (100%, (M+1)+), 508.3 (52%, (M-FMOC+1)'~).
17,18-Dilzydroxy-S-(~ anzinoplzenyl)-l~-(4-nzethoxyplzenyl) chlorin and 7,8-dihydroxy ~-(~l-caminopfzenyl)-1 ~-(4-nzetlzoxyplzenyl) chlorin regioisomers 5-(4-aminophenyl)-15-(4-methoxyphenyl)porphyrin (28 mg, 55.2 p,mol) was converted to a mixture of chlorin diol regioisomers using the general chlorin formation procedure given earlier. The crude reaction mixture was then chromatographed on flash silica-gel (200 ml), (dry loaded on to 20 ml flash silica-gel from DCM and a little methanol to ensure complete solubility) eluting with 1% methanol in DCM to elute first some unreacted starting material then the higher Rf chlorin isomer as a browny-purple crystalline solid. The lower Rt~ isomer was obtained by further elution with 2.5%
methanol in DCM and gave also a browny-purple crystalline solid.
~Hiah t chlorin regioisomer (2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-aminophenyl) chlorin, from nOe measurements and JPP paper): (8.5 mg, 30%); m.p.
165°C
(decomposed); UV-VIS (CHZC12) Amax (relative intensity) 401 (0.99), 414 (1.0), (0.08), 535 (0.07), 582 (0.035), 636 (0.22) nm; UV-VIS (CHZC12) (fluorescence) 7~max 639 nm (~, excitation 412 nm); 8H(270 MHz, 10% MeOH-d4 in CDC13) 9.95 (1H, s, H), 9.42 ( 1 H, s, 20-H), 9.17 ( 1 H, d, J =4. 8 Hz, ~3 H), 9.03 ( 1 H, d, J=4.0 Hz, ~3-H), 8. 97 (2H, s, ,(3-H) 8.78 (1H, d, J = 4.8 Hz, ,(3-H), 8.51 (1H, d, J = 4.8 Hz, ,f3-H), 8.05 (2H, d, J =
8.9 Hz, v Ar), 7.94 (2H, d, J = 8.1 Hz, o' Ar), 7.25 (2H, d, J = 8.9 Hz, m Ar), 7.12 (2H, d, J = 8 .1 Hz, na '-Ar), 6.42 ( 1 H, d, J = 6. 5 Hz, 17-H), 6. 03 ( 1 H, d, J =
6. 5 Hz, I ~-H), 4.08 (3H, s, CH;), (NH's exchanged), (OH's not observed).; MS (MALDI) m/z = 642.2 ( 100%, (M+1 )~).
Low Rt~ chlorin regioisomer (2,3-dihydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl) chlorin from nOe measurements and JPP paper): (8.5 mg, 30%); m.p. 168°C
(decomposed); UV-VIS (CHZCl2) ~.max (relative intensity) 401(0.99), 413 (1.0), (0.08), 536 (0.06), 586 (0.025), 637 (0.20) nm; UV-VIS (CH2C12) (fluorescence) 7~max 639 nm (7~ excitation 412 nm); 8H(270 MHz, 10% MeOH-d4 in CDC13) 9.96 (1H, s, H), 9. 40 ( 1 H, s, I 0-H), 9.18 ( 1 H, d, J =4. 8 Hz, /.3 H), 9. 05 ( 1 H, d, J=4. 8 Hz, ~3 H), 8. 9 8 ( 1 H, d, J = 4. 0, ,~3 H) 8. 92 ( 1 H, d, J = 4. 0 Hz, /.~H), 8 . 74 ( 1 H, d, J = 4. 0 Hz, ~3-H), 8. 5 8 ( 1 H, d, J = 4. 0 Hz, (3-H), 8.13 ( 1 H, d, J = 8. 9 Hz, o Ar), 8. 08 ( 1 H, d, J = 8. 9 Hz, o Ar), 7. 9 5 ( 1 H, d, J = 8 .1 Hz, o ' Ar), 7. 79 ( 1 H, d, J = 8.1 Hz, o '-Ar), 7.
3 6 ( 1 H, d, J = 8 . 9 Hz, nz-Ar), 7. 3 0 ( 1 H, d, J = 8. 9 Hz, m Ar), 7.11 ( 1 H, d, J = 8.1 Hz, n2 ' Ar), 7.05 ( 1 H, d, J =
8 .1 Hz, ni '-Ar), 6. 42 ( 1 H, d, J = 6. 5 Hz, 7-H), 6. 09 ( 1 H, d, J = 6. 5 Hz, ~-H), 4.11 (3 H, s, CH;), (NH'.s exchanged), (OH's not observed); MS (MALDI) m/z = 642.2 (100%, (M+1 )T).
17,18-1)ihydrowy-~-(4-isotlaiocycttcatophenyl)-1~-(4 tnetho~yplaenyl)chloritt (higherRf regioi,sosoer) To a stirred solution of l, l'-thiocarbonyldi-2(1 H)-pyridone (1.07 eq., 7.6 mg, 43.5 mmol) in DCM (25 ml), (dried via passage through an activated alumina column) was added a solution of 17,18-dihydroxy-5-(4-methoxyphenyl)-15-(4-aminophenyl)chlorin (17.5 mg, 23.2 Omol) in DCM (10 ml). The reaction flask was covered with aluminium foil to exclude light and left to stir under NZ for 2 h, at which time TLC
indicated complete loss of starting material. The reaction mixture was then washed with water (2 x 50 ml) and saturated brine (50 ml) then dried (anhyd. Na2S0:~). The organic extract was then filtered and concentrated on to 10 ml flash silica-gel and chromatographed on flash silica-gel ( 100 ml), eluting with 1 % methanol in DCM to elute the required isothiocyanato chlorin diol (NB. traces~of all TDP must be removed prior to concentration of product from column chromatography otherwise some decomposition to 3 higher Rf byproducts occurs. These have not been identified at this time). The title compound was isolated as a browny-purple crystalline solid (17 mg, 90%); m.p. 155°C
(decomposed);
UV-VIS (CHZCl2) a,may (relative intensity) 410 (1.0) 505 (0.09), 534 (0.06), 586 (0.04), 637 (0.18) nm; UV-VIS (CHZC12) (fluorescence) ~,ma~ 639 nm (~, excitation 412 nm);
bH(270 MHz, 10% MeOH-d~ in CDC13) 10.0 (1H, s, I D-H), 9.45 (1H, s, 20-H), 9.20 (1H, d, J =4. 8 Hz, ,(3-H), 9. 06 ( 1 H, d, J=4. 0 Hz, ~3-H), 9.02 ( 1 H, d, J = 4 . 8 Hz, ~3 I~ 8 . 84 ( 1 H, d, J = 4. 8 Hz, ,Q-H), 8. 64 ( 1 H, d, J = 4. 0 Hz, ,!1--I~, 8 . 5 5 ( 1 H, d, J = 4. 8 Hz, ,Q H), 8. 21 ( 1 H, d, J = 8.1 Hz, v Ar), 8.15 ( 1 H, d, J = 8 .1 Hz, o-Ar), 8. 05 ( 1 H, d, J = 8. 9 Hz, o '-Ar) 7.93 (1H, d, J = 8.9 Hz, a' An), 7.65 (2H, m, »z-AY), 7.24 (2H, m, »~' Ar), 6.43 (1H, d, J =
6.5 Hz, 17-H), 6.04 (1H, d, J = 6.5 Hz, 18-I~, 4.08 (3H, s, CH;), (NH's exchanged), (OH'.s not observed); MS (MALDI) m/z = 583.7 (100%, M+); HRMS calcd. for C~:~HZ~N;03S: 584.1757. Found: 584.1756 ((M+1)*).
7, 8,17.18-Tetrahydrowy-~-(4-f luoretzomethyla»zinophenyl)-1 ~-(4-nzetlzovyplaetzyl) b~ccteriochloritc (cisltratzs stereoisotners) 5-(4-Fluorenomethylaminophenyl)-15-(4-methoxyphenyl)porphyrin (35 mg, 48.0 ~mol) was converted to a mixture of bacteriochlorin stereoisomers using the general bacteriochlorin formation procedure given earlier. The crude reaction mixture was then chromatographed on flash silica-gel (200 ml), (dry loaded on to 20 ml flash silica-gel from DCNI and a little methanol to ensure complete solubility) eluting initially with 1%
methanol in DCM to elute the higher Rf chlorin byproducts, then 2% methanol/
DCM to elute separately the two stereoisomeric bacteriochlorins. The higher R~-tnafi,s bacteriochlorin isomer was isolated as a pinky-green crystalline solid, (6 mg, 15%); m.p.
142"C (decomposed); UV-VIS (CH2C12) ~.ma;; (relative intensity) 374 (1.0) 512 (0.23), 702 (0.52) nm; UV-VIS (CHZC12) (fluorescence) ~nlax 708 nm (~, excitation 512 nm);
8H(270 MHz, 10 % MeOH-da in CDC13) 9.20 (2H, s, 10-H, 20-I~, 8.78 (2H, d, J
=4.0 Hz, (3-I~, 8.36 (2H, d, J = 4.0 Hz, ,(3 H), 7.95 (2H, m, o-Aj~), 7.85 (2H, d, J = 7.3 Hz, .flure~r~ern~-Ar), 7.79 (2H, m, o'-Ar), 7.65 (2H, m, na'-An), 7.47-7.38 (6H, m,.fhaoretzo-Ar), 7.24 (2H, m, rn-Ar), 6.27-6.24 (2H, 2 x d (overlapping), J = 6.5 Hz, 7-H, 17-I~, 5.85 (2H, d, J = 6.5 Hz, 8-H, 18-I~, 4.65 (2H, d, J = 7.2 Hz, CHI), 4.39 (1H, t, J
= 7.2 Hz, C.I~, 4.06 (3H, s, CH;), -1.94 (2H, br. s (partly exchanged), NH), (OH's not observed);
MS (MALDI) m/z = 800.4 (100%, (M+1)+).
The lower Rt~ ci.s-bacteriochlorin isomer was isolated as a pinky-green crystalline solid, (8.5 mg, 21%); m.p. 148°C (decomposed); UV-VIS (CH2C12) ?~max (relative intensity) 374 (1.0) 512 (0.24), 703 (0.54) nm; UV-VIS (CHZC12) (fluorescence) ~,max 708 nm (~, excitation 512 nm); bH(270 MHz, 10 % MeOH-d4 in CDCl3) 9.12 (2H, s, 10-H, 20-H), 8.76 (2H, d, J =4.8 Hz, (3-HJ, 8.34 (2H, 2 x d (overlapping), J = 4.8 Hz, ,(3 I~, 8.02 (2H, m, o-Ar), 7.85 (2H, d (obscurred), J = 8.0 Hz, o' Ar), 7.83 (2H, d, J = 7.3 Hz,, fZuorefao-Ar), 7.76 (2H, d, J = 8.0 Hz, na'-An), 7.50-7.38 (6H, m, fluof~er2o AY), 7.24 (2H, m, m At~), G.27-6.23 (2H, 2 x d (overlapping), J = 6.5 Hz, 7-H, 17-H), 5.85-5.82 (2H, 2 x d (overlapping), J = 6.5 Hz, 8-H, 18-H), 4.65 (2H, d, J = 7.2 Hz, CHI), 4.39 ( 1H, t, J = 7.2 Hz, CH), 4.05 (3H, s, CH3), -1.88 (2H, br. s (partly exchanged), NH), (OH's not observed); MS (MALDI) m/z = 800.4 (100%, (M+1)+).
7, 8.17.18-Tetralzydroxy-S-(4-isothiocytcnatoplzenyl)-1 ~-(4-rnethoxyplzenyl) bacterioclzlorin (lower Rf cis stereoisomer) ~1 solution of 7,8,17,18-tetrahydroxy-5-(4-fluorenomethyaminophenyl)-15-(4-methoxyphenyl) bacteriochlorin (lower Rf cis stereoisomer), (8.5 mg, 10.7 p,mol) in 25%
methanol in DCM (1.25 ml) was treated with piperidine (~0 eq., 53 p,l , 0.53 mmol) and left to stir for a period of 3 h. at room temperature under NZ with the light excluded. The reaction mixture was concentrated irmcrcuo to remove all traces of piperidine (high vacuum needed). To a stirred solution of 1,1'-thiocarbonyldi-2(1 H)-pyridone (1.07 eq., 7.6 mg, 43.5 mmol) in DCM (25 ml), (dried vicr passage through an activated alumina column) was added a solution of 2,3,12,13-tetrahydroxy-5-(4-aminophenyl)-15-(4-methoxyphenyl)bacteriochlorin (6.1 mg, 10.7 ymol) in DCM (10 ml). The reaction flask was covered with aluminium foil to exclude light and left to stir under NZ for 2 h, at which time TLC indicated complete loss of starting material. The reaction mixture was then washed with water (2 x 50 ml) and saturated brine (50 ml) then dried (arzhyd.
Na~SO:~). The organic extract was thenfiltered and concentrated on to 10 ml flash silica-gel and chromatographed on flash silica-gel (100 ml), eluting with 2% methanol in DCM
to elute the required isothionato bacteriochlorin tetrol (NB. traces of all TDP must be removed prior to concentration of product from column chromatography otherwise some decomposition occurs). The Lower Rf cis-bacteriochlorin isomer was isolated as a pinky-green crystalline solid, (5.0 mg, 76%); m_p. 132°C (decomposed); UV-VIS
(CHzCl2) ?~max (relative intensity) 375 (1.0) 516 (0.22), 702 (0.48) nm; UV-VIS (CHzCl2) (fluorescence) ~,",as 709 nm (~, excitation 516 nm); 8H(270 MHz, 10 % MeOH-d;~ in CDC13) 9.20 (1H, s, n~esn-H), 9.18 ( 1 H, s, me.so '-H), 8. 77 (2H, d, J =4. 8 Hz, /3-H), 8.40 ( 1 H, d, J = 4. 8 Hz, ,(I-H), 8.34 ( 1H, d, J = 4.8 Hz, ~-H), 8.14 (2H, m, c~-Ar), 8.05 (2H, m, o' An), 7.42-7.08 (4H, m, .5~-1.5-n? Ar), 6.20 (2H, 2 x d (overlapping), J = 6.5 Hz, 7-H, 17-H), 5.98 (1H, d, J
= 6.5 Hz, 8-H), 5.93 (1H, d, J = 6.5 Hz, 18-H), 4.04 (3H, s, CH3), -1.80 (2H, br. s (partly exchanged), NH), (pH's not observed); MS (MALDI) m/z = 618.9 (100%, (M+1)T);
HRMS calcd. for C3~IIZgNsOSS: 618.1815. Found: 618.1810 ((M+1)''-).
Further synthetic protocols and methodology protocols are also described in Sutton et al, Por~h~ Chlorin and Bacteriochlorin I~~th;~~yanates Synthesis and Potential Applications in Fluorescence Ima~in,g and Photod;rnamic Ther~v (Journal of Phthalocyaniraes ~ Photosensitisers - in press) and in Oliver J Clarke, Isothioc ay nato P r h. rip f r i n' i n h n i i h n ~.
fluorescence imagi~r~(PhD thesis, April 2001, University ofEssex); the entire contents of each of which are incorporated herein by reference.
Methodology Description 1 ~ General Bioconjug~,ation rotocol Hexahydroxy PITC + Antibody A stock solution of hexahydroxy PITC in DMSO was prepared to a molarity of 0.027, this solution was desiccated and stored at 0°C until required. A
solution of antibody was extensively dialysed against sterilised PBS to remove any trace of azide.
The dialysed antibody solution was then adjusted to a concentration of 10 mg/mL via centrifugal concentration and separated into 250 ~,L aliquots.
A 1 M solution of sodium bicarbonate was prepared and adjusted to pH 9.0 with M sodium hydroxide.
To a 250 p,L aliquot of antibody was added 30 pL of 1 M sodium bicarbonate. A
predetermined volume of hexahydroxy PITC stock solution was then added to give a desired molar ratio (MR) of porphyrin to antibody. For example an MR of 20 was achieved via the addition of 10 p.L of stock solution to 250 p.L of antibody at 10 mg/mL.
In order to maintain a constant concentration of DMSO in the bioconjugation reaction mixture, all aliquots of stock solution were diluted to 25 ~.L with further portions of DMSO.
DesiredVol. of (C] of Vol, of Vol. of Vol.
1 M of MR antibody antibody sodium PITC stockextra solution solution bicarbonatesolution DMSO
2 0 25 0 p,L 10 mg/mL 3 0 p,L 10 p,L 15 p,L
250 ~.L 10 mglmL 30 ~,L 5 ~L 20 p.L
25 0 p,L 10 mg/mL 3 0 p,L 2. 5 ~L 22.
S
~,L
250 yL 10 mglmL 30 yL 1.25 p,L 23.75 ~,L
Table 1.0 Quantities of reagents for bioconjugation Following addition of PITC the bioconjugation reaction was agitated gently for hour at 25°C. After 1 hour the crude bioconjugation reaction mixture was loaded directly onto the top of a prepacked PD10 size exclusion column pre-equilibrated with sterile PBS
(25 mL). The column was eluted with sterile PBS. Antibody-porphyrin conjugate was eluted in the first coloured band/fraction. The antibody-porphyrin conjugate concentration following dilution during chromatography was determined as 1.25 mg/mL.
The degree of labelling (DOL) of porphyrin to antibody was calculated via standard spectroscopic methods using known constants of molar absorptivity for both porphyrin and protein.
Antibody-porphyrin conjugates were stored, without further concentration, in PBS
+ azide at 0°C unless otherwise stated.
1V lVlethylpyridinium chloride PITC + Antibody A stack solution of N methylpyridinium chloride PITC in DMSO was prepared to a molarity of 0.027, this solution was desiccated and stored at 0°C
until required. A
solution of antibody was extensively dialysed against sterilised PBS to remove any trace of azide. The dialysed antibody solution was then adjusted to a concentration of 10 mg/mL vicr centrifugal concentration and separated into 250 1.~L aliquots.
A 1 NI solution of sodium bicarbonate was prepared and adjusted to pH 9.0 with M sodium hydroxide.
To a 250 ~,L aliquot of antibody was added 250 p,L of sterile PBS then 60 yL
of 1 M sodium bicarbonate. A predetermined volume of N methylpyridinium chloride PITC
stock solution was then added to give a desired molar ratio (MR) of porphyrin to antibody. For example an MR of 20 was achieved via the addition of 10 p,L of stock solution to 500 p,L of antibody at 5 mg/mL. In order to maintain a constant concentration of DMSO in the bioconjugation reaction mixture, all aliquots of stock solution were diluted to 25 p,L with further portions of DMSO, DesiredVol. of [C] of Vol. of Vol. of Vol.
1 M of MR antibody antibody sodium PITC stockextra solution solution bicarbonatesolution DMSO
30 500 l.~L 5 mg/mL 60 ~.L 10 ~,L 15 p,L
500 ~.L 5 mg/mL 60 ~.L 5 p,L 20 p,L
5 500 p.L 5 mg/mL 60 p.L 2.Sp.L 22.5 ~,L
2.5 500 1~L 5 mg/mL 60 yL 1.25 yL 23.75 ~,L
Table 2.0 Quantities of reagents for bioconjugation Following addition of PITC the bioconjugation reaction was agitated gently for hour at 25°C. After 1 hour the crude bioconjugation reaction mixture was loaded directly onto the top of a prepacked PD10 size exclusion column pre-equilibrated with sterile PBS
(25 mL). The column was eluted with sterile PBS. Antibody-porphyrin conjugate was eluted in the first coloured band/fraction. The antibody-porphyrin conjugate concentration following dilution during chromatography was determined as 1.25 mg/mL.
The degree of labelling (DOL) of porphyrin to antibody was calculated via standard spectroscopic methods using known constants of molar absorptivity for both porphyrin and protein.
Antibody-porphyrin conjugates were stored, without further concentration, in PBS
+ azide at 0°C unless otherwise stated.
Methodology Description 2 ~ Standard Photocytotoxi i~Y
Cells are grown to confluence or appropriate density then washed 2 times with PBS
(phosphate buffered saline) to eliminate all trace of FBS (foetal bovine serum). Cell density is adjusted to 1.5x106 cells/ml in medium without FBS and these are then incubated for 1 hour in the dark (37 degrees C, 5% C02 ) with a range of photosensitiser/conjugate concentrations. Post incubation, cells are washed further with medium (without FBS )to eliminate unbound photosensitiser, then resuspended and seeded in 96 wells plates (1x10' cells/well) in quadruplate.Plates are then either irradiated (3.GJ/cm2 of filtered red light 0600nm ) or left in the dark as "dark toxicity controls" for the same period of time (~14 minutes).Five microliters (5%/well) of FBS is added after the irradiation/dark period and the plates are returned to the incubator overnight. Twenty to 24 hours after treatment, 10 pl of MTT solution (Sigma Thiazolyl blue, 4.8x10-4M in PBS)is added per well and the plates are returned to the incubator until color develops (between 1 and 4 hours). A solution of acid-alcohol (100p1/well of 0.04N HCL
in isopropanol) is the added and mixed thoroughly to dissolve the dark blue crystals. Plates are then read at 570nm in a microplate reader and the % cell survival calculated against controls.
Methodology Description 3 : Initial Flow~vtometrY Chromouhore Anal, i~
The two fluorochromic probes were generated from separate reactions of 2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-isothiocyanatophenyl)chlorin (higher Rf regioisomer) and 2,3,12,13-tetrahydroxy-5-(4-isothionatophenyl)-15-(4-methoxyphenyl) bacteriochlorin (lower Rf ci.r stereoisomer) with avidin under the standard bioconjugation protocols given earlier. An initial flow experiment has been undertaken utilising these separate avidin conjugates with RAJI cells and biotin monoclonal antibodies (HLA-DR1, L243), (laser excitation 488 nm, collecting emissions at < 640 nm (FL2) > 670 nm (FL3)). Data indicated that the signals from the DPBC samples were much higher due to good match to emission filter (FL3). Samples containing avidin DPCH or. DPBC
conjugates with L243 antibodies indicated modest increases in fluorescence compared to controls. Using higher concentrations of avidin-DPCH/DPBC the peak fluorescence increased, which may either be due to the initial concentrations of conjugates being too Low to saturate receptors or to a lesser extent to some non-covalent binding.
Control samples with avidin-DPCH/DPBC (no antibody) showed some background fluorescence in the absence of L243 antibodies, suggesting that some non-specific binding of the conjugates to the RAJI cells had occurred or that a small quantity of non-covalently bound fluorophore had transferred from the protein to the cell surface. A FITC-avidin control indicated that a slightly higher signal was present in FL2 which appears also in FL3 due to a broad emission band. In the presence of L243 antibody the mean signal increased by 150%. This indicates that non-covalent binding is less significant with FITC-avidin conjugates.
Experiments have been undertaken to determine the level of non-covalent binding of fluorophore to the protein surface (BSA and avidin). 'Blank' bioconjugations using mixtures of the unreactive DPCH and DPBC derivatives 2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-acetomidophenyl)chlorin (higher Rf regioisomer) and 2,3,12,13-tetrahydroxy-5-(4-acetomidophenyl)-15-(4-methoxyphenyl) bacteriochlorin (higher Rr trar~s stereoisomer) with both BSA and avidin have been carried out and the resultant protein solutions have been purified by gel filtration (PD-10) as described for the reactive probes described earlier. UV analysis indicated that approximately similar amounts of unreactive probes non-covalently bind to the proteins. For BSA or avidin, 1 unreactive DPCH binds to each protein molecule, whereas DPBC is less than 1 due probably to its increased polarity and non-amphiphilic nature.
Initial studies have been undertaken to remove non-covalently bound fluorophore from the protein (BSA and avidin) using SDS-PAGE. When the 'blank' bioconjugation mixtures were subjected to SDS-PAGE separation of all non-covalently bound fluorophore was achieved (UV/fluorescence of a solubilised gel segment at 66000 D for BSA and 16500 D for avidin monomer indicated no signal). Further to these investigations, we have been able to show that fluorophore which is non-covalently bound to BSA (or avidin) transfers to the surface of HeLa cells. When HeLa cells were added to solutions of the non-covalent fluorophore-protein complexes, and incubated for 20 min, fluorescence was removed from the solution with removal of the HeLa cells. This effect was much more marked with 2,3-dihydroxy-5-(4-methoxyphenyl)-15-(4-acetomidophenyl)chlorin (higher Rf regioisomer) than with 2,3,12,13-tetrahydroxy-5-(4-acetomidophenyl)-15-(4-methoxyphenyl) bacteriochlorin (higher Rt trar2s stereoisomer).
Re-suspension of the cells and measurement of the fluorescence indicated a 10-fold increase in fluorescence in the case of the DPCH, whereas the DPBC only showed a modest increase. These measurements suggest that there is significant fluorescence quenching of both DPCH and DPBC by the protein and that the DPCH's amphiphilic nature has allowed incorporation into the HeLa cell membrane resulting in restoration of almost complete fluorescence. The DPBC, being non-amphiphilic, may complex to the surface of the HeLa cell in a similar manner as it does to the protein resulting in similar fluorescence quenching.
Since the fluorophore conjugates can be purified by SDS-PAGE we have investigated the use of preparative electrophoresis as a technique for removal of non-covalently bound fluorophore. To this end we have used a Centrilutor~ micro-electroeluter bought from Millipore. This device has allowed recovery of pure protein fluorophore conjugates from SDS gels.
VIethodologv Description 4 : Elution of Conjugates from SDS PAGE Utili ing Micro-Electroeluter ~ Working in greatly subdued lighting, the SDS-PAGE of the required protein conjugate was cut into small strips and added to the centrilutor sample tubes and the tops closed (no more than half full, 3-4 sample tube used).
~ The lower buffer chamber of the electroeluter was filled with degassed SDS
running buffer up to the level of the first electrode.
~ 3 to 4 Centricon~ centrifugal devices ( -30 used for BSA conjugates and YM-33 for avidin conjugates) from Millipore were inserted firmly into the holes in the upper buffer chamber rack of the electroeluter from below (with filter membrane lowest) and the vacant holes of the rack were stoppered with stoppers provided, from the underside of the rack.
~ The upper buffer chamber was placed into the lower buffer chamber with both electrodes aligned on the same side of the electroelutor.
~ The upper buffer chamber was then filled with degassed SDS running buffer (as before) until all Centricon~ unit tops were completely immersed. If no leaks were detected the air bubbles trapped below the Centricon~ units were removed vicz an angled plastic pipette(reinforced with paper clip).
~ The centrilutor sample tubes were then placed into the top of the Centricon~
units, ensuring the sample tube fitted snugly and filled completely with sample buffer (air bubbles were removed as described earlier).
~ The safety cover of the electroelutor was added and the power supply connected (200 V, 50 mA used).
~ After a period of 2-3 h. the power supply was removed and the Centricon~
filter extracted from the upper buffer chamber of the electroelutor.
~ The filtrate vial was added to the filter unit and a retentate top added.
The excess buffer was then removed by centrifugation at SOOOG (BSA) and 7,SOOG (avidin) for 2 h. Fresh 0.5 M phosphate buffer (pH 7.0) was added to the Centricon~ unit and the procedure was repeated to ensure all SDS was removed.
~ The concentrated purified conjugates were then collected in the retentate vials of the filter units by inversion and centrifugation. Sodium azide (2 M, 20 ml) was added and the conjugates were stored at 4°C.
Methodolo~,y Descri~ion 5 ~ FACS Conjugate Bindin"
a Protocol Wash flask of cells with phosphate buffered saline (PBS) pH 7.3. Treat with SmM EDTA in PBS for 10 min at 37C. Tap flask to dislodge cells, place in SOmL
polypropylene tube and pellet at 400g 3 min. Resuspend in 10 mL PBS and count cells.
Place 2 x 10' in FRCS tube (Falcon 2054) and wash with 1mL PBS by centrifugation (4008 3min) and resuspension by agitation Block cells in 500 ~L 2% Marvel milk powder in PBS, 1% BSA 30 min RT
Wash cells in 1 mL PBSBSA/Azide centifuge and resuspend pellet (as above) Add 10 p.L appropriate antibody dilution. Incubate on ice lh Wash cells in 1 mL PBS/BSA/Azide centifuge and resuspend pellet (as above) Add 50 pL Rabbit anti-mouse:FITC (Serotec, 1/100 dilution) and incubate on ice in the dark 1 h Wash cells in 1 mL PBS/BSA/Azide centifuge (as above) and resuspend pellet in 400 pL PBS/BSA/Azide.
Run samples through FACS machine using CellQuest acquisition software to collect data.
PB S/B SA/AZIDE
250 mL PBS
0.6258 BSA
1.56 mL Sodium Azide (1.6M) Methodologw Descrip tion 6 : SDS-PAGE
Separating gel Component % of gel 5 20 Acrylamide/Bis (40% w/v) 1.67mL 6.66mL
I.SM Tris-HCl (pH 8.8) 2.SmL 2.SmL
Water 5.67mL 0.7mL
TEMED 10 pL 10 pL
10% Ammonium persulphate 50 pL 50 pL
SDS 100 ~L 100 pL
For gradient gel 5-20%
a gradient mixer connected to a peristaltic pump is used.
Stacking gel (3%) Component mL
Acrylamide/Bis (40% w/v) 1.3 1M Tris-HC1 (pH 6.8) 1.25 Water 7.4 TEMED 20 pL
10,/ Ammonium persulphate50 ~tL
SDS 100 pL
Running buffer 0.0251VI Tris, 0.192M 0.1% SDS, pH8.3 in water.
glycine, Sample buffer 1M Tris-HC1 pH 6.8 l3mL , 20% SDS 6.SmL
Glycerol 5.2mL
0.5% Bromophenol blue 0.26mL
Biorad Protean 2 equipment was used in accordance with manufacturer's instructions Samples (total volume 15-20 11L containing 1-10 pg sample protein) were loaded onto a gel.
Gels were run at 200V for approximately lh. Gels were then scanned by light, after which they were stained using Coomassie blue stain and subsequently destained using acetic acid/methanol.
Further exemplification of the invention It has been demonstrated in our original work, described inter alia in Sutton, J., Fernandez, N. and Boyle, R.W. (2000) Functionalised Diphenylchlorins and Bacteriochlorins - Their Synthesis and Biocon~L,gation for Targeted Photodynamic Therapy and Tumour Cell Ima,g'~ng, J. Porphyrit~s and Phthalocyanines 4, 655-658; and Clarke, O.J. and Boyle, R.W. (1999) Isothioc, a~~o~~ r~ ins useful intermediates fir the con~iuaation of ~r_phyrins with biomolecules anr~ solid supports. ,L C. S.
Chem.
C:omnaura. 2231-2232, each of which is incorporated herein by reference, that a set of porphyrin, chlorin and bacteriochlorin molecules can be efficiently conjugated to proteins via a stable thiourea bond, and that these conjugates have potential as fluorescence imaging agents.
As exemplification of the present invention, we now describe the use of this method to form conjugates between monoclonal antibodies having high specificity for human cancer cells, and our set of porphyrin based photosensitisers.
Conjugates formed in this way have been assayed for photodynamic activity against the corresponding carcinoma cells, and also for their ability to selectively bind to, and photosensitise, these target cells in the presence of non-target cells. We also demonstrate the specific internalisation of porphyrin-BSA conjugates into HeLa cells.
Our examples utilise 5,10,15-tris(3,5-dihydroxyphenyl)-20-(4-isothiocyanatophenyl) porphyrin (OH6) and 5,10,15-tris(pyridyl)-20-(4-isothiocyanatophenyl)porphyrin (PYR), as we have found from our previous studies that the pattern of hydrophilic substituents around the photoactive porphyrin core of each of these chromophores leads to efficient conjugation with proteins; hydrophilic substituents also minimise non-covalent binding of photosensitiser to protein, often found with more hydrophobic porphyrins. Synthetic protocols for these chromophores are described in Examples 1 and 2 above respectively.
(OH6) (PYR) Example 25 - stable con~iugation to antibodie OHG and PYR were prepared as described in Examples 1 and 2 above respectively. Antibody 17. lA was selected for the bioconjugation procedure.
17. lA is an antibody which reacts specifically with a receptor that is over-expressed on colorectal cancer cells, in particular Colo 320 cells (ECACC, deposit no. 87061205).
However, any antibody which reacts against any antigen that is over-expressed on a suitable cell line may be utilised in accordance with the invention. Examples of such antibodies include Ber-EP4 and MOK-31, each of which is commercially available from DAKO Ltd, Ely, Cambridgeshire, and each of which is reactive against an antigen that is over-expressed on epithelial cells.
To increase the buffer pH of the antibody preparation to approximately pH9, prior to and for the purposes of the bioconjugation procedure, the monoclonal antibody preparation was either buffer-exchanged from a phosphate to an acetate buffer using a Centricon centrifuge or was subjected to dialysis so as to exchange the phosphate buffer for an acetate buffer.
Each of OH6 and PYR was separately conjugated with l7.lA monoclonal antibody in accordance with the method described in Methodology Description 1, to obtain a range of conjugation dilutions having respective MRs of 2.5, 5, 10 and 20..
The acetate-buffered antibody preparation and range of conjugation dilutions obtained therefrom were subjected to SDS-PAGE in accordance with the method described in Methodology Description 6. The results are shown in Figures 1-3 respectively. Figure 1 shows a gel loaded with buffer-exchanged l7.lA antibody (lane 1), and buffer-exchanged antibody/OH6 conjugations at MRs 2.5 (lanes 2, 3), 5 (lanes 4, 5), (lanes G, 7) and 20 (lanes 8, 9) and molecular weight markers (lane 10).
Figure 2 shows a gel loaded with dialysed 17. lA antibody (lane 1), and dialysed antibody/OH6 conjugations at MRs 2.5 (lanes 2, 3), 5 (lanes 4, 5), 10 (lanes 6, 7) and 20 (lanes 8, 9) and molecular weight markers {lane 10). Figure 3 shows a gel loaded with buffer-exchanged 17. lA antibody (lane 1), and buffer-exchanged antibody/PYR conjugations at MRs 2.5 (lanes 2, G), 5 (lanes 3, 7), 10 (lanes 4, 8) and 20 (lanes 5, 9) and molecular weight markers {lane 10).
As seen in these Figures, neither the buffer-exchange nor dialysis procedures disrupt the antibody structure, the light and heavy chains remaining associated with one another and migrating together on each of the gels (lane 1). Conjugation of OH6 and PYR at each of the MRs can also be seen on the;gels (lanes 2-9).
Example 26 - FACS anal FACS analyses were run in accordance with Methodology Description 5.
Figure 4 shows results derived utilising FITC-labelled l7.lA and Colo 320 cells (3 repeats) and indicates that binding of the antibody to the cells has occurred (ie the Colo 320 cells express the antigen specific to 17. lA).
Figure 5 shows results derived utilising OH6/l7.lA conjugate and Colo 320 cells with a FITC-labelled anti-17. lA antibody for detection (3 repeats) and indicates that the OHG/l7.lA conjugate has bound to the cells.
Figure 6 shows results derived utilising PYR/l7.lA conjugate and Colo 320 cells with a FITC-labelled anti-17. lA antibody for detection (3 repeats) and indicates that the PYR/17. lA conjugate has bound to the cells.
Figure 7 shows results derived utilising FITC-labelled OX-34 which is an antibody of the same class (IgG2a) as 17. lA but with a different antigen specificity (3 repeats). The results indicate that OX-34 has not bound to the Colo 320 cells and hence that there are no binding sites for OX-34 on Colo 320 cells.
Example 27 - Photocytotoxicitv experiments Photocytotoxicity tests in accordance with the method described in Methodology Description 2 were performed on Colo 320 cells utilising various antibody conjugates.
Figures 8 and 9 show the results of control experiments performed using OHG/OX-34 and PYR/OX-34 conjugates respectively. As described in Example 16 0X-34 has been found to lack specificity for any antigens expressed on the surface of Colo 320 cells. Accordingly, as expected these control experiments show no photocytotoxicity following irradiation.
Figures 10 and 11 show the results of further control experiments performed using "capped" OHG and PYR respectively. The "capping" procedure involved reacting the NCS group on each chromophore with propylamine, so as to block serum protein conjugation. Figure 10 shows no cytotoxicity in the dark, indicating that OH6 is non-toxic to Colo 320 cells. On irradiation, however, some photocytotoxicity is observed, indicating that an amount of the capped OH6 has been transferred to the surface of the Colo 320 cells. Figure 11 meanwhile shoves some cytotoxicity in the dark, suggesting that PYR is to some extent cytotoxic to Colo 320 cells, and increased photocytotoxicity on irradiation, which again indicates that an amount of the capped PYR has been transferred to the surface of the Colo 320 cells.
In the absence of any antibody, transfer of the capped chromophores to the cell membrane is probably attributable to the amphiphilic nature of the capped chromophores, which possess both hydrophilic groups around the porphyrin core and a hydrophobic propylamine "capping" group. This renders them particularly susceptible to becoming embedded in a lipid membrane such as the Colo 320 cell membrane.
Figures 12 and 13 show results obtained using OH6/l7.lA and PYR/l7.lA
conjugates respectively, at various conjugation dilutions (2.5, 5, 10, 20 for OH6/l7.lA;
and 20 for PYR/17, lA). The results indicate a significant increase in cytotoxicity on irradiation, indicating that the binding of the bioconjugates to the cell surface confers photosensitivity upon the cells. Hence, these species are suitable candidates for PDT.
Example 28 - hotod;~namic theraw in vivo Protocols for performing and assessing photodynamic therapy in vivo, utilising the conjugates of the invention, are variously described in R Boyle et al, Br.
J. Cancer ( 1992) 65:813-817; R Boyle et al, Br. .I. Cancer (1993) 67:1177-1181; R Boyle et al, Br.
.l. Cancer ( 1996) 73 :49-53; and Lapointe et al, .I. Nuclear Medicine, Vol.
40, No. 5 (May 1999) 876-882; the contents of each of which are incorporated herein by reference.
As described in these papers, tumours may be induced or transplanted into animals such as mice, and the animal may then be injected with a quantity of photosensitiser in accordance with the invention conjugated to an antibody with specificity for an antigen which is specifically expressed or over-expressed on the surface of the tumour cells. Thereafter, the animal may be subjected to irradiation, and the effects on the tumour assessed, qualitatively or metrically, with reference to tumour metabolism (as described in Lapointe et al, J: Nuclear Medicine, Vol. 40, No. 5 (May 1999) 876-882). As described in R Boyle et al, Bj-. J. Cancer (1996) 73:49-53, the distribution of the photosensitiser in vivo may also be measured, by biodistribution and/or vascular stasis assays.
Example 29 - Confocal Laser Scanning Microsco~"Y
A preliminary examination of the intracellular localisation of a conjugate of 10,15,20-tris(3,5-dihydroxyphenyl)5-isothiocyanatophenylporphyrin (OH6-NCS) with BSA was carried out using confocal laser scanning microscopy. The readily available epithelial human carcinoma cell line HeLa was selected for incubation with the conjugate. All incubations were performed' in triplicate with sub-confluent cultures of HeLa cells, including a series of control solutions of unlabelled BSA, 10,15,20-tris(3,5-dihydroxyphenyl)5-aminophenylporphyrin porphyrin (OH6-NH2, amino precursor of OH6-NCS), and PBS on its own. Cells were seeded onto coverslips in 35 mm dishes.
Fluorescence images of cells were obtained with a Bio-Rad Radiance2000 confocal laser scanning microscope (Bio-Rad Microscience, Cambridge, MA) on an inverted Olympus IX70 microscope using a 60x (NA 1.4) oil immersion objective lens.
The illumination source was the 514 nm line from a 25 mW argon ion laser.
Porphyrins were visualised with a 514 nm band-pass excitation filter, a 510 nm dichroic mirror, and a 570 nm long-pass emission filter.
Each field of cells was sectioned 3-dimensionally by recording images from a series of focal planes. Movement from one focal plane to another was achieved by a stepper motor attached to the fine focus control of the microscope, the step sizes (in the range 0.5 l.~m to 1.25 ~~m) being chosen with regard to the aperture size being used, so that there would be some overlap between adjacent sections. Enough vertical sections were taken so that the tops and bottoms of all the cells in each field would be recorded.
Each image collected was the average of four scans at the confocal microscope's normal scan rate. During each imaging session calibration images were taken of: (i) a microscope slide containing medium, in order to measure background levels;
(ii) a slide containing ITC porphyrin OH6-NCS dissolved in DMSO; and (iii) a slide bearing only un-probed HeLa cells.
Image data acquisition and remote microscope operation was carried out using the Bio-Rad Lasersharp2000 software. All images were managed using Confocal Assistant version 4.02, (build 101) 1994-1996 Todd Clark Brelje. Artificial colour was applied using standard Bio-Rad look-up tables (LUT).
A preliminary evaluation of the fluorescence of OH6-NCS at each of the excitation laser lines available on the CLSM set-up was carried out for a 0.01 mM
solution of OH6 in DMSO. Figure 14 shows the UV-visible spectrum of OH6-NCS
identifying its principal absorption bands. Unfortunately, no laser line was available in order to excite OH6-NCS at its Soret band ~,max. Figure 15 demonstrates the relative intensities of fluorescence emission for OH6-NCS when excited at 422 nm (optimal), and at the four wavelengths of the argon ion laser, 457, 476, 488, and 514 nm.
It was determined that the intensity of fluorescence emitted by a solution of NCS when excited at 514 nm was roughly three times greater than fluorescence emission at excitation wavelengths of 457, 476, and 488 nm. The UV-visible absorption spectrum of OH6-NCS showed that the 516 nm argon-ion laser line was the only excitation source compatible with OH6-NCS. The three strongest laser lines, 457, 476, and 488 nm all excited in the region between the Soret and first Q band of OH6-NCS, whereas the 514 line overlapped well with the Q band at 516 nm.
Cell cultures separately incubated with conjugate OH6-NCS-BSA and each of the three controls, were subsequently washed and fixed. Coverslips containing the incubated cells were then cautiously mounted onto standard glass microscope slides ready to be imaged. All four argon-ion laser lines were tested, but, as expected satisfactory resolution of fluorescence could only be achieved using the 514 nm laser line.
A Z-series fluorescence image of HeLa cells incubated with OH6-NCS-BSA is shown in Figure 1G (this Figure should be viewed from top left to bottom right).
Consecutive sections were scanned with a 2l.tM step between each focal plane resolved by the microscope, thus enabling three dimensional visualisation of the localisation of the conjugate within the cell. Clearly the conjugate OH6-NCS-BSA had entered the cell, no studies of the nature of cellular uptake were conducted, however it is most likely that uptake had taken place via endocytosis. It can be seen that the conjugate has not entered the nucleus and appears to be largely distributed throughout the cytoplasm.
When imaged, cells incubated with the BSA control or the PBS control, showed only very low, barely detectable levels of fluorescence, attributed to normal levels of cellular autofluorescence. The localisation of OH6-NHZ (unconjugated porphyrin control), is shown in Figure 17, which shows a CLSM image of porphyrin control cells with zoom view. No fluorescence was found to emanate from inside the cells, instead it appeared that the majority of OH6-NH? had become localised on the plasma membrane.
Evidently the BSA component of the conjugate is required in order to facilitate the transport of porphyrin to the interior of the cell.
In summary, it has been shown that the cellular localisation of porphyrin-BSA
conjugates, constructed via the formation of covalent thiourea linkages, can be imaged using conventional CLSM techniques. Unconjugated porphyrin OH6-NH2 was not found to penetrate the cellular membrane, whereas a significant level of fluorescence was detected from inside cells incubated with OH6-NCS-BSA, indicating good conjugate penetration.
~J
Claims (8)
- A porphyrin chromophore of formula (I) below:
or a chlorin chromophore of any of formulas (II), (III), (IV), or (V) below:
or a bacteriochlorin chromophore of any of formulas (VI) and (VII) below:
wherein R1 is an aryl moiety which is linked to a conjugating group Z which is capable of conjugating the chromophore to a polypeptide molecule for delivering said chromophore to a specific biological target in vitro or in vivo;
R2 is a hydrophilic aryl moiety;
R3 is H or a hydrophilic aryl or hydrophilic non-aromatic moiety;
and each of X1, X2, X3 and X4 is independently selected from H, OH, halogen, C1-3 alkyl and OC1-3 alkyl, or X1 and X2 and/or X3 and X4 together form a bridging moiety selected from O, CH2, CH C1-3 alkyl, or C(C1-3 alkyl)2, such that X1 and X2 and/or X3 and X4 with the adjacent C-C bond form an epoxide or cyclopropanyl structure;
wherein one or both of said R2 and said R3 comprises either a phenyl ring which is substituted one or more times, preferably at least two times, by one or more hydrophilic substituents which serve to increase the hydrophilicity of said R2 and/or said R3, or a heteroaryl ring, such as a quartenised pyridyl (pyridiniumyl) ring, which ring is optionally substituted one or more times, preferably at least two times, by one or more hydrophilic substituents which serve to increase the hydrophilicity of said R2 and/or said R3;
said one or more hydrophilic substituents being independently selected from hydroxy;
alkoxy such as methoxy or ethoxy; C2-C15 polyethylene glycol; quartenised pyridyl (pyridiniumyl) such as N-methylpyridiniumyl; mono-, di- or poly-saccharide; C1-6alkylsulfonate; a phosphonium group R4P(R5)(R6)(R7), wherein R4 is a single bond or C1-6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl ring such as a phenyl ring, a heteroaryl ring such as a pyridyl ring, and a C1-6 alkyl chain, which aryl ring, heteroaryl ring or C1-6 alkyl chain is unsubstituted or is substituted one or more times by hydroxy, C1-6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group R8OP(O)(OR9)(OR10) or R8P(O)(OR9)(OR10) respectively, wherein R8 is a single bond or C1-6 alkyl, and each of R9 and R10 is independently selected from hydrogen and C1-6 alkyl;
wherein each of said R1, R2 and R3 is optionally further substituted one or more times by -OH, -CN, -NO2, halogen, -T or-OT, where T is a C1-C15 alkyl, cycloalkyl or aryl group or a hydroxylated, halogenated, sulphated, sulphonated or aminated derivative thereof or a carboxylic acid, ester, ether, polyether, amide, aldehyde or ketone derivative thereof. - 2 A chromophore as claimed in claim 1, wherein said aryl moiety R1 comprises a phenyl ring, which phenyl ring is either linked by a single bond to the macrocyclic core of said chromophore or is linked thereto by a C1-6 branched or linear alkyl chain.
- 3 A chromophore as claimed in any of claims 1-3, wherein R3 is H or is a hydrophilic alkyl moiety, such as a C1-6 alkyl chain which is substituted one or more times by one or more hydrophilic substituents such as hydroxy or C2-15 polyethylene glycol.
- 4 A chromophore as claimed in any of claims 1-3, wherein R3 comprises a hydrophilic aryl moiety which is the same as said hydrophilic aryl moiety R2.
A chromophore as claimed in any preceding claim, wherein one or both of said and said R3 is or are independently selected from m,m-(dihydroxy)phenyl or a PEGylated derivative thereof; m,m,p-(trihydroxy)phenyl or a PEGylated derivative thereof; o,p,o-(trihydroxy)phenyl or a PEGylated derivative thereof; m- or p-((C1-6)alkyltriphenylphosphonium)phenyl such as p-(methyltriphenylphosphonium)phenyl m- or p-(C1-6alkylphosphono-di-alkoxy)phenyl such as p-methylphosphono-di-ethoxy)phenyl m- or p-(C1-6alkylphosphonato-di-alkoxy)phenyl such as p-methylphosphonato-di-ethoxy)phenyl m- or p-(N-methyl-pyridiniumyl)phenyl meta- or para- sugar-substituted phenyl such as pentose-, hexose- or disaccharide-substituted phenyl and a quartenised pyridyl (pyridiniumyl) group such as a p-N-(C1-6alkyl)pyridiniumyl group or m-N-(C1-6alkyl)pyridiniumyl group such as m-N-methylpyridiniumyl or p-N-methylpyridiniumyl and a zwitterionic group, such as p-N-(C1-6alkylsulfonate)pyridiniumyl or m-N-(C1-6alkylsulfonate)pyridiniumyl; in particular, p-N-(propylsulfonate)pyridiniumyl or m-N-(propylsulfonate)pyridiniumyl 6 A chromophore as claimed in claim 1, characterised in that said R3 is H and said R2 is selected from:
where W1 is C1-6 alkyl or a hydrophilic substituent selected from hydroxy;
alkoxy such as methoxy or ethoxy; C2-C15 polyethylene glycol; quartenised pyridyl (pyridiniumyl) such as N-methylpyridiniumyl; mono-, di- or poly-saccharide; C1-6alkylsulfonate; a phosphonium group R4P(R5)(R6)(R7), wherein R4 is a single bond or C1-6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl ring such as a phenyl ring, a heteroaryl ring such as a pyridyl ring, and a C1-6 alkyl chain, which aryl ring, heteroaryl ring or C1-6 alkyl chain is unsubstituted or is substituted one or more times by hydroxy, C1-6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group R8OP(O)(OR9)(OR10) or R8P(O)(OR9)(OR10) respectively, wherein R8 is a single bond or C1-6 alkyl, and each of R9 and R10 is independently selected from hydrogen and C1-6 alkyl; and where W2 is hydrogen, C1-6 alkyl, a heterocyclic group or an aromatic group.
7 A chromophore as claimed in claim 1, characterised in that said R2 and said R3 are the same one of:
wherein W3 is hydrogen or a hydrophilic substituent selected from hydroxy;
alkoxy such as methoxy or ethoxy; C2-C15 polyethylene glycol; quartenised pyridyl (pyridiniumyl) such as N-methylpyridiniumyl; mono-, di- or poly-saccharide; C1-6alkylsulfonate; a phosphonium group R4P(R5)(R6)(R7), wherein R4 is a single bond or C1-6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl ring such as a phenyl ring, a heteroaryl ring such as a pyridyl ring, and a C1-6 alkyl chain, which aryl ring, heteroaryl ring or C1-6 alkyl chain is unsubstituted or is substituted one or more times by hydroxy, C1-6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group R8OP(O)(OR9)(OR10) or R8P(O)(OR9)(OR10) respectively, wherein R8 is a single bond or C1-6 alkyl, and each of R9 and R10 is independently selected from hydrogen and C1-6 alkyl; or wherein W4 is selected from OH, ONa, and O(C1-6 alkyl).
8 A chromophore as claimed in claim 1, wherein said R3 is and said R2 is a group wherein W5 is a hydrophilic substituent selected from hydroxy; alkoxy such as methoxy or ethoxy; C2-C15 polyethylene glycol; quartenised pyridyl (pyridiniumyl) such as N-methylpyridiniumyl; mono-, di- or poly-saccharide; C1-6alkylsulfonate; a phosphonium group R4P(R5)(R6)(R7), wherein R4 is a single bond or C1-6 alkyl, and each of R5, R6 and R7 is independently selected from hydrogen, an aryl ring such as a phenyl ring, a heteroaryl ring such as a pyridyl ring, and a C1-6 alkyl chain, which aryl ring, heteroaryl ring or C1-6 alkyl chain is unsubstituted or is substituted one or more times by hydroxy, C1-6 alkyl or alkoxy, aryl, oxo, halogen, nitro, amino or cyano; or a phosphate or phosphonate group R8OP(O)(OR9)(OR10) or R8P(O)(OR9)(OR10) respectively, wherein R8 is a single bond or C1-6 alkyl, and each of R9 and R10 is independently selected from hydrogen and C1-6 alkyl; and X is C or N.
9 A 5,15-diphenylporphyrin, 5,15-diphenylchlorin or 5,15-diphenylbacteriochlorin chromophore, wherein each of the ortho-, meta-, and/or para- positions of each of the 5-and 15- phenyl groups is substituted by a substituent P1-P5 and Q1-Q5 respectively which is independently H or an inert substituent which in combination with the other substituents P1-P5 and Q1-Q5 does not substantially impair the fluorescent properties of the chromophore; and the chromophore further comprises a conjugating group Z
which is capable of conjugating the chromophore to a polypeptide molecule for delivering said chromophore to a specific biological target in vitro or in vivo.
A chromophore as claimed in claim 9, which is selected from the following compounds:
Statement Under Article 19(1) The claims of the above PCT patent application have been amended in order to define the subject matter of this application more clearly over the prior art.
Basis for the amended claims may be found as follows in the application as filed:
Claim 1 is based on original claims 1 and 3-5 Claim 2 is unamended Claims 3 and 4 correspond to original claims 7 and 8 - Claim 5 corresponds to original claim 6
- Claim 6 is based on pages 10-11 of the description as filed
- Claim 7 is based on pages 12-13 of the description as filed
- Claim 8 is based on page 18 of the description as filed Claims 9-43 are unamended wherein each of X1, X2, X3 and X4 is independently selected from H, OH, halogen, C1-3 alkyl and OC1-3 alkyl, or X1 and X2 and/or X3 and X4 together form a bridging moiety selected from O, CH2, CH C1-3 alkyl, or C(C1-3 alkyl)2, such that X1 and X2 and/or X3 and X4 with the adjacent C-C bond form an epoxide or cyclopropanyl structure.
11 A chromophore as claimed in claim 9 or claim 10, wherein each of said P1-P5 is the same or substantially the same as the corresponding one of said Q1-Q5, such that said two primary phenyl rings are symmetrically substituted.
12 A chromophore as claimed in claim 9 or claim 10, wherein one or more of said P1-P; is not the same as the corresponding one of said Q1-Q;, such that said two primary phenyl rings are not symmetrically substituted.
13 A chromophore as claimed in any of claims 9-12, wherein said substituents and Q1-Q5 collectively provide a degree of steric hindrance around the core of said chromophore which is sufficient to reduce the rate of spontaneous oxidation of said chromophore, such that said chromophore is substantially inert in air, but which does not to a substantial extent inhibit selective addition or substitution at the 2, 3, 7, 8, 12, 13, 17 or 18 positions around the core of said chromophore.
14 A chromophore as claimed in any of claims 9-13, wherein one or more of said substituents P1-P5 and Q1-Q5 comprises H, -OH, -CN, -NO2, halogen, -T or-OT, where T
is a C1-C15 alkyl, cycloalkyl or aryl group or a hydroxylated, halogenated, sulphated or aminated derivative thereof or a carboxylic acid, ester, ether, polyether, amide, aldehyde or ketone derivative thereof; or a C3-C12 cycloalkyl and/or aryl ring structure, or between two and six, preferably two - three, fused or linked C3-C12 cycloalkyl and/or aryl ring structures, each of which ring structures may optionally comprise one or more N, O or S
atoms.
15 A chromophore as claimed in any of claims 9-14, wherein one or more of said substituents P1-P5 and Q1-Q5 consists of a member independently selected from the group consisting of A1Z1A14; wherein Z1 is Z2, Z2A5 or Z2A5A6; A1 and A5 are independently selected from -(CA2A2)n-, -C(Y)(CA2A3)n-, -C(Y)Y'(CA2A3)n-, -C(Y)NA4(CA2A3)n-, -NA4C(Y)(CA2A3)n-, -NA4(CA2A3)n, -YC(Y')(CA2A3)n-and -Y(CA2A3)n-; n = 0 - 6; Y and Y' are independently O or S; A2, A3 and A4 are independently H or C1-2 alkyl which is unsubstituted or substituted by one or more fluorines; A6 = -(C2H4O)m or -S(O)p; m = 1 - 12; p = 0 - 2; Z2 is a single bond or Z3; Z; is selected from Z4, Z5 and Z6, wherein Z3 is unsubstituted or substituted one or more times by OH, halo, CN, NO2, A1A10, A6A8, NA10A11, C(Y)A7, C(Y)Y'A7, Y(CH2)q Y'A7, Y(CH2)q A7, C(Y)NA10A11, Y(CH2)q C(Y')NA10A11, Y(CH2)q C(Y')A9, NA10C(Y)NA10A11, NA10C(Y)A11, NA10C(Y)Y'A9, NA10C(Y)Z6, C(NA10)NA10A11, C(NCN)NA10A11, C(NCN)SA9, NA10C(NCN)SA9, NA10C(NCN)NA10A11, NA10S(O)2A9, S(O)r A9, NA10C(Y)C(Y')NA10A11, NA10C(Y)C(Y')A10 or Z6; q = 0, 1 or 2; r = 0 - 2; A7 is independently selected from H and A9; A8 is O or A9; A9 is C1-4. alkyl which is unsubstituted or substituted by one or more fluorines; A10 is OA9 or A11; A11 is A7 or when A10 and A11 are as NA10A11 they may together with the nitrogen form a 5 to 7 membered ring comprising only carbon atoms or carbon atoms and at least one heteroatom selected from O, N and S; Z4 is C6-12 aryl or aryloxyC1-3alkyl; Z5 is selected from furanyl, tetrahydrofuranyl, indanyl, indenyl, tetrahydropyranyl, pyranyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, thienyl, C3-8 cycloalkyl or C4-8 cycloalkyl containing one or two unsaturated bonds, and C7-11 polycycloalkyl;
Z6 is selected from N-azolyl, dioxadiazinyl, dioxadiazolyl, dioxanyl, 2-N-dioxatriazinyl, dioxazinyl, N-dioxazolyl, dioxolyl, dithiadiazinyl, dithiadiazolyl, N-dithiatriazinyl, dithiazinyl, N-dithiazolyl, 1-N-imidazolyl, N-morpholinyl, pyrollyl, tetrazolyl, thiazolyl, triazolyl, oxazinyl, oxazolyl, naphthydrinyl, oxadiazinyl, oxadiazolyl, oxatetrazinyl, oxatriazinyl, oxatriazolyl, oxazinyl, oxazolyl, pentazinyl, phthalazinyl, N-piperidinyl, N,N-piperazinyl, 1-N-pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, tetrathiazinyl, tetrazinyl, 1-N-tetrazolyl, tetroxazinyl, thiadiazinyl, thiadiazoyl, thiatetrazinyl, thiatriazinyl, thiatriazolyl, thiazolyl, triazinyl, 1-N-triazolyl, trioxadazinyl, trioxanyl, trioxazinyl, trioxazolyl, trithiadiazinyl, trithiazinyl, trithiadiazolyl;
wherein Z4, Z5 or Z6 may be fused to one or more other members selected independently from Z4, Z5 and Z6;
A14 is hydrogen, methyl, hydroxyl, aryl, halo substituted aryl, aryloxyC1-3 alkyl, halo substituted aryloxyC1-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, C3-6 cycloalkyl, or a C4-6 cycloalkyl containing one or two unsaturated bonds, wherein the cycloalkyl or heterocyclic moiety is unsubstituted or substituted by 1 to 3 methyl groups, one ethyl group, or a hydroxyl group.
16 A chromophore as claimed in any of claims 9-15, wherein one of said P1-P5 and said Q1-Q5 is a conjugating substituent which comprises said conjugating group Z.
17 A chromophore as claimed in claim 16, wherein said conjugating substituent consists of a member selected from the group consisting of A1Z1Z; wherein Z1 is Z2, Z2A5 or Z2A5A6; A1 and A5 are independently selected from -(CA2A3)n-, -C(Y)(CA2A3)n-, -C(Y)Y'(CA2A3)n-, -C(Y)NA4(CA2A3)n-, -NA4C(Y)(CA2A3)n-, -NA4(CA2A3)n, -YC(Y')(CA2A3)n- and -Y(CA2A3)n-; n = 0 - 6; Y and Y' are independently O or S; A2, A3 and A4 are independently H or C1-2 alkyl which is unsubstituted or substituted by one or more fluorines; A6 = -(C2H4O)m- or -S(O)p; m = 1 - 12; p = 0 - 2; Z2 is a single bond or Z3; Z3 is selected from Z4., Z5 and Z6, wherein Z3 is unsubstituted or substituted one or more times by OH, halo, CN, NO2, A1A10, A6A8, NA10A11, C(Y)A7, C(Y)Y'A7, Y(CH2)q Y'A7, Y(CH2)q A7, C(Y)NA10A11, Y(CH2)q C(Y')NA10A11, Y(CH2)q C(Y')A9, NA10C(Y)NA10A11, NA10C(Y)A11, NA10C(Y)Y'A9, NA10C(Y)Z6, C(NA10)NA10A11, C(NCN)NA10A11, C(NCN)SA9, NA10C(NCN)SA9, NA10C(NCN)NA10A11, NA10S(O)2A9, S(O)r A9, NA10C(Y)C(Y')NA10A11, NA10C(Y)C(Y')A10 or Z6; q = 0, 1 or 2; r = 0 - 2; A7 is independently selected from H and A9; A8 is O or A9; A9 is C1-4 alkyl which is unsubstituted or substituted by one or more fluorines; A10 is OA9 or A11; A11 is A7 or when A10 and A11 are as NA10A11 they may together with the nitrogen form a 5 to 7 membered ring comprising only carbon atoms or carbon atoms and at least one heteroatom selected from O, N and S; Z4 is C6-12 aryl or aryloxyC1-3alkyl; Z5 is selected from furanyl, tetrahydrofuranyl, indanyl, indenyl, tetrahydropyranyl, pyranyl, thiopyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, thienyl, C3-8 cycloalkyl or C4-8 cycloalkyl containing one or two unsaturated bonds, and C7-11 polycycloalkyl;
Z6 is selected from N-azolyl, dioxadiazinyl, dioxadiazolyl, dioxanyl, 2-N-dioxatriazinyl, dioxazinyl, N-dioxazolyl, dioxolyl, dithiadiazinyl, dithiadiazolyl, N-dithiatriazinyl, dithiazinyl, N-dithiazolyl, 1-N-imidazolyl, N-morpholinyl, pyrollyl, tetrazolyl, thiazolyl, triazolyl, oxazinyl, oxazolyl, naphthydrinyl, oxadiazinyl, oxadiazolyl, oxatetrazinyl, oxatriazinyl, oxatriazolyl, oxazinyl, oxazolyl, pentazinyl, phthalazinyl, N-piperidinyl, N,N-piperazinyl, 1-N-pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, tetrathiazinyl, tetrazinyl, 1-N-tetrazolyl, tetroxazinyl, thiadiazinyl, thiadiazoyl, thiatetrazinyl, thiatriazinyl, thiatriazolyl, thiazolyl, triazinyl, 1-N-triazolyl, trioxadazinyl, trioxanyl, trioxazinyl, trioxazolyl, trithiadiazinyl, trithiazinyl, trithiadiazolyl;
wherein Z4, Z5 or Z6 may be fused to one or more other members selected independently from Z4, Z5 and Z6.
18 A chromophore as claimed in any of claims 9-17, which has a structure set out as (x), (y) or (z) below:
wherein R and R' may be any of the following combinations:
R R' 4-Me 4-NCS
4-Br 4-NCS
4-CO2Me ~4-NCS
3,4,5-tris(OMe) ~4-NCS
4-NCS ~4-OMe 4-NCS ~4-Me 4-NCS ~4-CO2Me 4-NCS ~4-Br 4-NCS ~4-CN
4-NCS ~4-CO2Me 19 A chromophore as claimed in any preceding claim, wherein each or some of X1-X4 is H or OH.
20 A chromophore as claimed in any preceding claim, wherein said conjugating group Z comprises a bonding group which is capable of bonding covalently to a polypeptide molecule; such as an isocyanate, isothiocyanate, or NHS ester group; or -NH2, -NH(C1-6 alkyl), maleamide, iodoacetamide, ketone or aldehyde.
21 A chromophore as claimed in claim 20, wherein said conjugating group Z
comprises a linking moiety having a relatively high degree of inflexibility and/or steric hindrance, which linking moiety is adapted to link said bonding group to the macrocyclic core of said chromophore.
22 A set of fluorochromic markers for multicolour fluorochromic analysis, comprising at least two chromophores selected from the group consisting of a porphyrin chramophore, a chlorin chromophore and a bacteriochlorin chromophore, each of which chromophores comprises the same porphyrin skeleton, each of which chromophores comprises one or more substituents on said porphyrin skeleton, one of which substituents is a conjugating substituent L comprising a conjugating group Z, wherein Z is a conjugating group capable of conjugating each of said chromophores to a polypeptide molecule for delivering each chromophore to one of a plurality of different specific biological targets.
23 A set of chromophores as claimed in claim 22, comprising two or more of a porphyrin in accordance with any of claims 1-21, the corresponding chlorin, and the corresponding bacteriochlorin.
24 A chromophore as claimed in any of claims 1-21 or a set as claimed in claim or claim 23, wherein said conjugating group Z is conjugated to a binding protein which is adapted to bind specifically to said biological target; or is conjugated to a bridging polypeptide which is adapted to bind to a complementary bridging polypeptide so as to couple said chromophore to said complementary bridging polypeptide.
25 A chromophore or a set as claimed in claim 24, wherein said bridging polypeptide is bound to said complementary bridging polypeptide, and said complementary bridging polypeptide comprises or is coupled to or fused with a binding protein which is adapted to bind specifically to said biological target.
26 A kit of chromophores comprising a chromophore or set of chromophores in accordance with any preceding claim, wherein said or each chromophore is conjugated to a bridging polypeptide that is adapted to bind to a complementary bridging polypeptide so as to couple the chromophore to said complementary bridging polypeptide;
and a construct or plurality of constructs each of which comprises said complementary bridging polypeptide fused or coupled to a binding protein which is adapted to bind specifically to said biological target; the arrangement being such that said chromophore or each chromophore in the kit is adapted to bind to a different construct in the kit with specificity for said specific biological target, so as to link said or each chromophore to a binding protein with specificity for said specific biological target.
27 A chromophore, set of chromophores or kit of chromophores in accordance with any of claims 24-26, wherein said binding protein comprises an antibody such as a monoclonal or polyclonal antibody or a fragment thereof with specificity for a target specific molecule on the surface of said biological target.
28 A chromophore or set of kit of chromophores as claimed in claim 27, wherein said antibody is a phage antibody, that is an antibody expressed on the surface of a bacteriophage.
29 A chromophore, set of chromophores or kit of chromophores in accordance with any of claims 24-26, wherein said binding protein comprises a protein which is adapted to bind to one or more cell surface molecules or receptors, such as a serum albumin protein; or a low density lipoprotein, such as a fatty acid chain, which is adapted for insertion into a cell membrane.
30 A chromophore or set of kit of chromophores as claimed in any of claims 24-29, wherein said bridging polypeptide comprises calmodulin and said complementary bridging polypeptide comprises calmodulin binding peptide; or vice versa; or said bridging polypeptide comprises avidin or streptavidin and said complementary bridging polypeptide comprises biotin; or vice versa.
31 A kit of chromophores as claimed in claim 30, wherein said or each chromophore is conjugated to avidin, and said or each construct comprises a biotinylated monoclonal antibody with specificity for a target specific molecule on the surface of said biological target.
32 A method for attaching a chromophore in accordance with any of claims 1-30 to said specific biological target or targets; comprising the steps of providing a kit in accordance with any of claims 26-31, and introducing the components of said kit into the vicinity of said specific biological target or targets, under conditions suitable for enabling the binding of said or each binding protein to said specific biological target or targets.
33 A chromophore or set of kit of chromophores as claimed in any preceding claim, wherein said specific biological target is a cell or a membrane, such as a cancer cell, a tumour cell, a cell infected with HIV or with any other microbe or virus, a cell responsible for detrimental activity in auto-immune disease, a foreign or diseased cell, or any other such cell 34 A method for fluorescence-activated sorting of target cells from a mixture of cells, comprising the step of attaching to said target cells a chromophore in accordance with any of claims 1-30 or a set of chromophores in accordance with any of claims 22-30, illuminating said mixture of cells so as to cause fluorescence of one or more of said chromophores attached to said target cells, imparting a charge to the fluorescing cells, and passing said mixture of cells through a polarised environment so as to cause or allow said charged cells to be separated from said mixture.
35 A method for the visualisation and/or counting of a plurality of target cells, said target cells including cells of two or three different cell types, comprising the steps of providing a chromophore set in accordance with any of claims 22-30, which chromophore set comprises two or three chromophores each of which is adapted to be delivered to a different one of said cell types; attaching said chromophores in the set to said target cells; illuminating said target cells so as to cause the emission of fluorescence by said chromophores; detecting the fluorescent emission bands produced by each of said chromophores; and optionally measuring for each of said bands the area under an emission/wavelength curve, so as to obtain a measure of the number of fluorescent cells of each respective cell type.
36 A method for causing the death of a target cell, comprising the step of attaching a chromophore in accordance with any of claims 1-21 to said cell and illuminating said cell so as to cause the production of singlet oxygen in the vicinity of said cell, thereby causing the death of the cell.
37 A method for treating a disease or disorder which is characterised by the presence in the body of diseased or undesired cells, such as tumours, cancers, viral infections such as HIV infection, or autoimmune disorders such as rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a patient in need thereof an effective amount of a chromophore in accordance with any of claims 1-21, which chromophore is adapted to be targeted to a target cell specific molecule on the surface of said diseased or undesired cells for attachment thereto, such that the chromaphore is caused to be attached to said cells, and illuminating said cells with light so as to cause the production of singlet oxygen in the vicinity of said cells, thereby killing said cells.
38 A pharmaceutical composition for administration to a patient for the treatment of a disease or disorder which is characterised by the presence in the body of diseased or undesired cells, such as tumours, cancers, viral infections such as HIV
infection, or autoimmune disorders such as rheumatoid arthritis or multiple sclerosis, which composition comprises a chromophore in accordance with any of claims 1-21 that is adapted to be delivered to said diseased or undesired cells, and a suitable carrier.
39 Use of a chromophore in accordance with any of claims 1-21 in the production of a medicament, for use in the treatment of patients suffering from a disease or disorder which is characterised by the presence in the body of diseased or undesirable cells, such as tumours, cancers, viral infections including HIV infection, and autoimmune disorders including rheumatoid arthritis or multiple sclerosis; said chromophore being adapted for delivery to said diseased or undesired cells.
40 A method for separating a mixture which comprises one or more hydrophilic chromophores each having a hydrophilic or amphiphilic moiety, and a plurality of less hydrophilic substances and/or molecules, comprising the step of introducing said mixture to a hydrophobic eluting solvent, and passing said mixture and said eluting solvent over a hydrophilic or polar solid phase, such that said one or more chromophores are arrested on said solid phase whilst said substances and/or molecules are eluted or substantially eluted from said solid phase by said eluting solvent.
41 A method for the synthesis of a 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore having selected substituents at the 5, 10, 1 S and 20 meso-positions thereof; comprising the steps of providing a 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore; attaching a leaving group Q
to the 10 and 20 meso-positions of said chromophore, which leaving group Q is selected from halide and triflate; providing a coupling reagent (R11O)(R12O)BR13, wherein R11 and R12 are independently selected from H or C1-6 alkyl, or R11 and R12 together constitute a C1-6 alkyl chain bridging said two O atoms, and R13 is vinyl or aryl, such as a hydrophilic aryl moiety as hereinbefore defined in relation to R3; and reacting said chromophore with said coupling reagent in the presence of a base selected from potassium phosphate, sodium phosphate, caesium carbonate and barium hydroxide, and a Pd0 catalyst; such that said R« replaces said leaving group Q at the 10- and 20- meso positions of said chromophore.
42 A method as claimed in claim 41, wherein said 5,15-di-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore is a chromophore in accordance with any of claims 1-21, or a protected form thereof.
43 A method as claimed in claim 41 or claim 42, wherein said R13 is vinyl, and said 5,10,15,20-tetra-meso-substituted porphyrin, chlorin or bacteriochlorin chromophore is subjected following said coupling reaction to an osmylation reaction utilising OsO4, such as to convert said 10- and 20- vinyl substituents to hydroxyalkyl.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21407500P | 2000-06-26 | 2000-06-26 | |
US60/214,075 | 2000-06-26 | ||
GB0113784A GB0113784D0 (en) | 2000-06-26 | 2001-06-06 | Novel compounds |
GB0113784.3 | 2001-06-06 | ||
PCT/GB2001/002846 WO2002000662A1 (en) | 2000-06-26 | 2001-06-26 | Improvements in and relating to chromophores |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2414089A1 true CA2414089A1 (en) | 2002-01-03 |
Family
ID=26246162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002414089A Abandoned CA2414089A1 (en) | 2000-06-26 | 2001-06-26 | Improvements in and relating to chromophores |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1294726A2 (en) |
JP (1) | JP2004501923A (en) |
AU (1) | AU783640B2 (en) |
CA (1) | CA2414089A1 (en) |
NZ (1) | NZ523011A (en) |
WO (1) | WO2002000662A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0130778D0 (en) * | 2001-12-21 | 2002-02-06 | Catalyst Biomedica Ltd | Novel compounds |
DE102006045307A1 (en) * | 2006-09-26 | 2008-04-03 | Siemens Ag | Electrochromic formulation, method of preparation and electrochromic organic device |
ES2932287T3 (en) * | 2008-09-18 | 2023-01-17 | Biolitec Unternehmensberatungs Ii Ag | Novel method and application of asymmetrically meso-substituted porphyrins and chlorins for PDT |
GB0904825D0 (en) * | 2009-03-20 | 2009-05-06 | Photobiotics Ltd | Biological materials and uses thereof |
EP2526103B1 (en) * | 2010-01-22 | 2016-05-04 | Council of Scientific & Industrial Research | A process for the preparation of novel porphyrin derivatives and their use as pdt agents and fluorescence probes |
CN103575898B (en) * | 2012-07-23 | 2015-09-09 | 苏州长光华医生物试剂有限公司 | A kind ofly detect kit of TPD52L1 albumen and preparation method thereof |
CN103575901B (en) * | 2012-07-23 | 2015-10-21 | 苏州长光华医生物试剂有限公司 | A kind ofly detect kit of EGFR albumen and preparation method thereof |
US11999885B2 (en) | 2016-06-10 | 2024-06-04 | Nirvana Sciences Inc. | Hydroporphyrin beads with narrow fluorescence emissions |
US11904026B2 (en) | 2017-02-03 | 2024-02-20 | Nirvana Sciences Inc. | Metallohydroporphyrins for photoacoustic imaging |
CN110662748A (en) | 2017-02-03 | 2020-01-07 | 尼尔瓦纳科学股份有限公司 | Hydroporphyrins for photoacoustic imaging |
KR101879725B1 (en) * | 2017-08-08 | 2018-07-18 | 건국대학교 산학협력단 | A novel diaminomaleonitrile porphyrin derivative, composition for detecting mercury ion comprising the same and method for detecting mercury ion using the same |
CN109734856B (en) * | 2019-01-04 | 2021-07-27 | 华东师范大学 | Porphyrin-end-group-containing amphiphilic polypeptide block copolymer and preparation method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8429845D0 (en) * | 1984-11-26 | 1985-01-03 | Efamol Ltd | Porphyrins & cancer treatment |
US6183727B1 (en) * | 1998-05-19 | 2001-02-06 | Arizona Board Of Regents | Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis |
-
2001
- 2001-06-26 EP EP01949625A patent/EP1294726A2/en not_active Withdrawn
- 2001-06-26 JP JP2002505786A patent/JP2004501923A/en active Pending
- 2001-06-26 CA CA002414089A patent/CA2414089A1/en not_active Abandoned
- 2001-06-26 WO PCT/GB2001/002846 patent/WO2002000662A1/en active IP Right Grant
- 2001-06-26 AU AU70748/01A patent/AU783640B2/en not_active Ceased
- 2001-06-26 NZ NZ523011A patent/NZ523011A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU783640B2 (en) | 2005-11-17 |
WO2002000662A1 (en) | 2002-01-03 |
WO2002000662B1 (en) | 2002-04-04 |
NZ523011A (en) | 2004-07-30 |
EP1294726A2 (en) | 2003-03-26 |
JP2004501923A (en) | 2004-01-22 |
AU7074801A (en) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8097609B2 (en) | Swallowtail motifs for imparting water solubility to porphyrinic compounds | |
KR20200064059A (en) | Programmable dendritic drugs | |
CN112399996A (en) | Polymeric dyes having a backbone comprising organophosphate units | |
CN111565757A (en) | Alkyl phosphate polymers comprising bioactive compounds | |
JPH09500660A (en) | Highly relaxing monomer compound and multimeric compound | |
JPH02501141A (en) | Tetra-aza macrocycles and their metal complexes | |
CA2414089A1 (en) | Improvements in and relating to chromophores | |
JPH02196864A (en) | Polymer complex,its manufacture,and drug containing it and used for nmr,x-ray or ultrasonic diagnosis | |
Priem et al. | A novel sulfonated prosthetic group for [18 F]-radiolabelling and imparting water solubility of biomolecules and cyanine fluorophores | |
US20030203888A1 (en) | Chromophores | |
JP2014522404A (en) | Bacteriochlorinimide | |
CN110573502B (en) | Biocompatible modular tetrazine platform | |
Studer et al. | Synthesis of novel 1, 4, 7-triazacyclononane-N, N', N"-triacetic acid derivatives suitable for protein labeling | |
CN114195774A (en) | Photosensitizer with hypochlorous acid activated fluorescence and mitochondrion targeting functions and preparation method and application thereof | |
EP3774803A1 (en) | Pyclen-based macrocyclic ligands, chelates thereof and uses thereof | |
WO2018064961A1 (en) | Multi-modal bioprobe for bladder cancer imaging and photodynamic therapy | |
JP2004501923A5 (en) | ||
WO2003055887A1 (en) | Conjugated porphyrin, chlorin or bacteriochlorin chromophore | |
JPH05501857A (en) | Photosensitive Diels-alderporphyrin derivative | |
US9840522B2 (en) | Multi-modal bioprobe for bladder cancer imaging and photodynamic therapy | |
JPH03197468A (en) | Bifunctional large cyclic chelate ligand and its preparation | |
WO2019125153A1 (en) | Methods for preparing cell targeting conjugates and conjugates obtainable by said methods | |
US10836774B2 (en) | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds | |
CN117624167A (en) | Pyrrolobenzodiazepine-anthraimide hybrid molecule, and preparation method and application thereof | |
WO2023032995A1 (en) | Compound and labeled biomaterial using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |